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Abstract
Chapter 1 gives an overview of the fluorine chemistry field, from its early developments to
recent applications in medicinal chemistry. The development of asymmetric electrophilic or
nucleophilic installation of fluorine in organic molecules is highlighten.
Chapter 2 of this thesis discusses the enantioselective synthesis of α-fluoroamides. The study 
is applied to the synthesis of fluoroenantiomers of the bioactive molecule capsaicin and short-
chain analogues. The biological activity of these compounds is assayed with the TRPV1
receptor. Results show that enantioselective α-fluoroamides (R)-97, (R)-99 and (S)-99 can
generate differentiated biological responses, from TRPV1 agonists to TRPV1 antagonists.
Chapter 3 focuses on the optimisation and development of 2-(aminomethyl)piperidine (R)-
251 dihydrochloride. The development of 2-(aminomethyl)piperidine (R)-251 as its
ditetrafluoroborate salt proved to offer excellent reactivity and solubility for the preparation of
derivatives. This tetrafluoroborate salt was used to improve the syntheses of organocatalysts
2,2,2-trifluoro-N-(piperidin-2-ylmethyl)acetamide 363 and 4-methyl-N-(piperidin-2-
ylmethyl)benzenesulfonamide 364.The catalytic properties of these latter two molecules for
asymmetric Mannich reaction is demonstrated. Both (R)-363 and (R)-364 show up to 86% ee,
in a typical 20 mol% loading, but loading of (R)-363 as low as 5 mol% still induces the
catalysis.
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1- Fluorine in bioactive molecules
1.1- Discovery and development of fluorine chemistry
The history of fluorine chemistry can be traced to the 16th century when the German scholar
Agricola was the first to describe the use of fluoride in a mineral form (Figure 1.1).
Figure 1.1: Portraits of Agricola, Scheele and Moissan.
The mineral was fluorspar, composed of calcium fluoride (CaF2) and was used in metallurgy
to assist in fusion. In this respect, the etymology of fluorine derives from the latin fluere
(“to flow”).
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Studies on fluorspar were continued by Carl Wilhelm Scheele in the 17th century. He noticed
that the mineral would etch glass after acid treatment, and hence he can be attributed with the
discovery of hydrofluoric acid (HF).
Due to its very high reactivity and toxicity, elemental fluorine was only isolated in 1886. This
was achieved by Henry Moissan (Nobel Prize in 1906). The Moissan process starts with the
production of hydrofluoric acid by heating fluorspar (CaF2) at 250 °C in the presence of
sulfuric acid (H2SO4). Addition of potassium fluoride (KF) as an electrolyte forms potassium
bifluoride KHF2, which emits hydrogen gas at the cathode when electrolysed, and fluorine
gas is formed at the anode (Scheme 1.1).
Scheme 1.1: Moissan process for elemental fluorine production by electrolysis.
The method of production of fluorine (HF and F2) developed by Moissan has since been
extensively applied on the industrial scale and has allowed the development of fluorine
chemistry in both research and industry.
An important example of an industrial process resulting from fluorine reactivity is the
enrichment of fissionable U235 from natural uranium.1 This specialised application was
initiated during World War II, where it was used for the development of the nuclear bomb
(Manhattan Project). Elemental fluorine is used to generate volatile uranium hexafluoride
(UF6). In the reaction, uranium ore yellow cake (U3O8) is converted into uranium dioxide
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(UO2), which then reacts with F2 in a two step process to provide uranium hexafluoride (UF6)
via uranyl fluoride (UO2F2) (Scheme 1.2).
Scheme 1.2: Uranium hexafluoride (UF6) synthesis.
Uranium hexafluoride is heated to a gaseous state allowing the separation of isotopomers
U235 and U238 through diffusion membranes or by centrifugation to provide the fissionable
uranium (U235) used in nuclear power stations.
The chemistry of fluorinated alkanes was first explored by Frédéric Swarts who developed a
fluorine exchange catalyst, enabling the conversion of chlorocarbons to mixed
chlorofluorocarbons (Scheme 1.3).
Scheme 1.3: Freon gas production.
This process was applied by General Motors during the 1930s for the industrial-scale
synthesis of Freon gases. This family of inert gases was extensively used as non-flammable
refrigerants until the end of the 1990s, when it was banned for ecological environmental
reasons.
Research on chlorofluorocarbons (CFCs) then led to a second major commercial product. In
1938, Roy Plunckett of the DuPont company discovered the perfluorinated polymer poly-
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tetrafluoroethylene (PTFE), now marketed as Teflon® or Gore-Tex®. The synthesis of PTFE
is initiated with the thermal fragmentation of CHClF2 into difluorocarbene, which then
homocouples to give tetrafluoroethylene (TFE). This monomer is subjected to radical
polymerisation to generate PTFE (Scheme 1.4).
Scheme 1.4: DuPont synthesis of perfluoroethylene (PTFE).
Fluorine also brought specific properties to compounds of biological and medicinal interest.
A major medical application appeared in the mid 1950s within the field of anaesthesiology.
The “fluorine revolution” led to the replacement of diethyl ether by fluorinated general
anaesthetics.2 The first of these products used on patients was Fluoroxene® 1 in 1953
(Figure 1.2). Halothane® 2 became the main anaesthetic in clinical use until the 1980s, and
was used in about 80% of all operations. The clear advantage of the fluorinated anaesthetics
was the reduction in flammability and therefore their ease of use. Currently Sevoflurane® 3
and Desflurane® 4 are the main anaesthetics used in surgery. Delivery is improved thanks to
their lower blood-gas partition coefficient. As a consequence, side-effects are reduced and
recovery times are shortened because of lower levels of metabolism.
Figure 1.2: Fluorinated anaesthetics.
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Fluorine has also contributed to the development of numerous agrochemicals: herbicides,
fungicides and insecticides. Fluorine incorporation has improved their efficiency in terms of
solubility and toxicology.3
The influence of fluorine attached to chiral centres on the biological properties of a bioactive
molecule was exemplified in 1954 by Joseph Fried and Emily F. Sabo with their synthesis of
corticosteroid 9α-fluorocortisone acetate 5 (Figure 1.3).4 In previous studies they described
the replacement of the 9α-hydrogen atom by halogens.5 The 9-halocorticoids showed an
enhanced glucocorticoid activity, which in the case of the chloro-derivatives exceeded that of
the parent hormones by a factor of four. They concluded the activity was inversely
proportional to the size of the halogen.
Figure 1.3: Examples of important fluorinated bioactives.
Three years later, 5-fluorouracil (5-FU) 6 was synthesised as a novel anti-tumour drug by
Charles Heidelberger, Robert Duschinsky and Robert Schnitzer at Hoffman-La Roche.6 5-FU
affects cellular reproduction, and it is especially active on fast growing cancer cells. This
molecule is indeed an analogue, but also an antimetabolite, of the pyrimidine nucleosides.
When incorporated into RNA, 5-FU inhibits RNA replication enzymes, thereby arresting
RNA synthesis and the subsequent growth of cancer cells.
Chapter 1
6
1.2- Controversial effects of fluorine on health
The synthesis of fluorinated organic and bioorganic compounds is a relatively new field that
emerged significantly in the 1970s, with an approximate rate of three drug candidates per
year (Figure 1.4).7, 8 There was a clear rise in fluorinated drugs around 1982, following early
developments on selective fluorination methods using new reagents such as
(diethylamino)sulfur trifluoride (DAST).9, 10 The percentage of fluorinated drugs (green bars)
has remained relatively constant at between 5-15% of all drugs launched annually over the
last thirty years. Since 2002 there has been an apparent increase (15-40%) in fluorinated
drugs by comparison with the total number of approved pharmaceuticals. However, the total
number of drugs introduced onto the market is now very low at less than twenty per year, by
comparison with the 50-60 per year in the 1980s.
Figure 1.4: Number of launched drugs and the percentage containing fluorine (green) between the
1957-2006 period.7
Significant methodology improvements in fluorination chemistry in recent years (discussed in
section 1.6), have resulted in an increasing number of fluorinated products of greater variety
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and structural complexity. Unfortunately the persistence and bio-accumulation of fluorine in
any form is an ongoing issue. For instance, fluoride ion enriched products such as toothpastes
or NaF enriched kitchen salts were introduced onto the market in the 1970s. Fluoride helps
the prevention of dental cavities by remineralisation of tooth enamel and renders it resistant
to acid damage,11, 12 but the addition of fluoride to food and to the water supply remains
controversial.
In the early 1930s, toxicity associated with high intakes of fluoride ion as well as indirect
contamination via ingestion of fluoride from food or fluoridated water was already noted.13
A more recent concern in the bio-accumulation of fluorinated products was formalised in
2003 by the United States Environmental Protection Agency (EPA) relating to population
exposure to perfluorooctanoic acid (PFOA) 7.
Figure 1.5: Perfluorinated acid PFOA.
According to the EPA, residual PFOA in Teflon® coatings or PFOA resulting from
degradation of PTFE at high temperature is potentially carcinogenic, by extrapolation on
human beings of tumours developed by rats and mice exposed to this chemical.14 At the
beginning of 2009, a study showed that blood serum levels of PFOA are potentially linked to
infertility for both women and men.15 If installation of fluorine on molecules is designed to
improve their efficiency, bio-accumulation of fluorinated compounds is clearly an issue that
will continue to be newsworthy.
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1.3- Significance of fluorine in natural products
The importance of fluorine in pharmaceuticals can be contrasted with the virtual absence of
natural fluorinated compounds. Much of the halogen contained in the earth’s crust (270-
740 ppm, compared to that of chlorine at 10-180 ppm) remains insoluble and therefore is not
bioavailable. Also, fluoride ion has a high solvation energy (439 kJ.mol-1)16 and is not free as
a nucleophile, thus few enzymes have evolved that can utilise it. To date, only five
fluorinated natural compounds have been ultimately identified either in plants or
microorganisms and there is no direct evidence of de novo biosynthesis of organofluoro-
metabolites in animals (Figure 1.6).17 In addition, eight metabolites of 10 have been found in
the seed lipids of Dichapetalum toxicarium, from Sierra Leone.18
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Figure 1.6: Examples of claimed fluorinated natural products.
Fluoroacetate 8 was discovered in 1943 by Marais from plant Dichapetalum cymosum,19 and
4-fluorothreonine 13 was isolated from the bacterium Streptomyces cattleya in 1986.20
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Recently, 5-fluorouracil 6 and derivatives were isolated from the marine sponge Phakellia
fusca collected in the South China Sea, although this is more likely the bioaccumulation of 5-
FU in industrial effluent.21 The bacterium Streptomyces calvus was found to produce
nucleocidin 12. The details of the full biosynthetic pathways to the metabolites have not been
elucidated, except in the case of Streptomyces cattleya, which produces fluoroacetate 8 and 4-
fluorothreonine 13.22-25
1.3.1- Metabolites from plants
The fluoroacetate metabolite 8 seems to be ubiquitously synthesized by plants in tropical and
subtropical regions but some have evolved a particular capacity for defense purposes.19
A co-evolution phenomenon has made endogenous animals resistant to fluoroacetate-
producing plants with the most dramatic effect in herbivores, which are more exposed to the
toxin.26 ω-Fluorofatty acids are almost certainly biosynthesised from fluoroacetate 8 via
fluoroacetyl CoA and fatty acid synthase.27
1.3.2- Metabolites from micro-organisms
Nucleocidin 12 was isolated in 1957, from the bacterium Streptomyces calvus even though
fluorine in its structure was only elucidated in 1969.28 It is an adenine-containing antibiotic of
broad spectrum activity that was revealed to be too toxic for clinical use. Novel attempts to
re-isolate this product, and therefore, determine the nature of the biological fluorination
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process have failed.29 It is possible that one essential plasmid encoding the gene for
nucleocidin biosynthesis has been lost during the freeze-drying process of the bacterium.
Streptomyces cattleya has proved to be of great interest as studies on this bacterium
demonstrated that it is able to produce fluoroacetate 8, and the amino acid 4-fluorothreonine
13 and a summary of the pathway is shown in Scheme 1.5.25, 30
Scheme 1.5: Biosynthetic pathway in Streptomyces cattleya.
4-Fluorothreonine 13 exhibits antimicrobial activity against a range of bacteria. The enzyme
that forms the C–F bond has been isolated and identified as 5’-fluoro-5’-deoxyadenosine
synthase, which is more commonly termed the “fluorinase”.31 The enzyme catalyses the
reaction of fluoride ion with S-adenosyl-L-methionine (SAM) 14 and generates 5’-fluoro-5’-
deoxyadenosine (5’FDA) 15 and L-methionine as products.
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1.4- Properties of fluorine
1.4.1- The fluorine atom
Fluorine has nine electrons distributed in two valence shells with the electronic configuration
1s2 2s2 2p5. The Van der Waals radius is 1.47 Å, which makes it the second smallest atom of
the periodic table after hydrogen (1.20 Å) able to make covalent bonds with carbon. Due to
its small size, electrons are strongly attracted to the nucleus and fluorine has been assigned
the most electronegative value in the periodic table (3.98 on Pauling scale, Table 1.1). The
high ionisation energy suggests removing an electron is unlikely. Indeed the only ionic form
of fluorine is the fluoride anion.
Atom Van der Waalsradius (Å)
Pauling
electronegativity
Polarisability
(Å3)
Ionisation energy
(kcal.mol-1)
H 1.20 2.20 0.667 313.6
F 1.47 3.98 0.557 401.8
O 1.52 3.44 0.82 314.0
N 1.55 3.04 1.10 335.1
C 1.70 2.55 1.76 240.5
Cl 1.75 3.16 2.18 299.0
Br 1.85 2.96 3.05 272.4
I 1.98 2.66 4.7 241.2
Table 1.1: Atomic parameters of fluorine relative to other common atoms.
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The case of fluoride is interesting as it generates ordered clusters with water, although the
solvation structure is not clear. It seems likely that F- shows a tetrahedral coordinated
solvation shell,32 although there are some indications that the coordination number is solute-
concentration-dependent.33 The nature of the cation can also significantly affect the hydration
state.34, 35 This propensity to solvation renders fluoride unreactive as a nucleophile.36
Elemental fluorine (F2) has a much lower bond energy (157 kJ.mol-1) relative to hydrogen
(H2) (434 kJ.mol-1) or chlorine (Cl2) (242 kJ.mol-1). Thus the reactivity of elemental fluorine
is very high.
1.4.2- Physical properties of the C–F bond
Incorporation of fluorine in place of hydrogen into organic molecules often leads to
decreased boiling points in the case of high levels of fluorination or perfluorination.
Polyfluorination also enhances density, viscosity or compressibility, making perfluorocarbons
relatively fluidic (see Table 1.2).
C6H14 CF3(CF2)2(CH2)3H C6F14
Boiling point (°C) 69 64 57
Density d25 (g.m-3) 0.655 1.265 1.672
Viscosity η25 (cP) 0.29 0.48 0.66
Compressibility β  
(10-6 atm-1)
150 198 254
Table 1.2: Some physical properties of non-, partially- and per-fluorinated compounds.
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Polarity is decreased according to the degree of fluorination, having impacts on the solubility.
In the extreme, perfluorocarbons are not miscible in organic solvents or water, rather forming
a third phase known as the “fluorous phase”. Effects on lipophilicity will be explored further
in section 1.5.1.2. This parameter is crucial in medicinal chemistry as it dictates the passage
of drug candidates through biological barriers.
1.4.3- Stereoelectronic properties of the C–F bond
1.4.3.1- Polarity
The high electronegativity of fluorine and its inductive electron withdrawing character
renders the C–F bond rather electrostatic than covalent in character. The C–F bond is
polarised from the carbon (δ+) to the fluorine (δ-), forming a large dipole which can interact
with other dipoles. This high electronegativity is also responsible for holding tightly the three
lone pairs and reduces their ability to become involved in resonance. When fluorine is bound
to sp2 carbon, an electron donating mesomeric effect can occur, but this is much weaker than
for oxygen or nitrogen (Figure 1.7).
Figure 1.7: Electronic effects of fluorine.
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1.4.3.2- Bond strength
Table 1.3 illustrates that fluorine forms a stronger bond to carbon than all of the other
halogens (entry 1-3). Indeed, fluorine forms the strongest bond to carbon. Fluorine also has
effects on proximate bonds, the strengthening effect being increased with the number of
fluorine substituents (entry 3 to 5). The reinforced strength of C–H and C–C bonds in
polyfluorinated compounds generates high thermal and oxidative stability of such
compounds.
Entry Molecule Bond dissociationenergy (kcal.mol-1)
1 H3C-F 108.3
2 H3C-Cl 82.9
3 H3C-CH3 88.8
4 H3C-CF3 101.2
5 F3C-F 130.5
Table1.3: C–X bond dissociation energy of halogenated compounds.
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1.5- Fluorine in medicinal chemistry
1.5.1- Effects of fluorine on the properties of organic molecules
1.5.1.1- Perturbation of pKa
Fluorine is strongly electron withdrawing when it is incorporated into organic molecules,
vide infra. This property affects the acidity of adjacent functional groups. For instance
fluorine substitution of amines renders them less basic.37 Table 1.4 illustrates that for each
fluorine added, the pKa is lowered by a similar magnitude.8 In addition, fluorine substitution
also makes alcohol and carboxylic acid functionality more acidic.
Amines pKa
Carboxylic acids
and alcohols pKa
CH3CH2NH3+ 10.7 CH3COOH 4.76
CH2FCH2NH3+ 9.0 CH2FCOOH 2.66
CHF2CH2NH3+ 7.3 CHF2COOH 1.24
CF3CH2NH3+ 5.7 CF3COOH 0.23
CH3CH3CH2NH3+ 10.7 CH3CH2OH 16.0
CH2FCH2CH2NH3+ 9.9 CF3CH2OH 12.37
CF3CH2NH3+ 8.7
Table 1.4: The effect of fluorine substitution on pKa values of organic amines, carboxylic acids and
alcohols.8
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Drugs pKa are evaluated early during the clinical development of a lead molecule, as it can
have strong effects on the drug metabolism. For example, novel indole derivatives 18-20
developed to treat migraine were studied for their bioavailability (Figure 1.8).38
Figure 1.8: Indole derivatives studied for their bioavailability.
Introduction of one or two fluorine atoms significantly reduces the basicity of the amine,
showing an improvement in the bioavailability of the lead compound 18, although this
compromised receptor affinity. The difluoro compound 20 was no longer basic enough to
achieve high binding affinity for the 5-HT1D migraine receptor (Table 1.5).
Structures pKa IC50 5-HT1D Bioavailablility
18 9.7 0.3 Poor
19 8.7 0.9 Good
20 6.7 78 NA
Table 1.5: Correlation between pKa of non-, mono- and difluorinated compounds and their IC50.38
1.5.1.2- Modulation of lipophilicity
The balance between lipophilicity
drug design. Drugs require a reasonable lipophilicity to pass through cell
provide good binding to the target protein
lipophilicity of the molecule, also expressed as the partition coefficient log
(usually 7.4). The “Lipinski’s rule of five”
empirically set up that log P
absorption of the drug. In general, fluorine substitution increases
not always the case. A study by Roche
correlated the effect of the substitution of hydrogen by fluorine
histogram of changes in log D
0.25 log D units shows the
significant tail under zero, for compounds with decreased lipophilicity.
Figure 1.9: Effect of mo
and overall molecular polarity is an important factor in
. The distribution coefficient (log
, used to predict good drug candidates
should be less than 5 to lead to better solubility and complete
lipophilicity;
on 293 compounds from their
on lipophilicity
in Figure 1.9 reveals a Gaussian distribution
average increase in lipophilicity. However, this
nofluorination on lipophilicity of drugs
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membranes and
D) measures the
P, at a given pH
, has
however this is
in-house database
.7 The
. The maximum at
data shows a
.7
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1.5.1.3- Steric and conformational changes
The steric change carried by the substitution of hydrogen or a hydroxyl group is minor, in
regards of the similar van der Waals radius (rv) of fluorine (1.47 Å) with that of oxygen
(1.57 Å) and hydrogen (1.20 Å). The electronic properties are altered by the replacement of
hydrogen by fluorine, but the replacement of oxygen is a most neutral change.
The methyl group is often isosterically replaced by the trifluoromethyl group to improve
lipophilicity, although it has about twice the volume.39
The combination of the steric influence of fluorinated groups and the electronegativity of
fluorine often generates a conformational change. A clear example is provided with
substituted benzene rings. A methoxyl substituent prefers to lie planar to the aromatic ring
whereas a O–CF3 group lies perpendicular. Therefore O–CF3 cannot be considered simply as
an isosteric analogue for O–CH3. This difference was applied in the design of more potent
inhibitors of the cholesteryl ester transfer protein (Figure 1.10).40
Figure 1.10: Structure of inhibitors of the cholesteryl ester transfer protein.
This protein functions to transfer the cholesteryl ester from high-density lipoprotein to low-
density lipoprotein, a process which alleviates coronary heart disease. Switching the R group
from OCH2CH3 to OCF2CF2H on 21 led to an 8-fold increase in potency. As confirmed by
DFT calculations, the pentafluoroethyl substituent is orientated out of the plane compared to
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the phenyl group, dramatically improving the binding efficiency to the target protein. In
addition, it is also suggested that the steric and electronic properties of Ph–OCF2CF2H are
similar to 2-phenylfuran, another non-planar substituent. This offers a new tool to medicinal
chemists as furans are metabolically unstable and therefore it can be of advantage to replace
them by OCF2CF2H.
1.5.2- Metabolic stability
Once a drug is administered, it is generally metabolised prior to distribution to the target site.
This metabolism is the physiological response of detoxification that occurs mainly in the
liver. Cytochrome P450 monooxygenases are primarily responsible for the oxidation of
xenobiotic compounds, decreasing their lipophilicity to enhance water solubility and hence
excretion.41
1.5.2.1- Oxidative mechanism
Oxidation of drugs by cytochrome P450 enzymes is often combated by selective fluorination.
This is exemplified by the lead optimisation of the cholesterol inhibitor Ezetimibe (Schering-
Plough) 23.41, 42
Part of the oxidative metabolism was blocked after incorporation of fluorine (Figure 1.11)
into the para positions of the phenyl groups. Such substitutions prevent oxidation of the
phenyl ring to phenol and dealkylation of the methoxyl group, because of the strong
electronic withdrawing effect of the fluorine deactivating the phenyl ring.
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Figure 1.11: Strategies to block aryl oxidative metabolism of Ezetimibe.42
In an extreme case, the incorporation of fluorine may bring excessive stability that prevents
the drug being metabolised. This has been exemplified by the cyclo-oxygenase 2 (COX 2)
inhibitor Celecoxib 25 which presented a very long biological half-life.43 Stability has been
altered by substituting the fluorine on lead compound 24 with a methyl group, which is more
inclined to be metabolised and excreted from the patient (Figure 1.12).
NN
F
H3CO2S
CF3
NN
Me
H3CO2S
CF3
oxidation blocked
24 Celecoxib 25
Figure 1.12: An example of retro-drug design with Celecoxib to decrease its metabolic half-life.43
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1.5.2.2- Hydrolytic metabolism
In vivo hydrolysis of some drugs can occur at acidic or neutral pH. For example, prostacyclin
(PGI2) 26 is a vasodilator, and used for vascular disease treatment. The labile enol ether
moiety of this compound is hydrolysed in vivo, with a half-life of 10 minutes, to give the
inactive compound 6-oxo-PGF1α.29 (Scheme 1.6).44
Scheme 1.6: Mechanism of the hydrolytic metabolism of prostacycline 26.44
Introducing fluorine into this molecule decreased the hydrolysis rate as a result of reducing
the electron density of the enol ether. The mono-fluorinated derivative 7-F-PGI2 30 has a
half-life of 30 days45 whereas the difluoro derivative AFP-07 31 has a half-life of 90 days,46
significantly extended from the initial time of 10 minute for 26 (Figure 1.13).45
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Figure 1.13: Blockage of hydrolytic metabolism with fluorine in prostacycline analogues.
1.5.2.3- In vivo racemisation
Racemisation of drugs can also occur under physiological conditions, as exemplified by
thalidomide 32 (Scheme 1.7). Thalidomide is a sedative hypnotic prescribed to mothers
during their pregnancy. It emerged that the (R)-enantiomer gives the sedative hypnotic
properties, whereas the (S)-enantiomer is responsible of the dramatic teratogenic side-effects.
It appears the acidic hydrogen situated on the stereogenic centre is able to epimerise rapidly
under physiological conditions, a process that can be prevented by substitution of the
hydrogen by fluorine such as in 32c.41
Scheme 1.7: Epimerisation of thalidomide 32.
Chapter 1
23
1.5.3- Protein–Ligand interactions
The presence of fluorine on a ligand will affect its binding to a target protein. The
fluorination can have a direct effect where it makes interactions with the protein. But indirect
effects can also result from the fluorine modulating the polarity of proximate functional
groups of the ligand, which then directly interact with the protein. As discussed in
Section 1.5.1.2, introduction of fluorine generally increases lipophilicity, which results in a
global and non-specific enhancement of the binding affinities of drugs. For example, the case
of 5HT1D agonists quoted in Section 1.5.1.1 illustrates how the change of acidity can
indirectly affect the binding.
1.5.3.1- Electrostatic interactions
Diederich and Müller introduced the concept of fluorophilicity/fluorophobicity of a protein
active site. They suggested that fluorine has specific properties which cannot easily be
classified as hydrophobic or lipophilic.47 They reported the systematic fluorine substitution of
a thrombin inhibitor in order to explore the fluorophilicity of the thrombin active site,
concluding that the C–F…C=O protein-ligand interactions increase binding affinities. Indeed,
the fluorinated thrombin inhibitor analogue 33 displayed a five-fold higher activity than the
corresponding non-fluorinated compound. The X-ray crystal structure of the protein-ligand
complex showed that the amide carbonyl groups on the protein backbone provided a
fluorophilic environment (Figure 1.14).
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Figure 1.14: Direct polar interaction between fluorine and an amide carbonyl group.47
As illustrated in Figure 1.14, the fluorine atom of the inhibitor 33 is making a direct polar
interaction with the carbonyl moiety of Asn 98 of thrombin and is positioned close to the
trigonal axis of the carbonyl. This result is interesting as amide carbonyl groups are numerous
and an integral part of protein active sites. Therefore, such a strategy offers a solution for
using fluorine to enhance ligand affinity in structure-based drug design.
1.5.3.2- Hydrogen bonding
Pauling stated that the strength of the hydrogen bond increases with the electronegativity of
the donor atom. Therefore, it is expected that for chlorine, nitrogen, oxygen and fluorine,
their hydrogen bonds strength should increase in this order. This hypothesis was corrected by
Pauling himself: “It is interesting that in general fluorine atoms attached to carbon do not
have significant power to act as proton acceptors in the formation of hydrogen bonds in the
way that would be anticipated from the large difference in electronegativity of fluorine and
carbon.”48
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Dunitz et al.49 and O’Hagan et al.50 evaluated, in parallel studies, the propensity of fluorine to
act as a hydrogen bonding acceptor. These studies reviewed short F…H contacts from X-ray
structures deposited in the Cambridge Crystallographic Data Center (CCDC) (Table 1.6).
Number of structures Short C–F
…H–X contact
(length)
Dunitz 5947 37 (≤ 2.3 Å) 
O’Hagan 548
166 (≤ 2.35 Å) 
1 (≤ 2.0 Å) 
Table 1.6: Studies of short C–F…H–X contact.50
Amongst the 37 compounds found by Dunitz et al. containing C–F…H–X distances less than
2.3 Å, only two could be considered as hydrogen bonds and the others as weak interactions.
They offered two reasons to explain this paradox. In the formation of a hydrogen bond,
donors and acceptors must present a similar proton affinity. Thus the energies of the two
orbitals competing for the proton must be close, which is not the case with fluorine as its 2p
orbital binding energy is 3 eV higher than that of oxygen (2p) and 6 eV higher than that of
nitrogen (2p).51
Other parameters highlighted the role played by electron delocalisation within molecules and
cooperativity in extended systems. Contrary to oxygen (carbonyl) and nitrogen (imine),
which both attract electrons through their π-systems, fluorine can only engage in single 
bonds. Covalently bonded fluorine shows a partial negative charge, but this is counter-
balanced with its low proton affinity (low basicity, low-lying lone pair orbitals, and tightness
of the electron shell). Therefore, covalently bonded fluorine can only engage in weak polar
interactions rather than hydrogen bonds.
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1.5.4- Fluorine in nuclear medicine
Radioisotopes are used in nuclear medicine for both diagnosis and treatment of disease.
Positron emission tomography (PET) is a non-invasive medical imaging technique that
allows the in vivo assessment, at a high-resolution level, of metabolic processes. The
applications are very varied, because diverse physiological parameters can be analysed, i.e.
blood flow, drug distribution metabolism.52 The most common isotopes (18F, 11C, 13N, 15O)
are also the most common elements in organic chemistry and, therefore, the constituents of
all biological molecules. The process of producing a radiolabeled PET tracer is a complex
task, but has to be carried out in the restricted time frame of the radioisotope short-life.
Because fluorine-18 has a longer half-life (110 min), it is the most suitable for clinical
research and investigations (Table 1.7).
Radionuclide 11C 13N 15O 18F
t1/2 (min) 20 10 2 110
Table 1.7: Common positron emitting radionuclides and their half-lives.
The 18F isotope is generated by a cyclotron, in which 18O enriched water is bombarded by
accelerated protons (H+). The resultant 18F fluoride ion is then introduced chemically into a
radiotracer via a potassium salt complex (Scheme 1.8).
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Scheme 1.8: Radiosynthesis of [18F]-FDG.
Currently, the number of radiotracers in clinical use is increasing, but the most commonly
used is 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]-FDG) 36. As a glucose analogue, this
compound is adapted to the detection of glucose metabolic pathways, including brain, kidney
or cancer cells detection.41 After its absorption, [18F]-FDG is phosphorylated at C-6, which
prevents its release from the cell. The absence of a hydroxyl group at the C-2 position blocks
36 entering the glycolysis pathway. Consequently, [18F]-FDG-6-phosphate remains within the
cell until the 18F decays and its accumulation is measured by a positron emission camera.53
The radiosynthesis of [18F]-FDG has been optimised and takes only 20 min in a two step
protocol. Fluorination occurs by nucleophilic substitution of [18F] fluoride to triflate as
illustrated in Scheme 1.8. The rapid hydrolysis of the acetylated sugar provides [18F]-FDG.
Beyond uses in oncology, a new field for radiotracers is now emerging to help in the drug
development process, as for in vivo visualisation of the drug biodistribution. With this
technique, Merck studied the NK1 receptor occupancy by the drug candidate Apprepitant 37,
a drug used to reduce nausea in patients undergoing chemotherapie (Figure 1.15).
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Figure 1.15: The drug Aprepitant and its tracer in PET imaging.54
The calculation of NK1 receptors prevalence is based on a comparison of brain PET images
before and after the drug trial. A selective radiotracer for NK1 receptors, [18F]SPA-RQC 38,
mimicking the core of Aprepitant 37 (highlighted in blue in Figure 1.15), was injected to
healthy volunteers.54 The purpose of this PET study is to evaluate drugs in early clinical
development with small amounts of product. Combination of this technique with structure-
activity relationships refines the approach towards drug development even though it requires
specifically designed radiotracers.
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1.6- Methods of fluorination
Approaches to chemical fluorination can be classified under three categories. The fluorine
atom can be installed via an electrophilic fluorinating reagent, a nucleophilic attack by
fluoride ion, or with the use of a fluorinated building-block. Recent developments have
generated the necessity to introduce fluorine in a stereoselective manner, notably in medicinal
chemistry. The following section will describe the most commonly used fluorinating reagents
and review the latest methods of asymmetric fluorination.
1.6.1- Nucleophilic reagents for fluorination
Fluoride ions are sensitive to solvation thus rendering them less nucleophilic. Conversely,
aprotic solvents such as DMF or acetonitrile strengthen the nucleophilicity, but also the
basicity of fluoride. The first sources of fluoride involved metallic fluorides with metals such
as potassium (KF), sodium (NaF), cesium (CsF) and silver (AgF). Ammonium fluorides such
as tetrabutylammonium fluoride (TBAF) 39 effectively improved the nucleophilicity of
fluoride. The large sterically hindered cation tetrabutylammonium can delocalize the positive
charge and thus reduces the ion pairing (Figure 1.16).
Figure 1.16: Common nucleophilic reagents for fluorination.
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Nucleophilic fluorination can be carried out with solutions of hydrofluoric acid (HF)
complexed to amines. Neat HF is not anymore considered in the laboratory day-to-day use
because of its high toxicity and corrosive properties. Olah’s reagent is a complex of HF and
pyridine (70:30). This reagent is still very corrosive and is often replaced by triethylamine in
Et3N-3HF.
The sulfur fluorides (S–F) reagents form another class of nucleophilic reagents where
fluoride is combined with a soft Lewis base. The first reagent was sulfur tetrafluoride SF4.
This toxic gas was not easy to handle and stability was improved by replacing one of the
fluorines by a dialkylamine. The dialkylamino group reduces the reactivity of the reagent due
to its inductive effect and steric hindrance. Amongst such regents are diethylaminosulfur
trifluoride (DAST) 40 and Deoxo-fluor® 41 (Figure 1.16). DAST55 still has the disadvantage
that it can decompose spontaneously, particularly on heating. The second generation reagent
Deoxo-fluor® emerged with improved stability over DAST and can be used at temperatures
above 90°C without degradation or danger of explosion. Deoxofluor is also cost-efficient and
can be used as an alternative for large scale syntheses.56
Other reagents such as Ishikawa’s reagent (F3CCHFCF2NEt2) and Yakorenko’s reagent
(ClCHFCF2NEt2) for fluorodeoxygenation reactions have been reported but their use and
availability remains limited. Tetrafluorodiethylamine (TFEDMA) 42 developed by DuPont®
is the adduct of tetrafluoroethylene and dimethylamine. 4-tert-Butyl-2,6-dimethylphenyl-
sulfur trifluoride marketed as FLUOLEAD® 43 is the latest fluorination reagent, introduced
onto the market in 2009, and therefore its scope is not yet well-defined (Figure 1.17).
Figure 1.17: Recently commercialised nucleophilic reagents.
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DAST is often used to mediate the fluorodeoxygenation of alcohols. The mechanism involves
nucleophilic attack by the hydroxyl group of the substrate to generate a reactive intermediate
45. The configuration at carbon is inverted after nucleophilic attack of the intermediate by
fluoride (Scheme 1.9).
Scheme 1.9: Mechanism of fluorodeoxygenation by DAST or Deoxo-fluor.
However DAST can also promote elimination reactions due to the strong basicity of fluorides
as illustrated in Scheme 1.10 where cyclooctanol 47 when treated with DAST, lead to the
formation of (Z)-cyclooctene 49 along the desired fluorocyclooctane 48.10
Scheme 1.10: DAST-mediated fluorodeoxygenation can induce elimination.10
Schlosser developed a strategy for opening epoxides to convert them in a stereoselective
manner to vicinal difluorides.57 The epoxide (R,S)-50 is first opened using HF/Et3N, with an
inversion of configuration at carbon. The second fluorine is introduced by nucleophilic attack
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of the hydroxyl group of (R,R)-51 by fluoride to give the anti vicinal difluoro product 52
(Scheme 1.11).
Scheme 1.11: Fluorodeoxygenation of alcohols.57
Recent work in the group at St-Andrews has consisted of controlling the installation of
several vicinal fluorines. The new compounds have a degree of fluorination intermediate
between alkanes and perfluoroalkanes. The research group has prepared single isomers of
compounds with four 53, five 54 and six 55 vicinal fluorine to study their conformations.58, 59
Figure 1.18: Example of four, five and six vicinal fluorine compounds.
The synthesis of the tetrafluoroisomer 53 started with 3 HF/Et3N mediated regioselective
ring-opening of the enantiopure (R)- butadiene oxide 56 as illustrated in Scheme 1.12. A loss
of enantiopurity was observed in the reaction, due to its partial SN1 character. However, a
very high enantiopurity was recovered during the homo cross-metathesis reaction of the allyl
fluoride 58. Separation of (S,S) and (S,R) isomers of 59 on silica gel chromatography allowed
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the major (S,S) product to be obtained in 98% ee. Dihydroxylation of the latter with
potassium permanganate generated the difluoro diol 60 in a 4:1 dr. After removal of the
minor isomer, the subsequent cyclic sulfate 61 was opened stereoselectively by nucleophilic
attack of fluoride ion using TBAF. The fourth fluorine atom was installed with Deoxo-fluor
after swapping the terminal protective groups from benzyl ethers to tosyl esters. In this study,
the absolute configuration of each stereocenter was confirmed by X-ray crystal structure
analysis. Interestingly, these all syn compound have a helical nature.
Scheme 1.12: Synthesis of a tetra- vicinal fluorinated compound.58
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1.6.2- Electrophilic reagents for fluorination
The first electrophilic fluorination reagent to be developed was elemental fluorine F2. This
reagent is highly reactive and has the disadvantage of being explosive and promoting
exothermic reactions. Despite its toxicity and lack of selectivity, it was used since the 1950s
on a routine basis in industry and on a large scale. Elemental fluorine F2 is generally diluted
in an inert gas such as nitrogen or argon.
A good example is the synthesis of the anti-cancer agent 5-fluorouracil (5-FU) 6 in acetic
acid as solvent (Scheme 1.13).60 Elemental fluorine requires specific equipment to handle
which limits its use in academic laboratories.
Scheme 1.13: Synthesis of 5-fluorouracil with elemental fluorine.60
A second generation of F+ reagents involved a fluorine atom directly bonded to oxygen or
nitrogen atoms. Hypofluorites reagents activate fluorine by oxygen. This class of reagents
(for instance CH3COOF, CF3OF) has been abandoned due to their lack of selectivity and
strong oxidative properties. Nitrogen offers a lower electronegativity relative to oxygen and
as a consequence, the N–F bond is stronger. This increased strength renders the reagents more
stable and easier for laboratory handling. N–F reagents have proved to be important in the
field of electrophilic fluorination reagents (Figure 1.19). Selectfluor (F-TEDA-BF4) 65 61 and
N-fluoropyridinium triflate 66 62 show greatly improved selectivity compared to F2. Another
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class of commonly used N–F reagents are the sulfonyl derivatives N-fluoro-O-benzene-
disulfonimide (NFOBS) 67,63 and N-fluorobenzenesulfonimide (NFSI) 68.64
Figure 1.19: Electrophilic reagents for fluorination.
1.6.3- Enantioselective monofluorination
Asymmetric fluorination has evolved rapidly over the last decade and many efficient methods
have been developed. Such fluorinations can be controlled in a regio- and stereo- selective
manner with the use of approaches driven by the substrate itself, the reagent, or the catalyst.
Such approaches are outlined in this section, including different methods to achieve the
stereoselective fluorination for molecules of wide general interest.
1.6.3.1- Substrate control
An important approach to stereoselective fluorination is to install the fluorine atom after
coupling of the target molecule to a chiral auxiliary. The chiral auxiliary requires removal
after the fluorination, which lengthens the synthetic pathway. However, many successful
examples of the use of an oxazolidinone as a chiral auxiliary have been provided by Evans or
Chapter 1
36
Davis (Scheme 1.14).65, 66 The diastereoselectivity of these reactions is controlled by the
oxazolidone enolate. Fluorination is then achieved by reactions with electrophilic fluorinating
reagents such as NFOBS or NFSI.
Scheme 1.14: Asymmetric fluorination using chiral oxazolidinone methodology.
1.6.3.2- Reagent control
Cinchona alkaloids offer non-expensive biomolecules for asymmetric organocatalysis. They
also have the potential for structural modification. The combination of cinchona alkaloids
with Selectfluor was developed independently by Cahard in France67 and Shibata in Japan
(Scheme 1.15).68
Scheme 1.15: Preparation of dihydroquinine electrophilic fluorinating reagent.
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In the following example, dihydroquinine 71 promoted the catalytic electrophilic
fluorodesilylation of 73 (Scheme 1.16).68
Scheme 1.16: Example of cinchona alkaloids mediated enantioselective fluorination.68
The N-fluoroalkaloid is generated in situ prior to electrophilic addition of the substrate. The
reaction involves a fluorine transfer from the reagent to the alkaloid to make a tertiary
fluoroammonium salt 72. This method requires stoichiometric amounts of cinchona alkaloids,
thus selectivity issues occur in the case of sub-stoichiometric conditions. The efficiency of
the method, however, is in the faster rate of transfer of fluorine onto the cinchona alkaloid
rather than the direct reaction of Selectfluor with the enolate.
1.6.3.3- Catalyst control
Catalyst control covers a large field of methods, from metal complexes to organocatalysts.
The TADDOL auxiliary chelates to various metals e.g. Mg, Pd, or Ti. TADDOL derivatives
can promote enantioselective synthesis as a stoichiometric chiral reagent, but they are also
widely used for catalytic hydrogenation or even metathesis polymerisation.
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Togni constructed a titanium-based TADDOL complex 75 to catalyse the first Lewis acid-
catalysed enantioselective α-fluorination of branched β-keto-esters 76 (Scheme 1.17).69
Scheme 1.17: TADDOL–modified titanium complex.69
The suggested mechanism of fluorination of the β-keto-esters 76 is illustrated below (Scheme
1.18), where titanium promotes the formation of the enolate complex. Consequently, the
TADDOL derivative blocks one face of the enolate complex and thus favors a Si-face attack.
Scheme 1.18: Ti-TADDOL orientates a Si-facial attack.
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Cahard and Shibata have also reported catalytic asymmetric fluorination of β-keto esters 
using PheBOX catalysts.70, 71 PheBOX is a C2-symmetric bis (oxazoline) metal complex,
used in association with NFSI as the source of F+. Their studies have also shown the
importance of the metal in the enantioselective process. The relative coordination symmetry
of the metal is found to control the enantioselectivity of the reaction. For instance, Cu and Ni
complexed to (S)-PheBOX 78, provide the opposite stereoinduction (Scheme 1.19).
Scheme 1.19: Reversible enantioselection induced by PheBOX-metal complexes.
Organocatalysts have been a growth area in recent years in organic chemistry. An early
example was described in 1971, with the enantioselective intramolecular aldol reaction
catalysed by (S)-proline. Fluorination of carbonyl compounds has taken advantage of chiral
amines as catalysts, with electrophilic fluorine reacting on enamine or iminium intermediates.
In 2005, the first asymmetric fluorination controlled by an organocatalyst was carried out on
aldehydes and ketones by Enders and Hüttl.72 Their best result was obtained on
cyclohexanone 82 with the silylated L-hydroxyproline 81, but the reaction proved to be slow
and with a poor enantioselectivity (34% ee) (Scheme 1.20).
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Scheme 1.20: Direct organocatalytic α-fluorination of cyclohexanone.72
There was a subsequent focus on this asymmetric fluorination, and in the same year,
Jørgensen, Barbas, and MacMillan all independently offered new solutions to decrease the
enolisation of the product by improving the design of the organocatalyst. For instance,
Jørgensen reported the enantioselective α-fluorination of an aldehyde 85 with NFSI and at
only 1% loading of catalyst (Scheme 1.21).73 The bulky silylated prolinol 84 proved to be
more reactive than the original L-proline. The high enantioselectivity (up to 97%) is
explained by blockage of the Re-face of the enamine intermediate by the bulky substituents of
the proline derivative.
Scheme 1.21: Jorgensen organocatalytic α-fluorination.73
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Barbas74 and MacMillan75 developed imidazolidones 87 and 88 for the α-fluorination of 
aldehydes (Figure 1.20).
Figure 1.20: Imidazolidinones for α-fluorination of aldehydes. 
They used higher loadings of their catalysts (20-30 mol%) and as in Jørgensen’s work, NFSI
proved the best source of F+ (Scheme 1.22).
Scheme 1.22: Enantioselective α-fluorination of aldehydes by imidazolidone organocatalysts.74, 75
Although the yields and enantioselectivities were excellent, for analyses and purification
purposes, the unstable α-fluorinated aldehydes had to be derivatized in situ either by
reduction to their corresponding alcohols or reaction to hydrazones.
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1.7-Conclusion
This chapter has highlighted the singular properties of fluorine and how it can be used to
influence the behaviour and metabolism of biologically active molecules. The introduction of
fluorine onto a lead molecule often increases its pharmacokinetic properties. Fluorine can
form weak interactions with proteins and provide a more active molecule. The recent
developments in asymmetric synthesis accompanied by the introduction to the market of new
fluorinating reagents have generated a variety of new methods for creating C–F bonds in
organic chemistry and in an enantioselective manner, either by electrophilic or nucleophilic
fluorination processes.
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2- α-Fluorinated capsaicins to alter the 
biological response of TRPV1 pain receptor
2.1- Introduction
Over the last decade TRPV1 (transient receptor potential vanilloid subtype 1) has become the
model receptor for pain signal integration. This receptor constitutes an alternative for pain
treatment to the commonly targeted COX pathway. Management of pain is essential for
patients and the discovery of a new drug target constitutes a prime economical interest for
pharmaceutical companies.
Pain is integrated as an electric signal on nerves by receptors sensitive to a broad array of
stimuli. Such polymodal nociceptors can detect variations in temperature (heat/cold),
mechanical changes (pressure, cuts) and chemical stimuli.1 Activation of these receptors
induces a gradual depolarisation of the membrane that can initiate action potentials when the
membrane potential (typically at -70 mV during resting) reaches a threshold of intensity
(-55 mV). Action potentials are conducted by the axon along the pain pathway to the central
nervous system (CNS).
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A strong noxious stimulus will spontaneously generate a physiological nociceptive pain,
which proves to be useful to the body in playing a role in the protection of healthy tissues.
Pain can also be induced by inflamed tissues. An inflammation is produced by the release of
inflammatory mediators present in the nociceptor, and would typically be associated with
symptomatic signs such as redness, heat, swelling and pain. The nociceptors have a unique
expression profile of receptors, and then show a wide range of reactivity in the transduction of
the stimuli into action potentials. The mechanism of transduction implies the opening of
cation channels that leads to the depolarisation of the neuron endings. Another consequence
of inflammation is the activation of additional ion channels and thus the intensity of sensory
potentials is increased. One of these ion channels is TRPV1 (VR1 on Figure 2.1), a receptor
with a preponderant action in the induction of thermal hyperalgesia.2
Figure 2.1: Sensitisation of neurons endings during inflammation.3
The TRPV1 receptor is also chemically activated by the plant natural product capsaicin 93.4
This receptor is of interest as a new drug target, as antagonists would expand the variety of
molecules used to manage pain. Indeed, current drugs on the market such as aspirin 94,
ibuprofen 95 and celecoxib 96 (non-steroidal anti-inflammatory drugs NSAIDs, Figure 2.2)
act on the cyclooxygenase (COX) pain pathway. They inhibit the synthesis of prostaglandins,
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which are responsible for stimulating the common inflammatory mediators with the TRPV1
pathway, histamine and bradykinine.5
Figure 2.2: Structures of capsaicin and common NSAIDs.
Recent advances show interest in molecules that simultaneously act on the COX and the
TRPV1 pathways.6 Therefore, drug candidates which target the TRPV1 receptor certainly
have potential as anti-inflammatory drug or for analgesic uses.
This study was aimed at testing the TRPV1 receptor response through various fluorinated
analogues of its chemical mediator capsaicin 93. It is proposed to investigate the synthesis of
enantiomers of selectively fluorinated capsaicins 97a/ 97b to establish whether fluorine could
be used as a tool to evaluate the binding conformation of capsaicin on the receptor.
Additionally, it was envisaged that fluorinated derivatives of capsaicin such as
fluorodihydrocapsaicin 98a/ 98b and shorter analogues 99a and 99b could be prepared and
explored as minimal capsaicin analogues (Figure 2.3).
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Figure 2.3: Target enantiomers fluoro-analogues of capsaicin.
The benefits brought to a molecule by the introduction of a single fluorine atom have been
discussed in Chapter 1.5, in particular the modulation of its lipophilicity and pKa. Nowadays,
this approach is established in pharmaceuticals during the drug development process.
However, this study investigates a new approach to the use of fluorine in medicinal chemistry,
in which the protein-ligand interactions are modified by a conformational change induced by
installing a fluorine atom α- to the amide carbonyl. Indeed when a C–F bond is placed on an 
open chain structure adjacent to a carbonyl group such as in α-fluoroamides 100,
stereoelectronic effects dictate that the C–F bond is preferentially aligned antiparallel to the
amide carbonyl and syn to the N–H (Figure 2.4).
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Figure 2.4: The conformational preference of α-fluoroamides 100.
This effect was previously described by O’Hagan et al. in a study evaluating the rotational
energy profile of N-methyl-2-fluoropropionamide 101, illustrated in Figure 2.5 (left).7 There
is a single minimum at 180° on the rotational energy profile of 101 calculated by ab initio
computation, which corresponds to the anti-parallel trans-conformer resulting from C–F/C=O
dipole-dipole relaxation. This trans-conformer is favoured over the syn by ~8 kcal.mol-1.
X-Ray structure analysis of N-phenyl-2-fluoropropionamide 102 also showed the trans-
conformation in the solid state (highlighted in red in Figure 2.5, right).
Figure 2.5: Rotational energy profile (101) and X-Ray structure (102) showing
the preferred anti geometry of NH–CO–CF.7
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Analysis of X-ray structures of α-fluoroamides confirms the planar preference, as in 2-fluoro-
N-(2-fluoroethyl)-propionamide 103 (2°) and N-methyl-2-fluoropropionamide 101 (9.9°).7, 8
A broader search in the Cambridge Structural Database (CSD) highlighted the preference for
the antiperiplanar conformation of non-cyclic structures with F–C–C=O dihedral angles
distributed between 150° and 200° (Figure 2.6).9
Figure 2.6: F–C–C=O dihedral angle in X-ray structures of α-fluoroamides in the CSD.9
As a consequence of this preference, the R2 and R3 groups connected to the fluorinated carbon
are orientated in the predicted manner (Figure 2.4), with fluorine showing limited steric
impact over hydrogen. Therefore, it is suggested that a C–F bond installed adjacent to an
amide group could be used as a design tool to influence the conformation of bioactive amides.
Extending this analysis to the case of capsaicin 93, for the enantiomers of α-fluorocapsaicin 
97, the alkenyl side-chain will be enantiomerically orientated in different directions for each
fluoro-enantiomer. Therefore the relative efficacies of these fluoro-enantiomers (S)-97a and
(R)-97b might report an enantiomeric preference for side-chain binding to the TRPV1
receptor. As a consequence, it informs on the local chiral environment of the receptor,
offering details on the spatial aspects of agonists or antagonist binding.
0
1
2
3
4
5
6
7
0 60 12
0
18
0
24
0
30
0
N
um
be
ro
fh
it
s
F–C–C=O dihedral angle
2.2- TRPV1 receptor
The vanilloid receptor (VR1)
and structurally related molecules
six members of the superfamily of Transient Receptors Potential
has been termed TRPV1. Initially discovered in the central nervous system,
found to be widely distributed
become the model receptor for the TRPV family. The steadily growing interest in this
receptor can be expressed by the number of publications: from 21 articles in 1998 to
average of 500 each year since 2006
determined, its functions are complex due to
Figure 2.7, and a detailed understanding of the control mechanisms
subjected to research.
Figure 2.
was cloned in 1997. It is an ion channel able to bind capsaicin
.10-12 Subsequently, this receptor was classified as one of the
(TRP) cation channel
in the body, even in non-neuronal tissues
. Although the structure of TRPV1
its multiple levels of regulation
of TRPV1 are
7: Mechanisms induced by TRPV1.
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2.2.1- Structure of TRPV1
TRPV1 is a non-selective calcium (Ca2+) channel. Its structure features six transmembrane
(TM) domains, with its N- and C- termini in the cytosol, and has a relatively conserved
hydrophobic pore domain between the fifth and the sixth TM domains (see Figure 2.8). This
topology is characteristic of ion channels and has already been reported in voltage-gated K+
channels.13
Figure 2.8: Model of the structure of transmembrane TRPV1.14
Regarding its primary structure, TRPV1 shares sequence homology with other receptors of
the TRPV family. The C- terminus contains the TRP domain, a 25 amino acid segment highly
conserved in the TRP superfamily. At the other extremity, the long amino terminus contains
three ankyrin-fold domains, which are motifs composed of 33 residues forming two helices
separated by a loop region (Figure 2.9). The ankyrin-repeat domain is a very common
structural motif that accommodates protein-protein interactions. In membrane proteins, this
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motif binds to cytosolic proteins.15 TRPV1 ankyrin-repeats has been found to bind to
calmodulin (CaM), the calcium-binding protein.16
Figure 2.9: Models of TRPV1 N-terminal and C-terminal domains.17
By itself, TRPV1 is a tetramer that forms a large signalling complex when associated with the
G protein-coupled receptor, phospholipase C, and protein kinase C.11 Interestingly, the
TRPV3 gene is adjacent to TRPV1 on the genome and it is co-expressed in neurones of dorsal
root ganglia (DRG), which allows the formation of heteromers with TRPV3 subunits. These
heteromers are thought to increase their functional diversity and, in the case of TRPV3, they
may reduce the response to capsaicin.18, 19
2.2.2- Activation of the TRPV1 receptor
The TRPV1 receptor is activated by capsaicin 93 and its analogues, such as the naturally
occurring resiniferatoxin (RTX) 104 from the Moroccan plant Euphorbia resinifera.4, 12 These
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molecules are lipophilic and the gap time between the injection of capsaicin and the resulting
pungent sensation suggests that the molecules are passing through the cell membrane to bind
to cytoplasmic sites of TRPV1.20 A few other molecules are structurally related to capsaicin
93, such as the endovanilloid neurotransmitter anandamide 105,21 which shows agonistic
properties and the synthetic capsazepine 106 that acts as a competitive antagonist.22
Figure 2.10: Examples of TRPV1 agonists.
2.2.2.1- The critical residues for binding to TRPV1
The primary sequence of TRPV1 has been studied by mutational analysis to discern the
critical amino acids for activation, and this approach revealed the importance of Tyr 511
(Y511) and Ser 512 (S512) for forming interactions with the vanilloid ligand. These amino
acids are located in the cytosol, on a loop region between the second and third TM domains
(Figure 2.11).23 The study has been extended to capsaicin analogues and Leu 547 (L547)
proved to have an influence on the agonist potency of RTX and the antagonist potency of
capsazepine.24, 25 It was finally found that Tyr 550 (Y550) contributes to vanilloid binding,
and Arg 114 (R114) and Glu 761 (E761) help the recognition of agonists.26, 27 These critical
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residues, though widely distributed in the primary sequence are indeed close to each other in
the functional receptor. A third locus, able to control ligand binding, has been found after
mutations in the lipophilic pore between the fifth and sixth TM domain.
The position of Tyr 511 on a cytoplasmic loop directed toward the lipid layer would suggest
that the vanilloid moiety of capsaicin 93 interacts with Tyr 511 and the surrounding amino
acids in the cytoplasm when the lipophilic moiety binds to the lipid interface of the second
and third TM domains.
Figure 2.11: Developing structural model: Domains and amino acids involved in TRPV1 function.11
The key residues responsible for sensitivity to the multiple stimuli can set off a response
cascade when activated. The conformational change induced in the TRPV1 receptor then
generates the calcium influx and favours interactions with other potential activating molecules
such as anandamide 105.28
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2.2.2.2- The activation stimuli
TRPV1 is also activated by stimuli such as acidic pH and high physiological temperature. It is
known that protons influence the receptor at two different levels. Firstly, protons from the
extracellular region potentiate the response to capsaicin and lower the minimum threshold of
temperature. Second, a further acidification (pH <5.3) causes the opening of the channel at
physiological temperature.29 Thus, protons do not interact directly with the vanilloid binding
site but increase the probability of channel opening.
The TRPV1 mechanisms of temperature sensitivity remain unclear. Analysis of the receptors
from the TRP family indicates that some are thermosensitive, in particular, TRPV1-TRPV4
with the presence of a heat-sensor domain confirmed in TRPV1.30 The major role played by
heat on TRPV1 activation is suggested by the existence of a phosphorylation mechanism
(phosphorylases) decreasing the temperature threshold.23, 29, 31
In the case of a selective activation of TRPV1 by capsaicin, the biological response is various,
generating either the expected pain signal, or paradoxically analgesia (Figure 2.8).11 This
desensitisation occurs after a prolonged exposure to capsaicin, and allows patients suffering
from diabetic neuropathies or rheumathoid arthritis to be treated with capsaicin.32 Long
exposure to capsaicin leads to the dephosphorylation of TRPV1, but this is inhibited by
phosphorylation of Ser 116 by PKA (protein kinase A). Calmodulin is also involved in the
desensitisation process. The protein binds to the first ankyrin domain and to the C- terminus
of TRPV1, on the 767-801 segment. Regulation of TRPV1 is also mediated by lipids, such as
anandamide 105, oleoylethanolamide 107 (OEA) and phosphatidylinositol 4,5-bisphosphate
(PIP2) 108 (Figure 2.12).21
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Figure 2.12: Example of lipids that regulates TRPV1.
2.2.3- Recent structural insights
Recently, the structure of TRPV1 was further resolved by electron cryomicroscopy. The
recombinant receptor gene (rat) was expressed in the yeast, Saccharomyces cerevisiae.
Cryomicroscopy is the technique of choice to study biological macromolecular assemblies in
their native environment. The resultant three-dimensional structure of the 500 KDa protein is
represented in Figure 2.13 as an isosurface.
Figure 2.13: 3-D representation of rat TRPV1 as deduced by cryomicrospcopy.33
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The structure is composed of two distinct parts and exhibits a clear four-fold symmetry. A
small compact region is believed to be the transmembrane region consistent with a channel
function. The larger region comprises 70% of the total volume and is proposed to be
orientated toward the cytoplasm and locates the N- and C-termini. The two regions have been
assigned by fitting crystal structures of homologous channel and isolated TRPV1 ankyrin
domains.33
Molecular modelling based on gene homology has also guided the developing structural
hypothesis. The full TRPV1 receptor has been constructed by assembling the different regions
following all available physical, biochemical and functional information (Figure 2.14).17
Figure 2.14: Global view of TRPV1 model inserted into the lipid bilayer
(left: closed state, right: desensitised state of TRPV1).17
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2.3- Capsaicinoids
2.3.1- Structural elucidation of the capsaicinoids
Capsaicinoids are a large family of natural products related to the parent capsaicin (8-methyl-
N-vanillyl-6-nonenamide) 93, discovered in 1961 by Japanese chemists.34 However, capsaicin
93 was already known to be the molecule giving chilli peppers (Capsicum) their spiciness.
Indeed, in 1919, Nelson showed the pungency of chillis resulted from vanillyl amides35 and
contributed to solving the structure of capsaicin in 1923.36 All capsaicinoids have a common
vanillylamine moiety, linked to a variable acyl group where variation affects the degree of the
pungency.37
The pungency is measured by the Scoville organoleptic test, a test of dilution of a pepper
extract in sugar syrup. The Scoville scale ranks 0 Scoville Heat Units (SHU) for Bell pepper,
30.000 SHU for cayenne pepper and reaches 1 million SHU for Naga Jolokia (Ghost pepper).
In comparison, pure capsaicin is evaluated at 16 million SHU and law enforcement grade
pepper sprays are formulated at 5 million SHU (see Table 2.1).
Because of their spiciness, capsaicinoids are used as repellents against mammals. For
example, veterinary surgery applies them to protect sutures. They can be added to coatings for
protection of seeds or cables, or additives in toxic products such as paints or liquid soaps to
prevent accidental ingestion.
Beyond their spiciness, capsaicinoids have been used through the ages in empirical medicine
to cure, for example, arthritic pain. It has also been shown in recent studies that capsaicin has
anti-inflammatory, anti-cancer and anti-obesity properties.
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Structure of R Capsaicinoid Pungency*
Capsaicin 93 16
Dihydrocapsaicin 109 15
Nordihydrocapsaicin 110 9
Homocapsaicin 111 8.6
Homodihydrocapsaicin 112 8.6
Pseudocapsaicin 113 NA
*Scoville Heat Units x106
Table 2.1: Structure and pungency of some capsaicinoids.
2.3.2- Biosynthesis of capsaicin
The capsaicinoids natural products are exclusive to the peppers (genre Capsicum). The
biosynthesis of capsaicin 93 by the key enzyme capsaicin synthase occurs in the epidermal
cells of the fruit placenta, easily recognised as it makes the white flesh surrounding the seeds.
The enzyme couples vanillylamine 118 and 8-methylnonenoate 120 to generate an amide
bond (Scheme 2.1). It is thought the steps leading from feruloyl-CoA 114 to vanillylamine
118 involving hydroxycinnamoylcoA hydratase/lyase and potentially an aminotransferase, are
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specific to peppers. The spiciness of the peppers is correlated to the amount of capsaicinoid
and depends on the gene expression of the enzymes driving the capsaicin biosynthetic
pathway.
capsaicin 93
vanillylamine 118
vanillin 117
4-hydroxy-3-methoxyphenyl- -hydroxypropionyl-CoA 116
feruloyl-CoA 115
caffeoyl-CoA 114
(E)-8-methylnon-6-enoic acid 120
isobutyryl-CoA 119
capsaicin synthase
putative
aminotransferase
hydroxycinnamoyl-CoA
hydratase/ lyase
hydroxycinnamoyl-CoA
hydratase/ lyase
caf feoyl-CoA-O-methyltransferase
fatty acid synthase
N
H
O
OH
MeO
O
HO
HO
HO
O
CoA
HO
MeO
O
CoA
HO
MeO
O
CoA
HO
HO
MeO
O
HO
MeO
NH2
CoA-S
O
Scheme 2.1: Biosynthesis of capsaicin 93.38
Chapter 2
64
2.4- Previous syntheses of capsaicin
The structure of the capsaicinoids is conveniently divided into two distinct parts, each being
responsible for an effect on TRPV1. The benzylamine moiety is retained through the family.
It is known to be responsible for binding to the TRPV1 receptor, and this essential role
restricts structural variation. Varying the length of the chain, the presence of functionalities or
the degree of saturation (Figure 2.15) tunes potency. The mid-region can also be modified
where the original amide bond is inverted or replaced by an ester, to generate derivatives such
as homovanillic acid amides and capsiates.
Figure 2.15: Structure of capsaicin.
Interest in capsaicinoids started at the beginning of the 20th century. After the synthesis of
vanillylacyl-amides reported by Nelson in 1919,35 Späth and Darling described the first
synthesis of capsaicin in 1930.39 The retro-synthesis of these compounds disconnects
capsaicin 93 at the amide bond. The benzylamine moiety derives from vanillin 117 and the
resultant lipidic precursor is therefore (E)-8-methylnon-6-enoic acid 120 (Scheme 2.2). Full
syntheses of capsaicin has been completed at various periods but any synthetic approach to
capsaicin or its derivatives requires high stereochemical control of the (E)-double bond.
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Scheme 2.2: Retrosynthesis of capsaicin.
2.4.1- Synthesis of vanillylamine
Nelson prepared vanillyl oxime 121 by heating vanillin 117 with hydroxylamine. The
resultant oxime was then reduced with sodium amalgam to generate the amine, and isolated as
the hydrochloride salt.40 Ganett assayed palladium and platinum to catalyse this reduction.41
PtO2 led to partial over-reduction and a method was developed using palladium on carbon to
provide the vanillylamine hydrochloride 118 (Scheme 2.3).
Scheme 2.3: Synthesis of vanillylamine hydrochloride.
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2.4.2- Syntheses of 8-methylnon-6-enoic acid
Späth and Darling were the first to prepare 8-methylnon-6-enoic acid 120 as shown in
Scheme 2.4. This involved an organozinc addition to acyl chloride 122. Reduction and
bromination then gave the acid 125. However the elimination of HBr gave rise to a mixture of
both E and Z isomers, and these geometric isomers could not be separated by
chromatography, distillation or crystallisation, so this synthesis was rather unsatisfactory.39
Scheme 2.4: Early approach to acyl moiety 120.39
In order to improve both the regio- and stereo- selectivity, Crombie and co-workers emerged
with an impressive solution.42 They treated 3-chloro-pyran 127 with sodium metal to generate
only the (E)- isomer of alcohol 128 by elimination. This stereospecificity arises as a
consequence of elimination from the 6-membered ring. This reaction proved to be
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regiospecific as only isobutyraldehyde was obtained after ozonolysis. Bromination of the
alcohol 128 into 129 followed by a malonate condensation/decarboxylation sequence
completed this elegant synthesis to 8-methylnon-6-enoic acid 120 (Scheme 2.5).
Scheme 2.5: Crombie’s controlled elimination route to 8-methylnon-6-enoic acid 120.42
2.4.3- The Wittig approach
The synthetic method developed by Crombie and described above (Scheme 2.5) was
successfully used for the synthesis of capsaicin 93. However, it suffered from a lack of
generality in its ability to provide a variety of capsaicinoids. Therefore, Gannet applied a
Wittig approach to construct the double-bond.41 This approach also offered more structural
variety.
The condensation of ω-oxo-esters 130 with an isopropylphosphonium salt 131 lead to the
predominant (Z)-alkene 132b with an E/Z ratio between 1:4 and 1:10, depending on the
conditions of the reaction, with the best results obtained with potassium tert-butoxide in
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DMF. The ylide produced during the reaction is not stabilised and consequently the (Z)-
isomer predominates (Scheme 2.6).
Scheme 2.6: Wittig approach to capsaicinoid synthesis.41
An alternative approach to obtain the (E)-series applied the Kocienski-Lythgoe-Julia
procedure, which allowed reductive elimination of a benzoyloxy-sulfone to obtain a 9:1 E/Z
mixture in good yields (70%).43 The method requires that ω-oxo-esters 130 are condensed
with isobutylphenyl sulfone 133 and benzoyl chloride, to generate the benzoyloxy-sulfone
134 as a 3:1 mixture of diastereoisomers. Subsequent treatment with sodium amalgam lead to
a non-stereospecific elimination, but giving the thermodynamically favoured (E)-alkene 132a
(Scheme 2.7).
Scheme 2.7: The Kocienski-Julia-Lythgoe procedure.43
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Introducing the (E)-double-bond can also be achieved by isomerisation of (Z)-products,
prepared by the Wittig chemistry. Gannett has reported a photochemical isomerization (hν,
hexane, I2 as catalyst) of the (Z)-side chain leading to an E/Z ratio of 7:3 from an initial ratio
of 1:10.41 Kaga and co-workers used a nitrous acid-induced isomerization of Z to E olefins for
a synthesis of capsaicin,44 a method previously reported by Sonnet for the synthesis of insect
sex pheromones and E-fatty acids such as for 135.45 This method allowed a maximum E/Z
ratio of 8:1 from a starting mixture of 1:11 (Scheme 2.8).
Scheme 2.8: Isomerisation of the double-bond.45
2.4.4- The Ortho-ester Claisen rearrangement
The (E)-olefination procedures reported above are based on regioselective elimination
mechanisms and show only moderate to good stereoselectivities. However, these methods did
generate reasonable amounts of capsaicinoids for biological investigations, particularly as
natural capsaicinoid extracts are contaminated with structurally related amides. In order to
eliminate any (Z)-capsaicinoids in these synthetic routes, Kaga developed a method based on
the use of the Claisen orthoester rearrangement (Scheme 2.9).46
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Scheme 2.9: Claisen rearrangement and malonic ester synthesis.46
The method requires that an allylic alcohol 137 is prepared by a Grignard reaction of the
corresponding aldehyde 136 with vinyl magnesium bromide. The product is then subjected to
a Claisen ortho-ester rearrangement by heating with triethyl orthoacetate in the presence of a
catalytic amount of propionic acid. The intermediate (E)-6-methyl-4-heptenoate 138 is
obtained with a very high E/Z ratio of >100:1. This route also presented the potential for an
iterative synthesis since all of the homologues were prepared via carbon chain elongation
either by cyanation or by malonic acid ester synthesis.
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2.5- Aims and objectives
As discussed previously, the fluoro-amide motif NH–CO–CF displays a strongly preferred
C–F/C=O trans planar conformation. It was envisaged that both enantiomers (S)-97a and
(R)-97b (see p. 50, Figure 2.3) would be prepared for comparative biological assay with the
TRPV1 receptor. It was also envisaged that enantiomers of shorter chain analogues of α-
fluorocapsaicin would be prepared for further comparison with the TRPV1 receptor.
In the case of fluorocapsaicin 97, the double-bond could be accessed by a “classical” Wittig
route or a cross-metathesis method, never previously been attempted for the synthesis of
capsaicinoids. Installation of fluorine would be explored using asymmetric oxazolidinone
methodology. A cross-metathesis strategy requires ethyl 6-heptenoate 175 coupled to the
chiral oxazolidinone. Three general strategies emerge (Scheme 2.10) with the cross-
metathesis being attempted on ester 144, the N-acyloxazolidinone 170 or the fluorinated
N-acyl oxazolidinone 172a.
Scheme 2.10: Three general approaches to 2-fluorocapsaicin analogues.
Chapter 2
72
The Wittig route could start from ethyl 6-hydroxyhexanoate 179, which requires to be
oxidised to the corresponding aldehyde 180 for reaction to generate (E)-ethyl 8-methyl-non-6-
enoate 181. Hydrolysis followed by coupling to a chiral oxazolidinone would then provide a
strategy for asymmetric fluorination as illustrated in Scheme 2.11.
Scheme 2.11: Wittig approach to 2-fluoro enantiomers of capsaicin.
Removal of the chiral oxazolidinone by standard methods would allow coupling to
vanillylamine 118 to complete the synthesis.
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The synthesis of (R) or (S)- 2-fluoro dehydrocapsaicins 98a/b is also envisaged by a
hydrogenation reaction of the corresponding fluorinated capsaicin 97 or one of the synthetic
precursors 187 or 174 (Scheme 2.12).
Scheme 2.12: Route to (S)-2-fluorodehydrocapsaicin 98a.
Scheme 2.13 shows the envisaged synthesis of short chain analogues of capsaicin by
deaminative fluorination of the amino acid leucine 224 to generate the corresponding 2-
fluorocarboxylic acid 227.
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Scheme 2.13: Deaminative fluorination to generate 99.
Alternatively, the synthesis of 2-fluoroacid 227 could be approached using the MacMillan
asymmetric fluorination to compare the enantioselectivity as illustrated in Scheme 2.14.
Scheme 2.14: Envisaged synthesis of 181 with Macmillan asymmetric fluorination strategy.
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2.6- Results and discussion
2.6.1- Synthesis of (S)-fluorocapsaicin 97a with Evans’oxazolidinone chiral
auxiliary
2.6.1.1- Cross-metathesis (CM) strategy
Cross-metathesis (CM) was addressed as a method of olefin introduction. Catalysts 142 and
143, are coordinating ruthenium to an N-heterocycle carbene ligand (Figure 2.16). They
tolerate a wide range of functional groups in the structure of the alkene.
Figure 2.16: Examples of CM catalysts.
Preliminary experiments were explored to evaluate the best conditions for the cross-
metathesis of olefins 144 and 145 to generate 146. Ethyl 6-heptenoate 144 was treated with
3-methyl-1-butene 145 (5-20 eq) using the Grubbs II catalyst 142 (5-30 mol%), for reactions
up to 2 days (Scheme 2.15).47
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Scheme 2.15: Assay of CM with ethyl 6-heptanoate 144.
Two products were isolated when 10 mol% catalyst was used, the desired product 146 and a
homodimer 147. Dimer 147 resulted from self cross-metathesis of 144. After purification, 146
was recovered but in a poor yield (12%). It was found that, after extended reaction times and
at any concentration of catalyst 142, the product 146 started to degrade, even though the
reaction had not gone to completion. It appeared that the volatility of 3-methyl-1-butene
prevented its entering the catalytic cycle despite a large excess (20 eq), and thus self-
metathesis of the alkene 144 (R1=) emerged as the major product (Scheme 2.16).48
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Scheme 2.16: The mechanism for cross-metathesis reaction.
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This initial study revealed that the self condensation side-reaction was significant.
Nevertheless, it was decided to prepare the enantiopure N-acylated oxazolidinones 170/171
for asymmetric fluorination studies (Figure 2.17). Successful fluorination would then provide
a suitable substrate for further CM exploration.
Figure 2.17: N-Acylated oxazolidinones substrates for CM and asymmetric fluorination.
A general method for the preparation of chiral N-acylated oxazolidinones 157 involved
condensation of the carbamate with an acyl chloride (Scheme 2.17). A wide range of
electrophiles including N-bromosuccinimide,49 di-tert-butylazodicarboxylate,50 tosyl azide,51
alkyl halide52 or electrophilic fluorinating reagents53 can then react with the enolate 158 to
insert specific functional groups α to the carbonyl, in an asymmetric manner. These reactions
are often highly stereoselective and have led to products 159-162 with diastereoisomeric
excesses (d.e.) higher than 90%.
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Scheme 2.17: Example of electrophilic insertion into enolates of oxazolidinone auxiliaries.49-54
Disubstitution at 5-position of the oxazolidinone ring is believed to prevent nucleophilic
attack to the carbamate carbonyl.55, 56 The heterocyclic core of the oxazolidinone is quite flat.
Substitution at C-4 is designed to hinder one face of the enolate and promote electrophilic
attack to the opposite face.57
The use of such chiral oxazolidinones constituted our method of choice as they have already
proven to be efficient for asymmetric electrophilic fluorination. In particular, Davis has
developed diastereoselective electrophilic fluorinations, using Evans’ oxazolidinones applied
to the synthesis of α-fluoroacids,53 α-fluoroketones58 and fluorinated carbohydrates.59
Marquez used the method for the synthesis of a fluorinated intermediate of an anti-HIV
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drug.60 Staunton, has also described the use of a chiral auxiliary for asymmetric fluorination
of analogues of the antibiotic tetronasin.61
The fluorination requires electrophilic fluorinating reagents to react with the enolate. The
strategy was first developed with NFOBS, but more recent studies have shown that NFSI
achieves the best stereoselectivity (Scheme 2.18).
Scheme 2.18: Electrophilic fluorination using oxazolidinone auxiliaries.
A summary of the conditions for these studies are reported in Table 2.2 and shows that
fluorinated products could be formed in good yields (up to 86%) and high diastereoselectivity
(de > 95%).62
Entry R1 R2 R3 F+ reagent Base Yield d.e.
1 H iPr nBu NFOBS LDA 85% 96%
2 H iPr tert-Bu NFOBS LDA 80% 97%
3 Ph Me Ph NFOBS LDA 86% 86%
4 Ph Me Ph NFSI NaHMDS 85% 97%
5 H Bn C5H9 NFSI LiHMDS 78% 98%
Table 2.2: Selective electrophilic α-fluorination using oxazolidinone auxiliaries.62
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Accordingly, in our case, the synthesis of N-acylated oxazolidinones 170 and 171 started with
the alkaline hydrolysis of ethyl 6-heptenoate 144, followed by acidic work-up to give
carboxylic acid 165, which was purified by distillation (Scheme 2.19).
Scheme 2.19: Hydrolysis of ethyl 6-heptenoate 144.
6-Heptenoic acid 165 (1 eq) was then treated with pivaloyl chloride 166 to generate the mixed
anhydride 167 (Scheme 2.20). This intermediate was immediately coupled to the Evans
auxiliaries 4-(S)-4-isopropyl-2-oxazolidinone 168 or 4-(S)-4-isopropyl-5,5-diphenyl-2-
oxazolidinone 169. The intermediate was pre-treated in a separate flask with n-butyllithium
(1 eq), and the coupling of 168 and 169 gave the respective acylated products 170 and 171 in
high yields (86% and 91% respectively).63 In some preparations, pivaloyl chloride 166, which
was in an excess (1.3 eq), reacted with the oxazolidinone to form the N-pivaloyloxazolidinone
side-product, but this was maintained at low level (<5%).
Scheme 2.20: Strategy to the chiral acylated auxiliary.
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The two oxazolidinones 168 and 169 were separately investigated in asymmetric fluorination
reactions. The fluorination is directed by the configuration of the isopropyl chain and the
phenyl substituents at position 5 of 169 should increase its ability to crystallise, an important
factor in improving the ultimate enantiopurity.
Asymmetric fluorination of 170 using lithium bis(trimethylsilylamide) (1.1 eq) and NFSI
(1.3 eq) was carried out at -78 oC.59 This gave 172 with an 80% conversion (GCMS) but the
apparatus had not been calibrated specifically before the analysis and the final result showed a
loss in the conversion as only 20% of 172 were recovered after purification (Scheme 2.21).
Scheme 2.21: Asymmetric fluorination of N-acyloxazolidinones.
Direct 19F NMR analysis of the product of 170 indicated a conversion into the two fluorinated
diastereoisomers 172a and 172b with an 82% diastereomeric excess. The major product was
assumed to be the (S,S)-172a stereoisomer. With 171, where the C-5 substituents were phenyl
groups, the diastereoisomer 173a was obtained but only with 38% de (see Figure 2.18). These
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results clearly suggest that the phenyl groups hinder the diastereoselective discrimination by
NFSI.
Figure 2.18: 19F NMR (282 MHz) spectra showing the diastereomeric ratios for the products of the
asymmetric fluorination reactions (A: (S,S)-172a, B: (S,R)-172b, C: (S,S)-173a, D: (S,R)-173b).
The previously optimised conditions for the cross-metathesis reaction for use with 3-methyl-
1-butene were explored for 172 (172a:172b 9:1) and 173 (173a:173b 7:3) (see Scheme 2.22).
A solution of 172 in DCM was treated with 3-methyl-1-butene (20 eq) and Grubbs II catalyst
142 (10 mol%) for 20 h at 40 °C. This gave (S,S,E)-174a as the major product and with a 54%
yield.
Scheme 2.22: Cross-metathesis reaction on N-fluoroacyl oxazolidinone 185.
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19F NMR of the crude mixture (Figure 2.19) indicated that the double-bond stereochemistry
was formed in a 87:13 ratio in favour of (E)-174a. It was also noted that (S,R)-172b present in
the initial mixture was quantitatively converted to one product that we assumed to be the
corresponding E-product of the cross-metathesis reaction (S,R,E)-174c.
Figure 2.19: 19F NMR (282 MHz) showing the conversion in E-and Z- alkenes 174
(A: (S,S,Z)-174b, B: (S,S,E)-174a, C: (S,S)-172a, D: (S,R,E)-174c, E: (S,R)-172b).
The diastereoselectivity of the fluorination process first described by Davis59 has been
confirmed in these reactions (82% for 172a). The diastereomeric ratio has been increased
after the CM by purification on silica gel where the two diastereoisomers were successfully
separated and the (S,S,E)-174a isomer was recovered in an enantiopure form.
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2.6.1.2- Wittig strategy41
The Wittig strategy was developed to obtain more material of 174a and 174c to explore the
syntheses of fluorocapsaicin 97a and 97b further. Treatment of triphenylphosphine 175 (1 eq)
with 1-iodo-2-methylpropane 176 (1 eq) in refluxing toluene provided the desired
phosphonium iodide 177 in good yield (> 80%) (Scheme 2.23). This phosphonium salt 177
(1.1 eq) was subsequently treated with n-butyllithium (1 eq) to give a solution of ylide 178
that was used directly in a Wittig condensation with aldehyde 180.
Scheme 2.23: Synthesis of the Wittig reagent.
The required aldehyde 180 was prepared by oxidation of ethyl 6-hydroxyhexanoate 179 (1 eq)
with pyridinium chlorochromate (PCC) (Scheme 2.24).
Scheme 2.24: Wittig condensation strategy to generate ester 181.
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However, treatment of ylide 178 (1 eq) with aldehyde 180 (1.3 eq) did not result in the desired
olefin 181, and only starting material was recovered.
In order to establish if the ylide was of good integrity, a reaction with hexanal 182 was carried
out under the same conditions, and this proceeded smoothly (82%) as illustrated in
Scheme 2.25. This observation suggested that the Wittig with aldehyde 180 was in some way
compromised by the ester function.
Scheme 2.25: Assay of Wittig condensation.
2.6.1.3- Inverse Wittig route
The Wittig method described by Kaga in 1989, based on an inverse reaction appears well
suited to the large scale synthesis of capsaicin.44 An eight step sequence could then afford the
desired fluoro-analogues of capsaicin. Recrystallisation of the intermediates was anticipated
to offer a method to improve the enantiomeric purity. After isomerisation of carboxylic acid
(Z)-187, and coupling to the 4-(S)-4-isopropyl-2-oxazolidinone 168, α-fluorination of 189
would then give the N-fluoroacyl oxazolidinone 174a. Hydrolytic cleavage and coupling to
vanillylamine 118 would then afford the desired fluorocapsaicin 97a.
Chapter 2
86
Accordingly, 6-bromohexanoic acid 184 was treated with triphenylphosphine to generate salt
185 in an almost quantitative reaction (97%). The reaction was judged completed when the
mixture went glassy. The use of toluene as a solvent gave 185 in a decreased yield (86%) and
therefore for future preparations the reaction was conducted without solvent (Scheme 2.26).
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Br
O
HO
P+
Ph
Ph
Ph
Br-
PPh3+
Neat
145 °C, 4 h
97%
184 185
Scheme 2.26: Preparation of phosphonium salt 185.
The phosphonium salt 185 was then treated with tBuOK (2 eq) to obtain the corresponding
ylide (not isolated) which was reacted directly with isobutylaldehyde 186. This gave a
mixture of (Z)- and (E)-187 isomers with a Z/E ratio of 90:10 as determined by 1H NMR. This
was similar to the ratio (92:8) reported in the literature (Scheme 2.27).44
Scheme 2.27: The retro-Wittig condensation to 8-methylnon 6-enoic acid 187.
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This isomer mixture of 187 was treated with 2 M sodium nitrate/6 M nitric acid to promote an
isomerisation to the E-isomer. This reaction gave an inverse E/Z ratio of 86:14, also similar to
the 89:11 ratio reported in the literature (Scheme 2.28).44
Scheme 2.28: Isomerisation of (Z)- to (E)-8-methylnon 6-enoic acid 187.
The coexistence of the Z and E isomers is illustrated on Figure 2.20.
Figure 2.20: 1H NMR (300 MHz) spectrum of E-187 (E:Z 86:14), expanding the alkene and iPr CH
signals.
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Coupling to the chiral auxiliary was achieved as described previously to give the N-acylated
oxazolidinone 189 (Scheme 2.29). The E/Z ratio of 86:14 was kept all over the synthesis.
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71%
NHO
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188
168166 NO
O O
189
O
Cl
Scheme 2.29: Synthesis of the chiral acylated auxiliary 189.
This product 189 was fluorinated using LiHMDS/NFSI to give 174a, according to the
established method described above. The conversion of 189 to 174a was good, consistent with
previous reactions (84% de, 83% conversion but only 20% isolated yield) (Scheme 2.30).
Scheme 2.30: Synthesis of (S,S,E)-174a.
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2.6.1.4- Removal of the Evans auxiliary
Removal of the Evans auxiliary is a challenge, particularly as racemisation needs to be
avoided. Several methods (Scheme 2.31) have been reported including lithium borohydride to
obtain the reduced alcohol 191,64 or with lithium hydroperoxide to release the carboxylic acid
192.65 Direct formation of a Weinreb amide 193 provides an aldehyde 194 or a ketone 195
after treatment with DIBAL or a Grignard reagent respectively.66 Finally, DIBAL affords the
aldehyde directly from the oxazolidino-imide, but it can also competitively reduce the
auxiliary and consequently decreases conversion to the aldehyde.67
Scheme 2.31: Alternative approaches for Evans auxiliary removal.
Two methods were explored for cleavage of the α-fluoroacyl moiety from the Evans auxiliary. 
Firstly, the Weinreb amide route was attempted and secondly, hydrolysis was explored with
lithium hydroxyperoxide. This latter method was already described by Evans but it was noted
that some racemisation of the α-fluorine stereogenic center could occur.65 Initial studies
toward this reaction were explored on (R)-3-phenylbutyric acid 196 as a model compound
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(Scheme 2.32). The synthesis of products 198 and 199 were realised under the same
conditions as described previously and in a straightforward manner.
Scheme 2.32: Synthesis of N-acyloxazolidinone model 198.
The fluorinated products were obtained with approximately 70% conversion. Two signals in
19F NMR, at -198.2 ppm and -196.4 ppm, in a ratio of 63:37 were observed in the crude
mixture. The major product was purified and isolated to give the (S,S,S)-199 in a 97/3 ratio
(51% yield) (Scheme 2.34).
Scheme 2.33: Fluorination of model compound.
The Weinreb amide 201 (96% de) was obtained after treatment of 199 with N,O-dimethyl-
hydroxylamine hydrochloride 200 (Scheme 2.34).58 Cleavage of 201 with DIBAL was
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attempted twice under the same conditions, but these reactions were unsuccessful and only the
starting material was recovered.68
Scheme 2.34: Deacylation via reduction of the Weinreb amide intermediate.
Therefore, in a further attempt to perform the acyl cleavage, 199 was treated with an aqueous
solution of H2O2 (35%) and lithium hydroxide (Scheme 2.35). To avoid racemisation of the
stereogenic centre carrying the fluorine under the literature conditions,69 only half an
equivalent of hydrogen peroxide was used to provide the α-fluorinated carboxylic acid 203 in
good yield (92%), and under these conditions, no racemisation was observed by 19F NMR
compared to 199.
Scheme 2.35: Exploration of deacylation with peroxides.
With this model study completed, N-acyl oxazolidinone 174a was treated similarly (Scheme
2.36) with lithium hydroperoxide, affording carboxylic acid 204 was obtained yield (95%).
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Two peaks were observed in the fluorine NMR of the product at -192.6 ppm and -192.7 ppm,
in a 1:9 ratio, corresponding respectively to (S,Z)-204 and (S,E)-204. At this stage, it was not
possible to determine whether any racemisation had occurred on this product and therefore
amide formation with (S)-1-phenylethylamine 205a was carried out as a double check to
create a set of diastereoisomers from the product.
Scheme 2.36: Hydrolysis of 174a.
The reaction with (S)-1-phenylethylamine 205 gave amide (S,S,E)-206a. As a control, a
diastereomeric mixture 206 with the racemic amide was also prepared.
Scheme 2.37: Study on fluorine racemisation.
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19F NMR of the synthesised amides shows two signals corresponding to (S,S,E)- and (S,S,Z)-
206 with a 92/8 ratio (Figure 2.21 right).
Racemic control Asymmetric analysis
Figure 2.21: 19F NMR of 206 (A: (R,S,E)-206c, B: (R,S,Z)-206d, C: (S,S,E)-206a, D: (S,S,Z)-206b).
For the racemic amide, four signals were observed, indicating now two different sets of
signals (Figure 2.21 left). The minor signals corresponded to the Z double-bond (9/1 ratio in
favour of the E). Accordingly it was concluded that no racemisation occurred during
deprotection.
2.6.1.5- Amide coupling to generate α-fluorocapsaicins 
The synthesis of oxime 207 was initially attempted by treatment of vanillin (1 eq) with
hydroxylammonium chloride (1.1 eq) in refluxing methanol using pyridine or triethylamine as
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a base, however, these reactions failed.41 In the event, the reaction was achieved in water at
80 °C, using sodium acetate (1 eq) as a base, and this gave oxime 121 in good yield (78%)
(Scheme 2.38).70
Scheme 2.38: Synthesis of the vanillylamine moiety.
Vanillylamine 118 was then prepared by direct hydrogenation of oxime 121 using 10%
palladium on charcoal. The reaction was carried out in ethanol, under acidic conditions using
concentrated hydrochloric acid. To avoid over-reduction of the aromatics, hydrogen was used
at atmospheric pressure. This reaction gave vanillylamine hydrochloride 118 in high yield
(98%) (see Scheme 2.38).
In order to complete the synthesis of (S)-97a, the α-fluorinated carboxylic acid 204 was
activated with HOBt (1.05 eq) and EDC (1.05 eq) before coupling to the vanillylamine 118.
This gave the fluorocapsaicin in a modest yield (32%) (Scheme 2.39).
Scheme 2.39: (S)-2-Fluorocapsaicin amide coupling.
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2.6.1.6- Route to dehydrocapsaicin
The synthesis of the 2-fluorinated dehydrocapsaicin was also explored to evaluate the
influence of the saturated chain when assayed with TRPV1, even though this structural
variation only causes a small loss of activity on the natural DHC. Direct hydrogenation of
oxazolidinone 174a was first attempted. A total synthesis of α-fluorodehydrocapsaicin was 
then explored from the saturated carboxylic acid 208.
Accordingly 174a was treated under the same conditions as previously described by Ganett41
for the synthesis of dehydrocapsaicin, using 10% palladium on charcoal. The reaction was
carried out in ethanol, under acidic conditions (conc. HCl), and hydrogen gas was introduced
at atmospheric pressure (Scheme 2.40).
Scheme 2.40: Direct hydrogenation of 174a.
Product 208 was obtained, in a modest yield and it proved difficult to improve the conversion.
However, the removal of the double-bond allowed us to determine with a high degree of
accuracy the diastereomeric excess of 208 and 19F NMR analysis revealed that 208 was
obtained with 96% ee. This result is to be compared with 199 and 203 and shows that the
stereo integrity of the fluorine is maintained along the synthesis.
In an alternative approach to obtain 208, the carboxylic acid 187b (as a 90/10 mixture of
Z/E isomers) was first treated with 10% palladium on charcoal. The reaction was carried out
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in ethanol, under acidic conditions (conc. HCl) and hydrogen was introduced at atmospheric
pressure to provide the saturated carboxylic acid 209 (Scheme 2.41).
Scheme 2.41: Hydrogenation of (Z)-8-methylnonenoic acid 209.
The saturated acid 209 was used directly for coupling to the oxazolidinone 168 in a
straightforward manner (Scheme 2.42).
Scheme 2.42: Synthesis of the N-acylated oxazolidinone 210.
The resultant N-acylated oxazolidinone 210 was then fluorinated as described earlier with
NFSI (Scheme 2.43), before undergoing hydrolysis to give carboxylic acid 211.
Scheme 2.43: Asymmetric fluorination of N-acyl oxazolidinone 210.
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In order to improve the conversion of the fluorination reaction, various fluorinating reagents
were assayed for reaction with 210, and the conditions are summarised in Table 2.3.
Entry Fluorinatingreagent Base Conditions
19F Peaks, Yield
1 NFSI 1.3 eq LiHMDS 1.1 eq i -194.5 ppm
44%
2 NFSI 1.3 eq LDA 1.1 eq i -194.5 ppm
<5%
3 Selectfluor 1.3 eq LiHMDS 1.1 eq ii -173.1, -115.1,
-102.6, -99.6, -93.4 ppm
4 Accufluor 1.5 eq LDA 2 eq iii -171.5, -187.9 ppm
i: THF,-78 °C, 3 h; ii: ACN, 0 °C then rt, 5d; iii: ACN, rt, 1d.
Table 2.3: Attempts of fluorination of N-acyl oxazolidinone 210.
Entry 1 shows that the reaction setup in conditions previously used didn’t go to completion
(44%), but a poorer result was obtained using LDA as a base (entry 2). Other electrophilic
fluorinating reagents proved to be less reactive and reactions were carried out at warmer
temperatures for up to 5 days but did not give identifiable products (entry 3-4).
Hydrolysis to 2-fluoromethylnonanoic acid 211 was achieved in the same conditions as for
2-fluoromethylnonenoic acid 204 (Scheme 2.44).
Scheme 2.44: Synthesis of 2-fluoromethylnonanoic acid.
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However in this case, product also contained the non-fluorinated acid 209 (<20%).
Purification by chromatography proved to be difficult and did not allow separation of the
fluorinated from the non-fluorinated product.
2.6.2- The use of imidazolidinones as organocatalyst for asymmetric α-
fluorination
When this work started, several organocatalytic methods had just been published separately
by Jørgensen,71 Barbas72 and MacMillan.73 Imidazolidinones such as 212 promote enamine
catalysis from aldehydes 213, reacting with a wide variety of electrophiles. For electrophilic
fluorination, the enamine intermediate 214a reacts with electrophilic NFSI to generate an α-
fluoroaldehyde 216 (Scheme 2.45).73
Scheme 2.45: MacMillan catalytic cycle.
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Macmillan’s method generates an α-fluoroaldehyde 216 which was reduced immediately to
facilitate enantiomeric analysis. The enantioselectivity of the reaction is generally high,
ranging from 91% to 99% ee.
Alongside the oxazolidinone project, Dr Margit Winkler at St. Andrews, explored the
MacMillan asymmetric fluorination method, to access the α-fluoroacid 204 in two steps from
the corresponding aldehyde 219.74 The synthetic route is shown in Scheme 2.46.
Scheme 2.46: Synthesis of fluorocapsaicin with MacMillan fluorination.74
The key reaction involved asymmetric fluorination following the conditions reported by
MacMillan.73 (R)- and (S)- α-Fluoroaldehydes 220a/b were thus obtained in high ee (90%).
However, imidazolidinone 212 is not very discriminating toward its substrate and thus this
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system also generated 15-20% of α,α-difluorinated aldehyde 221 (Figure 2.24, p.107 shows
the GC-MS trace).
Oxidation and then coupling of the resultant carboxylic acid to vanillylamine generated (R)-
and (S)- fluorinated capsaicin 97a/b (96% and 95% ee after recrystallisation from hexane).
The (E)-8-methylnon-6-enoyl chloride 217 was provided as “predominantly E” by Sigma-
Aldrich and GC-MS analysis revealed an E/Z ratio of 89:11. This ratio was similar to the
result of cross-metathesis reaction, and was unfortunately maintained all along the synthesis
of 97.
A suitable crystal was isolated and X-Ray crystallography confirmed the structure and
absolute stereochemistry of (S)-97a. It also revealed the expected anti planar orientation of
the C–F bond relative to the amide carbonyl (Figure 2.22).
Figure 2.22: X-Ray structure of fluorinated capsaicin (S)-97a.
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2.6.3- Analogues of capsaicin
2.6.3.1- Synthesis of shorter chain capsaicinoids analogues
A recent QSAR study on synthetic capsaicinoids of various chain length75 highlighted the
importance of the acyl moiety for low IC50 values against the TRPV1 receptor and correlated
it to the lipophilicity of the compound. It appears that the IC50 is between 0.188 and
0.728 mmol.L-1 when the acyl chain has 4 to 14 carbons. Shorter and longer chains have the
IC50 values increased, up to 4 mmol.L-1. This indicates that the capsaicinoid side-chain should
not be shorter than four carbons in length. On the other hand, highly lipophilic capsaicinoids
with C14, C18 or C18:1 chains do not activate the TRPV1 receptor in the endoplasmic
reticulum but generate instead a small increase in Ca2+ influx, suggesting that the agonistic
response is not only based on lipophilicity.76 It emerged from these studies that synthesis of
shorter chain capsaicinoids and an evaluation of their biological activity is worthy of
investigation.
2.6.3.2- Synthesis of the non-fluorinated short chain analogue
The synthesis of α-fluorinated short chain analogues of capsaicin was carried out to study the 
effect of the fluorine on the conformation of the molecule and the impact on the binding to the
TRPV1 receptor pocket. However, a comparison of (R)- and (S)- 99a/b with the non-
fluorinated analogue should determine the effect, if any, of the stereogenic fluorine. To this
end, a non-fluorinated analogue was also synthesised.
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Synthesis of the non-fluorinated analogue proved very straightforward and coupling with
HOBt/EDC between 118 and 4-methylvaleric acid 222 provided the desired amide 223 in
43% yield (Scheme 2.47).
Scheme 2.47: Synthesis of the capsaicin analogue 223.
2.6.3.3- Deaminative fluorination
A straightforward approach was then taken for the synthesis the shorter chain analogues of
capsaicin. A direct method to access appropriate α-fluoroacids involves diazotisation of α-
aminoacids, with HF as the mineral acid.77, 78 The diazonium intermediate is created by
treatment of the primary amine with sodium nitrate under acidic conditions (Scheme 2.48).
Scheme 2.48: Mechanism of deaminative fluorination on L-leucine.
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The instability of the diazonium carboxylic acid 225 leads to cyclisation to an α-lactone 226
with an inversion of configuration. Opening of 226 by fluoride ion then allows the formation
of the corresponding α-fluorocarboxylic acid 227. This mechanism involves a double
inversion with predominant overall retention of configuration. Therefore, the predominant
stereochemistry of the α-fluoroacid is dictated by the absolute stereochemistry of the starting 
amino acid.79
Accordingly L-leucine 224 was treated with sodium nitrate in a solution of HF/pyridine
(70/30) at -78 °C to allow the formation of the diazonium salt. This provided on work-up the
α-fluoroacid 227 in modest yield (45%) after distillation (Scheme 2.49).
Scheme 2.49: Deaminative fluorination and amide coupling to 99a.
α-Fluoroacid 227 was then coupled to vanillylamine 118 using a variety of conditions as
summarised in Scheme 2.49. The HOBt and EDC coupling combination proved poor for
capsaicin (32% yield after purification), although it seemed to be even lower in the case of 99
(11-17%). An attempt of coupling via an intermediate acylfluoride involved Deoxofluor
(1.2 eq) and provided a significantly improved yield to the reaction (24-28%).
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In order to establish that there was no racemisation in the coupling step from 227 to 99
(Scheme 2.50), chiral analysis of 227 was explored. Thus coupling of (R)- and (S)- 227a/b
with (S)-1-phenylethylamine 205a under the same coupling conditions (HOBt/EDC) used for
the capsaicin analogue, gave a product amide, (S,S)-228a or (S,R)-228b, with 96% de and
92% de respectively as outlined on Scheme 2.50.
Scheme 2.50: Amide derivatization of (S)-2-fluoroacid 227a to diastereoisomer 228a.
To assess if the difference in the de values was due to a kinetic resolution between the α-
fluoroacid enantiomers, a control experiment was carried out with racemic 227. The synthesis
of racemic 2-fluoroacid (R/S)-227 from DL-leucine was executed, followed by coupling to
(S)-1-phenylethylamine 205a. In this case, no kinetic resolution was observed, and both
diastereomers of 228 were formed in an equal ratio (Figure 2.23). This suggests that the
enantiomeric purity varies to some extent with the reaction conditions.
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Figure 2.23: 19F NMR showing the absence of kinetic resolution during the amide coupling
(A: synthesis of (S,R)-228b, B: synthesis of (S,S)-228a, C: synthesis of (S, R/S)-228,
peak a: (S,R)-228b, peak b: (S,S)-228a).
Chapter 2
106
This method of installing fluorine in an enantioselective enriched manner from an amino acid
proved to be efficient (1 step) and thus, it allowed both (R)- and (S)- fluoro enantiomers of 99
to be obtained. However, the method was less stereoselective for the (R)-enantiomer 99b than
the organocatalytic fluorination used for capsaicin (92% de for (R)-99b, but 96% de for
(S)-99a). Accordingly, the organocatalytic method was explored for comparison.
2.6.3.4- Asymmetric fluorination by organocatalysis
The enantioselective α-fluorination using MacMillan’s asymmetric fluorination method was 
evaluated in section 2.6.2. Developing this approach, a preliminary study on fluorination of
capronaldehyde 229 revealed that this method could be improved when the temperature was
decreased to -15 °C and the reaction time monitored carefully by GC-MS (Scheme 2.51).
Scheme 2.51: Optimisation of organocatalytic fluorination conditions on capronaldehyde 229.
Such optimised conditions decreased the 2,2-difluorooctanal side-product 231 to less than 5%,
relative to 20% of 2-difluoro-8-methylnon-6-enal 221 initially obtained, during the
fluorocapsaicin synthesis (Figure 2.24).
Figure 2.24: Typical MacMillan
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In this case, 2-fluoro octanaldehyde 230 was derivatized as imine 232 using the commercially
available (S)-1-methoxy-2-propylamine 231, by mixing in the NMR tube (Scheme 2.52).80
Scheme 2.52: Formation of diastereomeric imines to determinate de by 19F spectroscopy.
The diastereoisomeric imine formation allowed direct evaluation of the ee of the resultant
fluoroaldehyde 230 (92% de, relative to 95% ee by chiral GC-MS) by 19F spectroscopy
(Figure 2.25). In principle both (E) and (Z) imines can be formed but it is known that the
imine configuration is only E.81 This method appeared to be workable on crude mixtures and
was a good alternative to chiral GCMS.
Figure 2.25: 19F NMR of imine 232 showing a high diastereomeric excess (92% de)
(A: (S,E,S)-232b, B: (S,E,R)-232a).
Chapter 2
109
An attempt towards the preparation of the capsaicin analogue 99 was carried out. The
synthesis started with the PCC oxidation of 4-methylpentan-1-ol 233 (see scheme 2.53).
Fluorination was achieved with either (R)- or (S)- imidazolidinone catalysts 212.
The enantiomeric excess of the aldehyde was determined by derivatisation of an aliquot with
(S)-1-methoxy-2-propylamine 231 and a high de was observed (90% de for (R)-235b, 88% de
for (S)-235a). α-Fluorinated aldehyde 235b was oxidised with chromic acid to generate the
corresponding α-fluorinated carboxylic acid 227b without prior purification.
Scheme 2.53: Asymmetric organocatalytic fluorination to (R)-2-fluoro-4-methylpentanoic acid 227b.
Coupling of the acid 227b to vanillylamine 118, again with Deoxofluor, allowed recovery of
amide 99b (Scheme 2.54). There was no loss of enantiomeric purity during this reaction as
suggested by the control coupling in similar conditions of (S)-1-methoxy-2-propylamine 231
to 227b. Indeed, the control reaction gave amide 236b with 90% de (Scheme 2.54).
Scheme 2.54: Asymmetric organocatalytic fluorination of short chain fluorocapsaicin analogue 99b.
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2.7- α,α-Difluorinated analogues 
2.7.1- Theory study of α,α-difluoroamides 
The conformation of α-fluoroamides is well understood and has been described in section 2.6.
However, not much is known about the structure of α,α-difluoroamides, and only a few 
structures of α,α-difluoroamides are found in the Cambridge Structural Database. Installing a 
second fluorine atom α to an amide such as in 237 will certainly influence the conformation of
the amide but it has not been clearly established in what way. It is not clear whether
conformer 237 X will be favoured from the combination of the C–F/C=O dipole-dipole
relaxation to one C–F bond similar to the α-fluoroamides, or whether conformer 237 Y will be
favoured from the average dipole-dipole relaxation from the CF2 group and the amide (Figure
2.26).
Figure 2.26: Possible conformational preferences of α,α-fluoroamides 237.
The crystal structure of 2-(2-acetylaminophenyl)-2,2-difluoro-N-phenylacetamide 238
suggests the former model 237 X (Figure 2.27, left).82 However, in the X-ray structure of
239, the conformation of the simplest difluoroacetamide 239, none of the C–F bonds are
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strictly anti planar to the amide. They are gauche with torsion angles of around 30° and are
interestingly situated on the same side related to the amide plane, suggesting that in this
particular case a global repulsion occurs between the amide group NH2-CO and the difluoro
moiety (Figure 2.27, right).83 However this is a solid state structure and solid state
interactions will also perturb the conformation.
Figure 2.27: Examples of α,α-difluoroamides X-ray crystal structures.82, 83
A DFT theory study was therefore carried out examining the rotational energy profile of the
model compound N-methyl-α,α-difluoroacetamide 240 with B3LYP functional. The changing
dipole moment was also calculated during this analysis, as illustrated in Figure 2.28
(D. Buissonneaud, St. Andrews).
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Figure 2.28: DFT theoretical study showing the variation of the dipole moment and the global
minimum energy of α,α-difluoroamide 240.
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The dipole moment (red curve) is at a global maximum for a rotation angle of 60°, which
coincides with the position of the CF2 dipole syn to the C=O dipole (conformation A). The
dipole relaxation reaches a global minimum for an angle of 240°, which corresponds to the
position of the CF2 dipole anti to the C=O dipole (conformation C). However, the two global
energy minima (blue curve, conformations B and B’) coincide with 40° rotations to F–C–C–O
angles 200° or 280° (240 C). These 40° rotations relax the eclipsing interaction between the
C=O and H–CF2 bonds and thus the global minima B and B’ are a compromise between
dipole relaxation and steric relaxation.
2.7.2- Synthesis of 2,2-difluoro-4-methylpentanoic acid 242
2.7.2.1- α,α-Difluorination by organocatalysis 
In an effort to prepare the α,α-difluoro aldehyde 241, the MacMillan asymmetric fluorination
was monitored at room temperature to allow the second fluorination to proceed
(Scheme 2.55). The product mixture of α,α-difluoro aldehyde 241 was directly oxidised using
Jones reagent to give the corresponding α,α-difluoro acid 242 (91% yield on two steps).
Scheme 2.55: Organocatalytic synthesis of α,α-difluoroamide 242.
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2.7.2.2- α,α-Difluorination of α-ketoesters 
The nucleophilic difluorination of an α-ketone was also explored. The first step involved the
conversion of the α-ketoacid 243 as α-ketoester 245. Esterification of 243 with thionyl
chloride in methanol lead to a mixture of the desired ester 245 but also the corresponding α-
ketal 244 in a 30:70 ratio in favour of the ketal (Scheme 2.56). This mixture was then treated
with perchloric acid for 3-4 h to give a full conversion into the α-ketoester 245.84
Scheme 2.56: Synthesis of ketoester 245.
Difluorination was achieved with DAST and provided methyl 2,2-difluoro-4-
methylpentanoate 246 with a reasonable conversion. An attempt at this transformation with
the new reagent FLUOLEAD (2 eq), either at rt or at reflux of DCM did not give the desired
product. The high volatility of 246 depleted the yield to 55% even though solvent removal
was cautiously carried out at 0 °C.85
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2,2-Difluoro-4-methylpentanoic acid 242 was then obtained after hydrolysis of 246 in an
ethanolic solution of KOH (10 eq) and acidic work-up (86%) (Scheme 2.57).
Scheme 2.57: Preparation of α,α-difluorocarboxylic acid 242.
2.7.3- Amide coupling of α,α-difluoro acid 
The carboxylic acid 242 was treated with Deoxofluor in an attempt to couple with
vanillylamine 118, but this was not successful (Scheme 2.58). The high electronegativity of
the two fluorine atoms clearly deactivates the carboxylic acid group.
Scheme 2.58: Acyl fluoride mediated amide coupling to 247.
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In the same manner, the uronium salt TBTU 248 when used in excess (1.3 eq), was unable to
efficiently activate the α,α-difluoroacid and the difluorinated analogue of capsaicin 247 was
obtained in a very modest yield (9%) (Scheme 2.59).
Scheme 2.59: TBTU coupling of α,α-difluoroacids 242.
An improvement of the coupling was made using the acyl chloride 249. The one-pot reaction
was successful but the yield remained modest (19%) (Scheme 2.60).
Scheme 2.60: Amide coupling by formation of acyl chloride intermediate 249.
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2.7.4- α,α-Difluorination of α-ketoamides 
The amide coupling of the α,α-difluoro-carboxilic acid 242 proved to be very modest. In an
attempt to remedy this issue, an alternative pathway was attempted, involving amide coupling
of an α-ketoacid prior to the fluorination. Accordingly, 2-oxo-4-methylvaleric acid 243 was
activated using isobutylchloroformate and then vanillylamine 118 was added to give the α-
ketoamide 250 in a good yield (76%) (Scheme 2.60).
Scheme 2.60: Amide coupling with α-ketoacid 244.
The fluorination step was achieved by treating the α-keto amide 250 with DAST. The reaction
mixture gave a complex mixture, although 19F NMR analysis showed a peak at -104 ppm
suggesting the formation of the α,α-difluoramide 247. Despite considerable effort, the product
could not be isolated and the reaction proved unsatisfactory (Scheme 2.61).
Scheme 2.61: Difluorination of α-keto amides leads to α,α-difluoroamides 247.
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2.8- Biological evaluation
The synthetic analogues (S)-99a (96% ee), (R)-99b (92% ee), and 223 described in this
chapter were assayed with the TRPV1 receptor derived from rats. This work was carried out
by the group of Dr Roderick Scott at Aberdeen University (Scheme 2.50). For comparison
purposes, the results of the biological assays for (R)-97 (96% ee), (S)-97 (95% ee) are also
reported. The biological responses are then compared to that of natural capsaicin 93.
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Scheme 2.62: The set of molecules submitted to biological evaluation.
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2.8.1- Biological assay
2.8.1.1- Fluorinated enantiomers of capsaicin
Neurones expressing TRPV1 receptors are a subpopulation of dorsal root ganglia (DRG),
which are activated by capsaicin as it evokes a transient increase in intracellular Ca2+. In the
first study, neurones which showed a 90 % response to a capsaicin application (1 μM) were 
selected for the fluorocapsaicin assays. (S)- and (R)-fluorocapsaicin 97 also evoked an
increase in intracellular Ca2+ in a similar manner to capsaicin. The amplitude of the response
was not significantly different at equal concentrations (1 μM) of the enantiomers as illustrated 
on Figure 2.29 B and D. The fluorinated capsaicin enantiomers 97a/b were both agonists and
had a similar level of response. There was no obvious enantiomeric discrimination.
Figure 2.29: Evoked responses in cultured DRG neurones are similar for enantiomers of 97
(top: (R)-97b, bottom: (S)-97a).
Chapter 2
120
A second study was used to investigate (R)-fluorocapsaicin binding (Figure 2.30).
Capsazepine 106, a TRPV1 receptor antagonist, was used (1 mM) to compete with the (R)-
and (S)- enantiomers of 97.
Neurones were pre-treated with capsazepine 106 for 5 min before application of the
fluorinated analogues, and this inhibited the response to (S)-97a and (R)-97b. After washing,
the neurones recovered their sensitivity to capsaicin or its fluorinated analogues indicating
capsazepine 106 and fluorocapsaicins 97 are binding at the same site on the receptor.
Figure 2.30: Evoked responses by (R)-97b in cultured DRG neurones indicate an agonistic effect.
Experiments conducted at lower concentrations of the (R)-fluoro enantiomer 97b (330 and
250 nM) showed that responses of the fluorocapsaicins 97 were 20% lower than the
maximum response of capsaicin itself. Neurones recovered a full response to both of the
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fluoro-enantiomers at 500 nM. In conclusion, (S)-97a and (R)-97b displayed equal agonist
potency and a similar response to capsaicin. From this result was developed an extended
binding model where the side-chain is aligned along the molecular axis of 97 (Figure 2.31).
Figure 2.31: Supposed side-chain projection in the two enantiomers of 97.
2.8.1.2- Short fluorinated analogues of capsaicin
Biological evaluation for the short fluorinated analogue of capsaicin was carried out with
slight differences. Both (R)- and (S)-99 and also the non-fluorinated control 223 were
compared to capsaicin 93.
The cultured DRG neurons from neonatal rats were exposed to two applications of capsaicin
93 (100 nM, 10 times lower concentration than for α-fluorocapsaicins 97a/b) with a NaCl
media wash between the two applications (Figure 2.32).
Figure 2.32: Control experiment with capsaicin to select responsive neurones
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The results showed there was no significant difference in response between the two
applications of capsaicin, and that the neurons fully recovered their response.
The control analogue 223 was applied (100 nM)to neurones evoked by capsaicin (100 nM).
This analogue did not evoke any response from the neurones (Figure 2.33), whereas when
capsaicin 93 is conjointly applied, the response is significantly inhibited. This is consistent
with an antagonistic effect of the shorter chain analogue 223.
Figure 2.33: Non-fluorinated reference 223 shows partial antagonistic response to capsaicin
The same procedure was applied to the (R) enantiomer 99b (92% e.e.) and the result revealed
two responses depending on the sensitivity of the neurones. When neurones were not evoked
by capsaicin, 99b did not show a response by itself, but it could increase the apparent
sensitivity of neurones when co-applied with capsaicin. Thus cells that did not respond to the
first application of capsaicin subsequently responded when capsaicin was applied in the
presence of (R)-99b (Figure 2.34, left). However, in neurons already sensitive to capsaicin,
(R)-99b had no obvious effect on the capsaicin response (Figure 2.34, right).
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Figure 2.34: The two responses obtained from (R)-99b showing a full recovery of sensitivity (left)
and an absence of effect (right).
The result from the (S)-enantiomer proved the most clear of all the analogues. When (S)-99a
(96% e.e.) was applied alone it did not evoke a response in the neurones, and additionally it
totally inhibited the response to capsaicin when co-applied. To verify that the neurones did
not show any loss of sensitivity, capsaicin was then applied alone and evoked a strong
response from the neurones. Thus the (S)-enantiomer 99a clearly acted as a potent antagonist
to capsaicin (Figure 2.34).
Figure 2.35: A clear antagonistic effect of (S)-99a.
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These assays show that all capsaicin analogues 97a/b, 99a/b and 223 were bioactive and this
suggests that their vanilloid moieties are binding to the critical residues Tyr 511, Ser 512 and
Tyr 550 usually involved in vanilloid binding. The diversity of biological responses was most
probably generated by the differences in lipophilic binding.
Short chain analogue 223 show antagonistic properties as expected. Installation of fluorine in
(S)-99a increased the antagonistic potency in a similar manner to capsazepine 106. It may be
due to a specific conformation induced by the C–F bond or less likely a specific interaction of
the fluorine with the protein (see Chapter 1.5.3), amide carbonyl groups of which provide a
fluorophilic environment.
It is interesting that the short chain analogues 99a, 99b and 223 are active at ten times lower
concentration than capsaicin 93 or its fluorinated analogues 97a or 97b. In addition, the
compounds 99a and 99b performed differentiated biological responses, and these are
correlated to their respective stereoisomerism. Finally, the installation of fluorine on the
ligand 99a also increased its potency.
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2.9- Conclusion
In conclusion, (S)-fluorocapsaicin 97a and four short-chain analogues of capsaicin were
synthesised successfully by different methods. The short-chain difluorinated analogue 247
was also targeted for biological evaluation but proved challenging to prepare.
Biological assays on fluorinated capsaicins 97a/b proved that they acted as agonists of
TRPV1 receptor, in a similar manner and proportions to capsaicin 93.
Shortening the side-chain in compounds 99a and 223 reversed the biological response and
they now showed antagonist properties on TRPV1 receptor. The short-chain analogues also
gained in potency. When the α-fluorocapsaicins 97a/b lost potency below 500 nM, these
compounds still exerted full bioactivity at 100 nM.
Most interestingly, each short-chain analogue displayed a different response and this suggests
that the shorter chain is not in an extended form, as observed for 97a/b. The non-fluorinated
compound 223 is a partial antagonist. The (S)-fluoro-enantiomer 99a has its antagonist
properties enhanced and is a full antagonist to the TRPV1 receptor. Both of these compounds
were reversible antagonists on the TRPV1 receptor, suggesting they truly did locate at the
capsaicin binding-site. 99b does not show proper antagonist or agonist properties, and this
particular biological response has never been observed in capsaicinoids. The (R)-enantiomer
99b is of interest in that it can restore sensitivity to capsaicin when the receptor is blocked.
The mechanism of this specific action is worthy of further investigation.
There is a current interest in capsaicin antagonists such as capsazepine 106 and (S)-99a
emerges as a drug candidate compound. The TRPV1 receptor is a drug discovery target and
antagonists may provide therapies for pain disorders in the near future. Finally it was reported
for the first time that the enantioselective introduction of fluorine α- to an amide alters the 
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bioactivity of a short side-chain capsaicin analogue. The various and specific biological
responses to each compound are summarised in Figure 2.35.
Figure 2.36: Biological effects of enantioselective installation of fluorine on capsaicin analogues.
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3- Synthesis and organocatalysis from
structural motif 2-(aminomethyl)piperidine
3.1- Diamines in medicinal chemistry and catalysis
This chapter describes the development of the chiral diamine 2-(aminomethyl)piperidine 251
(Figure 3.1). An enantiopure synthesis is developed and its potential as a synthesis
intermediate or as an organocatalyst is explored.
NH
NH2
NH
NH2
(R)-251 (S)-251
Figure 3.1: (R)- and (S)-2-(aminomethyl)piperidine 251.
Linear diamines have been widely applied in a range of modern industrial fields. For
example, hydrazine (H2N-NH2) is often used as fuel for satellites and hexamethylenediamine
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(C6) 254 is a monomer of nylon-6,6. The 1,2-diamine moiety is a simple structural motif
found also in various natural products and bioactive molecules. Putrescine (C4) 252 and
cadaverine (C5) 253 are produced in metabolism by decarboxylation of their corresponding
amino acids L-ornithine and L-lysine respectively (Figure 3.2). Their odour is strong and
characteristic of putrefaction processes.
Figure 3.2: Examples of linear diamines.
Enantiomerically pure 1,2-diamines have found wide currency in catalytic asymmetric
synthesis, where they have been explored for diastereoselective and enantioselective
syntheses. Examples are described in section 3.1.3.
3.1.1- The occurrence of vicinal diamines in natural products
The 1,2-diamine motif is often found in heterocyclic moieties. Biotin 255 is an important
cofactor in enzymology where it is involved in the biosynthesis of fatty acids (Figure 3.3).
The structural skeleton contains a vicinal diamine moiety constrained as an imidazolidinone
ring system. The penicillin 256 and cephalosporin 257 antibiotics also contain 2,3-diamino
carboxylic acid residues. The alkaloid palau’amine 258 contains three 1,2-diamine moieties.
This alkaloid was discovered in a sea sponge and its first total synthesis was reported
recently.1
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Figure 3.3: The vicinal diamino moiety in natural products.
3.1.2- Applications in medicinal chemistry
The 1,2-diamine unit is also present in a large variety of compounds, many of which possess
useful biological activities. Indeed, vicinal diamines are important ligands used to co-ordinate
metals or organometallics, such as the antitumor compound oxaliplatine 259 (Figure 3.4).
Figure 3.4: The 1,2-diamine moiety in some important drugs.
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EDTA 260 was originally used to treat lead poisoning, but many EDTA derivatives are used
in nuclear medicine for the chelation of metallic radioactive isotopes.2 The diamine moiety is
also found in the antiviral drug Tamiflu® 261
3.1.3- Vicinal diamines in synthesis
The availability of enantiomerically pure vicinal diamines has fuelled the development of
chiral auxiliaries for asymmetric synthesis. Mangeney et al. developed a method to resolve
chiral aldehydes using vicinal diamines (Scheme 3.1).3 This involved treatment of racemic
aldehydes 262 with an enantiopure diamine 263 to generate diastereoisomeric imidazolines
264, which could then be separated by chromatography and resolved after hydrolysis.
Scheme 3.1: Resolution of racemic mixtures of aldehydes.3
The 1,2-diamine moiety is widely represented in the structures of chiral auxiliaries and
ligands. Hanessian et al. developed a method to obtain α-substituted-α-alkyl phosphonic 
acids, such as 269, via a chiral bicyclic phosphonamide, developed from (R,R)-
dimethylcyclohexane-1,2-diamine 266 (Scheme 3.2).4 This synthesis was efficient (71-84%)
and highly diastereoselective (68-98% de).
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N O
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N O
R
R' HO
P
HO O
R
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Cl2P(O)CH2R
R=Me, Ph, Cl, N3
1) Base
2) R'X
0 °C
71-84%
1M HCl
266 267 268 68-98% de 269
Scheme 3.2: Chiral bicyclic phosphonamide as a chiral auxiliary.4
In 1988, Cardillo et al. reported the alkylation of 3-acyl-imidazolidin-2-one 270 derived from
(S)- or (R)- ephedrine.5 This family of imidazolidin-2-ones has been used for asymmetric
enolate alkylations (94% de).6
Scheme 3.3: Asymmetric alkylation using oxazolidinone auxiliaries.5
Diamine chiral ligands have also been used in asymmetric synthesis. For example, Corey
performed the alkylation of aldehydes using dialkylzinc reagents.7 Nucleophilic addition of
diethylzinc to benzaldehyde 272 proved to be highly enantioselective (95% ee) using diamine
273 as the template for Li+ Lewis acid catalysis (Scheme 3.4).
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Scheme 3.4: Enantioselective ethylation of benzaldehydes.7
Noyori et al., used ruthenium complexes to reduce aromatic ketones by asymmetric hydrogen
transfer.8, 9 Using ruthenium complex 276 resulted in 58 to 99% ee, and 277 generated
products in the range 66-99% ee as illustrated in Scheme 3.5.
Scheme 3.5: 1,2-Diamino ligands and metal complexes for enantioselective reductions.8, 9
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3.1.4- Preparation of vicinal diamines
The requirement for specifically substituted vicinal diamines has generated numerous
approaches for their preparation. This section will focus on the preparation of heterocycles
containing the 1,2-vicinal diamine moiety.
Scheme 3.6 shows how O’brien et al. did the one-pot synthesis of diamines (R)-283 or (R)-
284 starting from (R)-styrene oxide 280.10 Pyrrolidine or piperidine reacts with the styrene
oxide to generate a tertiary alcohol, which on treatment with mesyl chloride forms the
aziridinium rings 281/282. The initial configuration of the epoxide is recovered in 283/284
after attack by a primary amine to the more substituted carbon of the aziridinium 281/282.
Scheme 3.6: Piperidine and pyrrolidine derivatives.10
Taylor et al. applied the Ritter reaction to a series of cyclic hydroxyamines, including 3-
hydroxy-pyrrolidine 285.11 The carbocation formed under acidic conditions provided the
expected acetamide 286 in 77% yield (Scheme 3.7).
Scheme 3.7: Application of Ritter reaction to cyclic β-hydroxamines synthesis.11
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When this reaction was attempted on 3-hydroxypiperidine 287, the acetamide 288 was
obtained but only as a minor product (20%). The major product (50%) was the alkene 289
(Scheme 3.8). The authors suggested that the formation of the aziridinium 290 would not
easily undergo reaction with acetonitrile and the system was prone to elimination.
N
Bn
Me
OH
N
Bn
Me
NHAc
H2SO4, ACN
0-5 °C N
Bn
Me
+
N+
Me
Bn
287 288 20% 289 50%
290
Scheme 3.8: The formation of the aziridinium intermediate favours the elimination reaction.11
To avoid such side-reactions, the nitrogen atoms were protected.12 For example, the
intramolecular reductive amination highlighted in Scheme 3.9 proceeds by the
monodeprotection of a carboxybenzyl group prior to cyclisation. This method enables the
synthesis of various substituted piperidines, such as 292.
Scheme 3.9: Intramolecular reductive amination.12
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3.2- Synthesis of enantiopure 2-(aminomethyl)piperidine
3.2.1- Previous syntheses of 2-(aminomethyl)piperidine
A racemic synthesis of 2-(aminomethyl)piperidine 251 was first reported in 1958 by
Mortimer in a study aimed at proving the structure of the alkaloid isopelletierene
(Scheme 3.10).13 N-Acetylated isopelletierene 293 was converted to oxime 294. A Beckmann
rearrangement was then induced under acidic conditions to generate the corresponding
diamide 295. The diamide intermediate was hydrolysed to generate 2-(aminomethyl)-
piperidine dihydrochloride 251.
Scheme 3.10: Beckmann rearrangement of isopelletierene.13
When isopelletierene oxime 296 was treated with phosphorus pentachloride in phenylethyl
ether, it formed 2-methyl-1,3-diazabicyclo[4:3:0]-2-nonene 297 (Scheme 3.11).
Scheme 3.11: Hydrolysis of amidine 297.14
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In this case, the Beckmann rearrangement product was subject to nucleophilic attack by the
secondary amine, which led to amidine cyclisation. 2-(Aminomethyl)piperidine 251 was then
obtained after hydrolysis of the amidine 297, and was isolated as its dipicrate salt.14
The synthesis of 2-(aminomethyl)piperidine 251 and its substituted derivative 2-
(ethylaminomethyl)piperidine 301 have also been described by the hydrolysis of 1,8-
diazabicyclo[4:3:0]nonanes 300 (Scheme 3.12).15
Scheme 3.12: Hydrolysis of 1,8-diazabicyclo[4:3:0]nonanes 300.15
300 was obtained after treatment of ethyl 2-(piperidin-2-yl)acetate 298 with isocyanic acid or
isocyanatoethane to give the corresponding hydantoin 299. Treatment of 5-phenylhydantoins
with lithium aluminium hydride is known to result in complete reduction to 4-
phenylimidazolidine. Such conditions were used to reduce 299 to 1,8-
diazabicyclo[4:3:0]nonanes 300, which were then hydrolysed with hydrochloric acid to
generate 251 or 2-(ethylaminomethyl)piperidine dihydrochloride 301.
Other reductive methods have been used to provide 251. 2-(Aminomethyl)pyridine 302 could
be hydrogenated using PtO2 as a catalyst, but best result was given with sodium metal.16, 17
Wong et al. also reported a resolution method of the dihydrochloride salt of 2-(aminomethyl)-
piperidine 251 to recover the product as a single stereoisomer. Thus the salt was crystallised
with dibenzoyl-(+)-tartaric acid ((+)-DBTA) to give (S)-2-(aminomethyl)piperidine 251
(Scheme 3.13).
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Scheme 3.13: Reduction of 2-(aminomethyl)pyridine with sodium metal and resolution of racemic 2-
aminomethylpiperidine 251 with (+)-DBTA.17
The first enantiopure synthesis of 2-(aminomethyl)piperidine 251 was reported by
Perumattam et al. in 1991 and started from (S)-pipecolic acid 303 (Scheme 3.14).18
Scheme 3.14: Asymmetric synthesis of Boc-protected 2-(aminomethyl)piperidine 308
from pipecolic acid.18
(S)-Pipecolic acid 303 was converted to its carboxamide 305 via the methyl ester 304.
Reduction of the amide 306 with LiAlH4 was achieved after benzyl protection of the
secondary amide. The primary amine of 307 was then Boc protected and the benzyl group
removed by hydrogenolysis to give 308.
Chapter 3
142
Another enantiopure synthesis was described from the (-)-2-cyano-6-phenyloxazolo-
piperidine 309 (Scheme 3.15).19 Precursor (-)-309 was prepared from (R)-(-)-phenylglycinol
and glutaraldehyde in the presence of KCN. The synthesis started from a reduction of 309
with lithium aluminium hydride which resulted in the diamino alcohol 310.
2-(Aminomethyl)piperidine (S)-251was obtained after hydrogenolysis of 310 with palladium
on charcoal and the diamine was isolated as its dihydrochloride salt.
N
CN
O
Ph
(-)-309
N
Ph
NH2
OH NH
NH2
H2, Pd/C
MeOH, HCl
6 h, rt
(S)-251
LiAlH4
Et2O
2 h, rt
2 HCl
310
Scheme 3.15: Reduction of an enantiopure cyanopiperidine.19
A cyanyl reduction was also reported by Nazabadioko et al.20 In this case, the authors started
with 2-cyano-6-phenyloxazolpiperidine (S)-313. The phenylmethanamine group was
incorporated by nucleophilic substitution on the alcohol (R)-311 activated as a triflate, a
process that occurred with an inversion of configuration. Cyclisation of intermediate (S)-312
generated the piperidine ring (Scheme 3.16).
Scheme 3.16: A cyclisation process to obtain an enantiopure cyanopiperidine (S)-313.20
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In a similar manner to that for 309, 2-cyano-6-phenyloxazolpiperidine (S)-313 was then
reduced with LiAlH4 to provide the corresponding diamine which was hydrogenated using
Pd(OH)2, to give the enantiopure 2-(aminomethyl)piperidine (S)-251 as the dihydrochloride
salt.
3.2.2- Aims of project
The importance of chiral diamines as catalysts in asymmetric synthesis renders improved
methods for the synthesis of (R)- and (S)- 2-(aminomethyl)piperidine attractive as these two
enantiomers are not commercially available. The approaches described above do not allow
reasonable quantities of (R)- and (S)- 251 to be obtained easily. This research aimed to
explore a practical route, as described in Scheme 3.16, in order to develop the enantiopure
amines as building-blocks for synthesis programmes in medicinal chemistry or for
applications in asymmetric catalysis.
Scheme 3.16: Synthetic approach to (R)- 251.
Figure 3.5 illustrates the structural diversity that was targeted from 2-(aminomethyl)-
piperidine in this research.
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Design of organocatalysts
N1,N4-cyclisation and N4,N4-polymerisation
Figure 3.5: New syntheses of 2-(aminomethyl)piperidine derivatives.
3.2.3- Enantioselective synthesis of 2-(aminomethyl)piperidine
3.2.3.1- Development of the cyclisation process
This novel approach starts from the amino acids (S)-L- and (R)-D- lysine and proved
convenient for gram scale synthesis of (R)- or (S)-2-(aminomethyl)piperidine 251.
(S)-L-Lysine 314 was converted to its pentabenzyl derivative (S)-315 by treatment with
benzyl bromide (7 eq) in ethanol, using potassium carbonate as a base (Scheme 3.17). The
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almost quantitative perbenzylation was followed by reduction of (S)-315 with LiAlH4 in an
efficient reaction where the resultant alcohol (S)-316 was obtained in 89% yield.
Scheme 3.17: Synthesis of perbenzylated alcohol (S)-316.
Initial investigations by G. Deniau (St. Andrews, 2006) aimed at obtaining the fluorinated
diamine (R)-N1,N6-tetrabenzyl-2-fluorohexane-1,6-diamine 319 (Scheme 3.18). It is known
that treatment of N,N-dibenzyl-α-aminoalcohols with nucleophilic fluorinating reagents 
produces an in situ aziridinium intermediate 317, which then undergoes ring opening by
fluoride ion attack (paths b and c) predominantly forming the more substituted alkyl fluorine
(path b) as illustrated in Scheme 3.18.21
Scheme 3.18: Reaction pathways on treatment of (S)-317 with Deoxofluor.
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When this reaction was carried out at -10 °C with Deoxofluor, it gave a mixture of three
compounds 318-320 in a ratio of 83:15:2 , in poor yield (11%). It was not anticipated that the
peripheral dibenzylamine would compete with the fluoride ion to open the aziridium
intermediate (path a), however this proved to be the more efficient process. This then opened
up the prospects of a new route to 2-(aminomethyl)piperidine 251.
The addition of silica gel (SiO2) to the suspension in solvent was anticipated to favour
intramolecular nucleophilic attack of N6 over the intermolecular attack by fluoride. This was
confirmed when an empirical amount of silica (200 mg for 200 mg of perbenzylated alcohol,
i.e. 8.2 eq) increased the conversion to piperidinium 318 (50%).
In this thesis, an alternative cyclisation was developed with a system involving DAST
(1.5 eq) and silica. The use of DAST at room temperature was even more efficient and the
conversion improved to above 60%. The conversion reached 80%, with minor traces of 319
and 320, when four equivalents of silica were added to the mixture.
Scheme 3.19: Proposed mechanism of amine cyclisation activated with DAST.
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The role of the silica appears to sequester fluoride ions from solution. Consequently, side-
reactions are reduced giving a cleaner reaction and more efficient conversion. The
diethylaminodifluorosulfinium formed, after elimination of one fluoride, is attacked by the
alcohol and the good leaving group formed promotes aziridine cyclisation (Scheme 3.19).
The aziridinium then undergoes ring opening by N6 attack.
An improved method for the cyclisation of the N,N’-tetrabenzylated alcohol 316 was now
considered because DAST cannot reasonably be used on a large scale for both safety and
economical reasons. Other reagents were investigated to promote the activation of the amino
alcohol 316. For instance, the use of methanesulfonic anhydride (Ms2O), methanesulfonyl
chloride (MsCl) and trifluoromethanesulfonic anhydride (Tf2O) had been reported to generate
aziridinium rings from N,N-dibenzyl-α-aminoalcohols.22-26 In the following example, mesyl
chloride promotes the formation of aziridinium 323 from the dialkylated (R)-phenylglycinol
322 (Scheme 3.20). Aziridinium 323 is then reacted with methylamine as a nucleophile to
generate the 1,2-diamine (S)-324 with 95% ee.
Scheme 3.20: Formation of aziridium ion 323 from (R)-phenylglycinol using mesyl chloride.22
In the same manner, the β-aminoalcohol (S)-325 gave the aziridinium 326 when treated with
trifluoromethanesulfonic anhydride. The ring-opening reaction is regioselective as
morpholine reacts preferentially on the less substituted carbon of the aziridinium ring to give
a mixture of regioisomers (S)-327 and (R)-328 in a 95:5 ratio respectively.
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Scheme 3.21: Formation of aziridium ion 326 from (S)-2-(dibenzylamino)-3-phenylpropan-1-ol using
trifluoromethanesulfonic anhydride.26
These reagents were now explored for formation and subsequent cyclisation of aziridinium
317 to generate 318. A summary of these outcomes is reported in Table 3.1.
Entry Reagent Base Conditions Result
1 Ms2O Et3N 1.5 eq
30 min at 0 °C,
then 8 h at rt
No cyclisation 
2 MsCl Et3N 1.5 eq
1 h at 0 °C,
then 8 h at rt
Chlorination
329 
3 Tf2O 2 eq
Et3N 2 eq
DMAP cat
2 h at 0 °C,
then 36 h at rt
Quantitative
conversion 318 
4 SOCl2 1.2 eq Pyr 1.2 eq
2 h at 0 °C, then
overnight at rt
No cyclisation 
5 POCl3 1.5 eq Et3N 1.5 eq
1 h at 0 °C, then
overnight at rt
No cyclisation 
6 Tf2O 2 eq
Et3N 2 eq
DMAP cat
2 h at 0 °C, then
overnight at reflux
Traces 318 
All reactions carried out in DCM, except entry 4: THF, and entry 5: diethyl ether.
Table 3.1: Reagents used to promote the cyclisation of (R)-316 to (R)-318.
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The reactions involving mesyl anhydride, thionyl chloride and phosphorus oxychloride failed
to promote any cyclisation (entries 1, 4, 5). The use of mesyl chloride (entry 2) resulted in the
regioselective chlorination of 316, perhaps not surprisingly, as chloride is more nucleophilic
than the dibenzylated amine (Scheme 3.22).
Scheme 3.22: Mesyl chloride promotes the synthesis of alkyl chloride 329.
Interestingly, the cyclisation of dibenzyl-α-aminoalcohol 330 was reported by Gmeiner et
al.27 In this case, the bicyclic product 331 was obtained in an enantiopure form, as a result of
the nucleophilic attack from the C2 carbon of the pyrrole ring on the aziridinium intermediate
(Scheme 3.23).
Scheme 3.23: Cyclisation of dibenzyl-α-aminoalcohol is induced by Tf2O.27
Accordingly, treatment of 316 with triflic anhydride (2 eq) resulted in an efficient cyclisation
to piperidine 318 after 36 h at room temperature (88% yield).
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It appears from these results that DAST/silica and particularly trifluromethanesulfonic
anhydride are suitable reagents to promote the cyclisation of (R)-316 to generate the
tetrabenzylpiperidinium salt 318 (Scheme 3.24).
Scheme 3.24: Cyclisation step induced by Tf2O or DAST/silica.
3.2.3.2- Hydrogenolysis of 318 and preparation of dihydrochloride 251
The next step in the process required debenzylation of 318. The compound was submitted to
hydrogenolysis with 10% Pd/C catalyst in an autoclave (from 5 bars, 2 h to 30 bars, 2 d) but
the debenzylation was only partially achieved, resulting in a mixture of mono-, di-, tri- and
tetra-benzylated 2-(aminomethyl)piperidines with the required 2-(aminomethyl)piperidine
251 in only 20% conversion (Scheme 3.25).
Scheme 3.25: Hydrogenolysis of (R)-318.
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The Pd/C catalyst was not efficient at promoting the reaction and instead, Pd(OH)2 was
evaluated. Hydrogenolysis was carried out on a continuous-flow hydrogenation system (“H-
cube”) which allowed higher pressures and temperature (Scheme 3.26). The micro-reactor
consisted of a pre-packed cartridge of Pd(OH)2 loaded at 20%. The reagent 318 was diluted
to a 0.1 M solution in ethanol at 40 °C and the pressure was varied from 30 to 50 bar, but this
did not significantly improve the conversion even after several passages of substrate through
the system (<40% conversion).
Scheme 3.26: Hydrogenolysis of (R)-318 under high pressure continuous-flow.
Hydrogen transfer was not enhanced at this micro-scale and transfer hydrogenation was then
investigated using ammonium formate (5 eq) as a continuous source of hydrogen. The
reaction was run at 85 °C at ambient pressure using 20% Pd(OH)2 as a catalyst
(Scheme 3.27). This proved successful and a quantitative conversion of 318 to 251 was
achieved after 24 h. In some reactions, a mixture of 2-(aminomethyl)piperidine and the
tetrabenzylated starting-material was observed as determined by 13C-NMR with no trace of
the intermediate benzylated products.
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Scheme 3.27: Hydrogenolysis using a continuous source of hydrogen.
This hydrogenolysis was less efficient when the cyclisation was carried out with
trifluoromethanesulfonic anhydride, but the reaction proceeded normally after a thorough
wash of the starting material with a saturated solution of NaHCO3 (pH 8), presumably to
remove the triflate counter-ion (19F NMR showed a peak at -79 ppm). Finally, (R)-251 was
converted to its dihydrochloride salt after filtering the catalyst, and the addition of
hydrochloric acid. A complete conversion to 251 was always achieved after a second
treatment in similar conditions.
The absolute stereochemistry of the diamine 251 was determined by X-Ray structure analysis
(Figure 3.6). The resultant stereochemistry is consistent with a single inversion of
configuration from the original (S)-L-Lysine starting material.
Figure 3.6: X-Ray analysis confirmed the structure and stereochemistry of (R)-251.
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Both the (R)- and (S)- enantiomers of 2-(aminomethyl)piperidine 251 were prepared on a
gram-scale by this method, involving cyclisation with either DAST/silica or
trifluoromethanesulfonic anhydride. All steps were optimised on this scale, including the
cyclisation and hydrogenolysis.
3.2.3.3- Preparation of 2-(aminomethyl)piperidine tetrafluoroborate salt
The 2-(aminomethyl)piperidine dihydrochloride salt proved to be very poorly soluble in
organic solvents. It was thought that a more lipophilic salt could enhance its solubility and
thus its utility in further synthesis. Therefore the tetrafluoroborate salt was explored. This
latter salt was obtained by treating the dihydrochloride salt with a solution of tetrafluoroboric
acid-diethyl ether complex. The conversion was essentially quantitative (98%) (Scheme 3.28)
and as anticipated the solubility was dramatically increased in solvents such as acetone or
acetonitrile.
Scheme 3.28: Preparation of 2-(aminomethyl)piperidine ditetrafluoroborate (R)-251.
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3.2.3.4- Enantiopurity and pKa analysis of dihydrochloride 251
The enantiopurity of dihydrochloride 251 was established in an NMR experiment by titration
of racemic and enantiopure samples of (R)-251 with O-methylmandelic acid 332 (1 to 5 eq).
The mixture of the diastereoisomeric salts from the racemic 2-(aminomethyl)piperidine could
be resolved by 1H NMR (400 MHz, MeOD) as illustrated in Figure 3.7. The different
patterns indicate that only a single enantiomer was formed during the synthesis. The red
square highlights the 1H NMR signals on positions 2, 6 and 7.
Figure 3.7: 1H NMR spectra of (S)-O-methylmandelic acid 332 salts of
(R)-251 (top) and (R/S)-251 (bottom)
The titration of enantiopure diamine dihydrochloride
by a potentiometric method. Figure 3.
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method. More accurate values were calc
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The derivative ƒ’= ∂(V)/∂(pH) (Figure 3.9) provided direct reading for pKa1 = 6.6 and
pKa2 = 9.9.
The pKa2 value is lowered relative to those of piperidine (pKa = 11.22)28 and 2-methyl-
piperidine (pKa = 10.99).29 The two pKa values are also decreased compared to those of
ethylenediamine (pKa1 = 7.16 and pKa2 = 10.21).30
In the literature, 2-aminomethylpiperidine 251 is always reported as a salt. The only reported
reaction of 251 salts involved N,N’-diprotection as a dicarbamate (Scheme 3.29).20 The
authors neutralised the dihydrochloride salt in a KOH solution (1 M) and extracted the free
base into DCM before treatment with CbzCl (55%).
Scheme 3.29: N,N’ Dicarbamate protection from 251 dihydrochloride.20
In our case, dissolution of the salt in a minimum volume of water and then treatment by
NaOH (1 M) to reach pH ≥12, followed by extraction into DCM, gave the expected diamine
251. The viscous liquid was submitted to distillation (35 °C, 0.1 mBar) but this resulted in
degradation products rather than isolation of the free base.
In the following study, the free base was generated in situ and the first reactions from (R)-2-
(aminomethyl)piperidine dihydrochloride or the tetrafluoroborate salt of 251 are described.
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3.3- Development of [4,4,0]-1,4-diazobicyclodecane 332 and its
derivatives
2-(Aminomethyl)piperidine 251 is a chiral bifunctional amine and its conversion to bicyclic
heterocycles was explored. Fused bicycles are readily accessible from 2-
(aminomethyl)piperidine, particularly via N1,N4 cyclisation to piperazines. Piperazines are
ubiquitous moieties in drug candidates, either as a core motif or as a substituent. An example
is [4,4,0]-1,4-diazobicyclodecane 333.
Recent drug candidates, as illustrated in Figure 3.10, have been designed by structure-
activity studies and their respective properties have been tuned by the presence of the [4,4,0]-
1,4-diazobicyclodecane 333 motif, most often under its racemic form. For instance, Merck
developed histone deacetylase (HDAC) inhibitors from nicotinamide. This class of
compounds including 334, shows an in vitro anti-proliferative effect on tumour cells.31 Merck
again synthesised bicyclic piperazine 335 as conformationally constrained piperazine.32 This
derivative was found to be a potent cannabinoid CB1 receptor agonist. Novartis conceived
the oestrogen receptor modulator 336 based on a tetraisoquinoline core. This series of
compounds is set up as an alternative to hormones in the prevention of breast cancers.33 The
Japanese pharmaceutical company Aska synthesized the selective 5-HT1 receptor agonists
337 for the treatment of irritable bowel syndrome (IBS).34
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Figure 3.10: Examples of drug candidates containing the [4,4,0]-1,4-diazobicyclodecane motif.
Compound 335 demonstrated higher in vivo potent antinociceptive activity than its lead
compound 340. The piperidine ring was tuned to lower the degradative metabolism, however
335 was also found to be metabolised in human liver microsomes. It appeared that the major
metabolite 338 resulted from a N1,N4-dealkylation as illustrated in Scheme 3.30.
Scheme 3.30: Metabolism of compound 335 in human liver microsomes.32
In this research, the synthesis of [4,4,0]-1,4-diazobicyclodecane 333 was achieved in two
steps from the diamine 251. Accordingly, racemic 2-(aminomethyl)piperidine 251 was heated
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at reflux with neat diethyl oxalate 341. Under these conditions, the cyclisation proved to be
fast and efficient and 2,3-diketopiperazine 342 was obtained in 92% yield (Scheme 3.31).
The diketopiperazine 342 was then reduced with a large excess of LiAlH4 (10 eq) in refluxing
THF to provide 333 (59%).
Scheme 3.31: Synthesis of [4,4,0]-1,4-diazobicyclodecane 333.
The synthesis of diketopiperazine 342 was anticipated to compete with the bis-product
intermediate 343 but this did not happen (see Scheme 3.32). In the event, this could be
achieved in an efficient reaction by reacting 2-(aminomethyl)-piperidine 251 with 0.5 eq of
diethyl oxalate at low temperature (96%).35
Scheme 3.32: Preparation of intermediate 338.
The four NH’s of 343 make it a potentially interesting tetradentate ligand. For example C-2
symmetric enantiopure tetraamide complexes of Rh or Ir were reported by Alcon to promote
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asymmetric hydrogenations.36 The structural analogue 344 was explored as a ligand for
diethyl zinc reactions. This catalytic system could promote enantioselective hydrosilylation
of ketones with polymethylhydrosiloxane as reductive agent, as shown in Scheme 3.33.37
Scheme 3.33: Zinc-catalyzed reduction of acetophenone 340.37
N1,N2-Bis(piperidin-2-ylmethyl)oxalamide 343 was submitted to a LiAlH4 reduction
(Scheme 3.34). The diamide 343 had poor solubility in THF and the reduction occurred very
slowly (16%). In an effort to improve the solubility a BH3-THF reaction was set up under
constant sonication,38 however this failed to improve the reaction.
Scheme 3.34: Reduction of 343 to 347.
Chapter 3
161
Other derivatives could be obtained from [4,4,0]-1,4-diazobicyclodecane 333, notably N-
alkylated products, via the reduction of intermediate N-acyl substituents. N-acylation/
reduction of 333 was carried out with appropriate electrophiles in a one-pot reaction.
Thus, the addition of ethyl acetate (1 eq) into the reaction before quenching LiAlH4, resulted
in a mixture of 333 and the N-ethyl derivative 348 in a 2:1 ratio (Scheme 3.35).
Scheme 3.35: Ethylation of 342 under reductive conditions.
This suggested an in situ acylation of the generated secondary amine by ethyl acetate, before
its reduction by hydrides. Accordingly, the level of ethyl acetate was varied and at about
10 eq a complete conversion to 348 was achieved (Table 3.2).
EtOAc (nb of eq) 1 2 5 10
Ratio 333/348 2:1 3:2 2:3 0:1
Table 3.2: Optimisation of acylation/reduction conditions to generate 348.
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As a consequence of the N-ethylation, the lipophilicity of the diamine was enhanced and the
product 348 was more readily partitioned than 333 into the organic phase during extraction,
leading to an efficient recovery of product (89%).
This N-alkylation process has the obvious advantage compared to direct alkylation with alkyl
halides, which generally leads to the formation of quaternary ammonium salts. This reaction
could be extended to the fluoromethyl derivative 350. An acylation/reduction was explored
with ethyl fluoroacetate, which gave the expected fluoroethyl derivative 350 in good yield
(76%).
Scheme 3.36: Formation of the fluoroethyl derivative 350.
For an enantiopure synthesis, on a small scale, it was found that the reactivity of the
dihydrochloride salt of 251 was extremely low. The neutralisation process in organic solvents
was slow and not effective due to the insolubility of the diHCl salt. To improve the contact
between the reagents, the reaction was carried out in a sealed tube. Treatment of (R)-251
diHCl with KOtBu (2 eq) for 12 h before addition of diethyl oxalate 341 and heating, in a
sealed tube, improved the reaction and allowed the recovery of (R)-342 in 21% yield
(Scheme 3.37)
The reduction to (R)-[4,4,0]-1,4-diazobicyclodecane 333 was then achieved as previously
described. This gave an enantiopure sample of (R)-333 in 54% yield
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Scheme 3.37: Enantiopure synthesis of (R)-[4,4,0]-1,4-diazobicyclodecane (R)-333.
Diamide (R)-342 crystallised very easily and X-Ray analysis of a suitable crystal confirmed
the structure and stereochemistry of (R)-342 (Figure 3.11).
Figure 3.11: X-Ray structure of (R)-342.
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3.4- 2-(Aminomethyl)piperidine as asymmetric organocatalyst
The second part of the 2-(aminomethyl)piperidine research concerned the synthesis of
derivatives with potential catalytic properties. In general, secondary amines can induce Lewis
base catalytic mechanisms either by forming enamine or iminium intermediates. The role of
piperidine 351 as a catalyst was exemplified in a Knoevenagel condensation39 where
piperidine reacts with an aldehyde e.g. 352 to generate an iminium intermediate 353 (Scheme
3.38).
Scheme 3.38: Mechanism of Knoevenagel condensation with piperidine as an organocatalyst.
Asymmetric organocatalysis have typically 5-20 mol% of catalyst. L-Proline has proved to be
very effective in this regard as have other enantiopure amines.40-42
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Attention is also drawn to the development of pyrrolidines notably to expand the scope of
catalysts for the model asymmetric Mannich reaction, as illustrated in Scheme 3.40.43-45
Scheme 3.39: Asymmetric Mannich-like reactions used to assay the catalytic properties of piperidine
derivatives.
The basicity of piperidine (pKaH = 11.1) is very similar to pyrrolidine (pKaH = 11.3), thus we
sought to evaluate 251 as an organocatalyst. In this study, three derivatives of 2-
(aminomethyl)piperidine 251 were targeted to tune the electronic properties. It is targeted to
obtain organocatalysts able to form strong hydrogen bonds during the transition state and thus
lower the activation barrier of the asymmetric Mannich reaction.
3.4.1- N-(Piperidin-2-ylmethyl)benzamide
N-Benzoylation of 251 appeared attractive to form an amide as hydrogen bond donor. This
was first attempted with benzoyl chloride (Scheme 3.40). In an attempt to ensure the
chemoselectivity, the amine moieties were initially protected with chlorotrimethylsilane.
N-Trimethylsilylation occurred with complete conversion of the starting material. The
mixture contained around 5% of the mono-protected diamine but no trace of a tri-protected
diamine could be detected (95% N1,N4-TMS, 5 % N1- and N4-TMS). However, in an
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attempted one-pot reaction, the N-benzoylation failed and after deprotection, only starting
material was recovered. Increasing the equivalence of freshly distillated benzoyl chloride (2
eq, rt, 2 h) did not improve the reaction.
Scheme 3.40: Regioselective N-benzoylation of rac-251.
However, direct acylation was more successful; treatment of 251 with ethyl benzoate (1.7 eq)
in various solvents was explored (Scheme 3.41). Reaction in ACN/water (6/1) proved to
offer the best preparation of 362 (62%). Over reaction to N1,N4-dibenzoylation was not
observed.
Scheme 3.41: Direct regioselective N-benzoylation on rac-251.
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3.4.2- 2,2,2-Trifluoro-N-(piperidin-2-ylmethyl)acetamide
In order to increase the potential hydrogen bonding donor ability of the catalyst, a synthesis
of trifluoroacetamide 363 was attempted.46 In this case, the enantiopure (R)-2-(aminomethyl)-
piperidine dihydrochloride was treated directly with either trifluoroacetic anhydride or ethyl
trifluoroacetate. Triethylamine and DIEA were explored as bases to neutralise the salt and the
conditions are summarised in Table 3.4.
Entryi Base Solvent Result
1 Et3N 3 eq MeOH 39% 
2 DIEA 2 eq MeOH 48% 
3 DIEA 3 eq MeOH Mixture of N
1-, N4- and
N1,N4-trifluoramide 
4 DIEA 5 eq MeOH Mixture of N
1-, N4- and
N1,N4-trifluoramide 
5 DIEA 2 eq ACN/water 6:1 No reaction 
6 DIEA 2 eq THF/DMF 1:1 54% 
i: All reactions 8 h, except entry 6, 14 h
Table 3.4: Exploration of conditions to (R)-363.
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Product (R)-363 was always obtained when 2 or 3 equivalents of base were used, except with
ACN/water (6:1) as the solvent. Furthermore, 3-5 equivalents of DIEA provided mixtures of
N1-, N4- and N1,N4-trifluoroamides. DMF assisted the dissolution of (R)-251 dihydrochloride
in THF, and the conversion was slightly higher after 14 h at reflux. This emerged as the
preferred conditions for reaction of the diHCl salt of 251 to provide (R)-363.
A later development in the programme recognised that the tetrafluoroborate salt of (R)-251
could be solubilised in THF and the nucleophilicity of the amine increased. This modification
dramatically improved the synthesis of (R)-363 (88% yield) and this protocol emerged as the
method of choice (Scheme 3.42).
Scheme 3.42: Optimised conditions for the synthesis of (R)-251.
The trifluoroacetate salt of 363 was a crystalline solid and the structure was confirmed by
X-Ray analysis. It was arbitrarily represented as the (R)-enantiomer.
Figure 3.12: X-Ray structure representing protonated (R)-363 (trifluoroacetate salt).
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high steric hindrance could then be evaluated, and for this purpose the benzene sulfonamide
364 was targeted.
Tosylation of the free base required 1 eq of tosyl chloride with potassium carbonate as a base
(Scheme 3.43). The reaction was carried out at low temperature (0 °C) and proved to be very
efficient giving the sulfonamide 364 in a 91% yield.
NH
NH2
NH
NH
S OO
TsCl 1 eq
K2CO3 1,2 eq
DCM
0 °C, 2 h
91%
251 364
Scheme 3.43: Regioselective tosylation of 251.
However to prepare an enantiopure sample of 364, it was important to find a suitable method
to address the poor solubility of the dihydrochloride salt. The use of DMF instead of DCM
provided the expected hydrochloride salt of 364 however in low yield (28%) (Scheme 3.44).
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Pre-packed resins have proven to be an efficient method to separate products according to
their relative affinity or by ion exchange. The use of basic resins, such as Amberlite IRA 400
and Dowex 1X8, was explored to sequester the hydrochlorides but this was not successful.
Scheme 3.44: Assays for tosylation of rac-251 dihydrochloride.
The use of silver carbonate as a base was explored and after a 3 h reaction with tosyl
chloride, 364 was obtained in a 66% yield (Scheme 3.45).
Scheme 3.45: Use of silver carbonate to precipitate hydrochlorides.
However the optically pure base (R)-364 was prepared in a better yield (79%) from its
tetrafluoroborate salt (R)-251. The tetrafluoroborate was successful when first treated with
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DIEA (Scheme 3.46). Then the conditions developed for the racemic diamine rac- 251 could
be used. Interestingly, the use of a unique base (DIEA, Et3N or K2CO3, 3 eq) in the reaction
did not result in an efficient conversion to allow tosylamide 364. K2CO3 acted to precipitate
HBF4 but the KBF4 salt generated dissolved slowly, suggesting a constant exchange of BF4-
with the diamine 251.
Scheme 3.46: Regioselective tosylation on tetrafluoroborate salt of (R)-251.
The structure of 360 was confirmed by X-ray structure analysis. Notably the product is the
free base without any counter ion. The (R)-enantiomer was arbitrarily represented in Figure
3.14.
Figure 3.14: X-Ray structure representing (R)-364.
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attention was drawn to tuning the pKaH of the piperidine and to provide good hydrogen bond
donor ability (Figure 3.16). The trifluoroacetamide moiety carried a reduced pKaH by 0.6
units, and the tosylamide moiety by 0.9 units. The effect of these substituents on the
diastereomeric ratio and enantiomeric excess of a model Mannich reaction is described in the
following section.
Figure 3.16: Calculated pKa of diamine 251, trifluoroacetamide 363 and tosylamide 364.47
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3.5- New catalyst for asymmetric Mannich reactions
One essential parameter for designing new organocatalysts is their pKa values. A systematic
study of proline derivatives highlighted a correlation between the increasing acidities of
proline amides and enhancement of enantioselectivity.46 To examine the scope of the (R)-2-
(aminomethyl)piperidine derivatives as catalysts, the conditions described by Ley et al.48 for
an asymmetric Mannich reaction were used as a frame of reference. The Mannich imine 359
is formed by reaction of p-anisidine 365 on ethyl glyoxalate 366, before dehydration of 367
on molecular sieves. This was achieved in a straightforward manner.
Scheme 3.47: Preparation of the Mannich imine 359.
3.5.1- Reactions catalysed by proline
As a pre-requisite to this study, a set of reference reactions was carried out to establish the
HPLC retention times of the product stereoisomers. A series of reactions catalysed by DL-
proline and separately by its enantiomers D- and L- proline (20 mol%, 24 h in iPrOH) were
conducted. Proline has already been shown to be an excellent catalyst for this reaction.49, 50
The data obtained in this study is shown in Table 3.5.
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Entry Catalyst Yield drsyn/antiii ee
iii
1 DL-Proline 97% 93:7 nsv
2 L-Proline 91% 94:6 97%
3 D-Proline 96% 94:6 98%iv
4 No catalyst 21% 60:40 nsv
5 TMPi 29% 53:47 nsv
i: 2,2,6,6- Tetramethylpiperidine; ii: determined by 1H NMR; iii: determined by HPLC on the major
syn diastereomer; iv: major syn diastereomer was (R,R)-360; v: not significant.
Table 3.5: Reference reactions to establish HPLC retention times of product stereoisomers 360.
The diastereomeric ratio (dr) was determined by 1H NMR, by examination of the NH-CH-
COOEt signals. 1H NMR for the proline catalysed reactions showed consistent syn/anti ratios
higher than 93:7 (entries 1-3). The retention time of the four enantiomers of 360 was
determined by chiral HPLC analysis (column Daicel Chiralpak AS-H, Hexane/iPrOH 9:1,
0.75 mL.min-1) of the DL-proline catalysed reaction at 26.2 min (anti 1), 34.0 min (syn 1),
38.7 min (anti 2) and 47.1 min (syn 2) as shown in Figure 3.17.
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Figure 3.17: HPLC analyses of 355 from control reactions catalysed by Proline
(top: DL-Proline, mid: L-Proline, bottom: D-Proline)
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In the absence of catalyst (entry 4, Table 3.5), the reaction occurred in 21% yield. This
highlights the role of the Mannich adduct 360 as an autocatalyst over long reaction times (24
h).51 DFT calculation have established that the transition state for the syn adduct was
preferred by 1.8 kcal.mol-1.52 In our case, a diastereomeric amplification was observed in
favour of the syn adduct (60:40 dr).
The control reaction with symmetrical 2,2,6,6-tetramethylpiperidine (entry 5) provided the
two sets of diastereomers with a low dr, however the reaction proceeded in only a modest
yield (29%), suggesting that TMP was not a good catalyst.
With this set of controls in place, (E)-N-4-methoxybenzyl-α-iminoglyoxalate 359 was reacted
with cyclohexanone 358 in the presence of organocatalysts 363 or 364. The outcomes of
these reactions are reported below.
3.5.2- Reaction with trifluoroacetamide organocatalyst 363
Conditions for the reaction catalysed by trifluoroacetamide 363 (20 mol%, 24 h, 0.5 mL of
cyclohexanone, 0.5 mL of solvent) were explored. The reaction was carried out in five polar
aprotic (DCM, THF, acetone, DMF, DMSO) and one polar protic (iPrOH) solvent (see Table
3.6). It was established that the yield is increased with the solvent polarity from 26% in DCM
to 44% in DMF. The highest yield observed was however in the neat reaction (61%), which
clearly benefited from a concentration effect. In reactions set up in solvents more polar than
acetone, there is no trace of the iminoester 359.
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NH
NH
F3C O
O
N
COOEt
+ O
COOEt
HN
OMe
363 20mol%
solvent,
rt, 24 h
MeO
358 359 (R,R)-360
Entry Solventi Yield drsyn/anti ee
1 DCM 26% 66:34 42%
2 iPrOH 45% 69:31 78%
3 THF 29% 63:37 53%
4 Acetone 38% 62:38 54%
5 DMF 44% 61:39 62%
6 DMSO 42% 70:30 78%
7 Water 41% 88:12 86%
8 Neat 61% 67:33 58%
i: Cyclohexanone/solvent 1:1.
Table 3.6: Conditions and outcomes of (R)-363 catalysed reactions.
The syn/anti ratios remained relatively stable through the reactions at ~65:35, with the
exception of iPrOH and DMSO, where it was improved (until 70:30 for DMSO).
Interestingly, 363 favoured the formation of the (R,R)-syn adduct of 360. The ee also
increased with the polarity of the solvent, again with the exception of iPrOH (78% ee). In a
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solvent like DMSO (78% ee, Figure 3.18), the HPLC trace shows enlarged peaks at their
bases. It is acknowledged that significant errors are induced in the measure of the ee. The ee
of the neat reaction (58%, Figure 3.19) is lower. To explore further the importance of a polar
protic solvent, a reaction was set up in water. The outcome was improved again with a dr
syn/anti of 88:12 and an ee of 86% (Figure 3.20). In water, cyclohexanone is not soluble and
a micellar suspension is formed with vigorous stirring. It is known that the concentration of
reactants within the micelle or at its aqueous interface can lead to a higher reaction rate.53
This environment appears to favourably affect the reaction. The presence of water for the
autocatalytic Mannich reaction has been noted previously.54 The authors reported that the ee
was dramatically improved (90% ee) but the effect of water was less interesting when the
Mannich imine was formed in situ (68% ee). The catalyst 363 shows equivalent
enantioselectivity but better diastereoselectivity than the autocatalytic Mannich reaction
(53:47 syn/anti ratio).
Figure 3.18: HPLC analysis of reaction in DMSO catalysed by 358 (crude mixture, up to 78% ee).
Figure 3.19: HPLC analysis of reaction in neat conditions catalysed by 358 (crude mixture, 58% ee).
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Figure 3.20: HPLC analysis of reaction in water catalysed by 363 (crude mixture, 86% ee).
The influence of catalyst loading was then explored for 363 as summarised in Table 3.7.
Entryi Catalyst 363
(mol%) Time Yield
dr
syn/anti ee
1 20 4 d 47% 69:31 45%
2 30 24 h 59% 69:31 73%
3 10 24 h 44% 69:31 63%
4 5 24 h 42% 64:36 31%
i: All reactions carried out in iPrOH
Table 3.7: Exploration of catalyst 363 loading and time effects on 360 formation.
In iPrOH, the diastereomeric ratio is constant at 69:31 between 10-30 mol%, however it
reduces at 5 mol% (Figure 3.21). A reaction run for 4 d at 20 mol% did not improve the
outcome (47% yield, 45% ee).
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Figure 3.21: 1H NMR of adduct 360 in a 363 catalysed (10 mol%, iPrOH, 24 h, rt) reaction.
3.5.3- Reactions with organocatalyst 364
The tosylamide 364 was now assayed as a catalyst for the formation of 360. At a catalyst
loading of 20 mol%, the yields were significantly higher and DMSO appeared to be the best
solvent. However, the dr was lower for each solvent (67:33 in favour of the syn adduct in
iPrOH) when compared to 363 as a catalyst. On the other hand, the ee significantly improved
for all the solvents tested (up to 85% ee in DMSO). Interestingly, the favoured enantiomer
was inverted with the (S,S)-syn adduct being favoured over the (R,R)-syn found for catalyst
363 (Figure 3.22).
O+
MeO
358
Entry
1
2
3
Table 3.
Figure 3.22: HPLC analysis of
This study aimed to evaluate
Mannich reaction. Both the trifluoroacetamide
catalysts. Overall the yields were good
N
COOEt
O
COOE
HN364 20mol%
solvent,
rt, 24 h
359 (S,S)-360
NH HN S
O
O
Solvent Yield drsyn/anti ee
iPrOH 50% 67:33 83%
DMSO 53% nd 85%
neat 59% 62:38 83%
8: Scope of solvents for catalyst 364.
neat reaction catalysed by 364 (crude mixture, 83% ee).
the catalytic properties of two piperidine
363 and tosylamide 364 proved
. The selectivity is high, generating
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OMe
derivatives for a
to be efficient
predominantly the
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syn adduct of 360. Overall the ratios were lower than that from the proline catalysed reactions
(up to 99:1 dr)48 but they were comparable to many other chiral catalysts, such as other amino
acids.55
The ee was significantly increased in the presence of DMSO and iPrOH (78% ee), but water
has the strongest effect on both the dr (88:12) and the ee (86%) for 363. Water seems to be
the most appropriate solvent for these reactions.
3.5.4- Mechanistic insights
The generally accepted mechanism of this Mannich reaction is shown in Scheme 3.48, where
the ketone will react with tosylamide 364, resulting in enamine 368 formation. The imine 359
then reacts with the enamine 368 to give the enantiomerically enriched Mannich adduct 360.
Scheme 3.48: Mechanism for the asymmetric Mannich reaction catalysed by 364.
Chapter 3
185
Both catalysts favoured formation of the syn-adduct. To explain the absolute stereochemistry,
two transition states have been proposed based on the literature (Figure 3.23).45, 55-58 When
the Si face of the chiral enamine is attacked by the Si face of the trans-imine, the formation of
the (S,S)-syn-adduct is induced, such as for tosylamide 364. The facial selectivity is induced
by steric repulsion between the catalyst and the PMP group. A nine-member ring is formed in
the transition state, stabilised by a hydrogen bond between the imine nitrogen and the
secondary amine of the catalyst. This ring appears to be more stable with a stronger shorter
hydrogen bond between the imine nitrogen and the amide or sulfonamide.
The reversal of the configuration with catalyst 363 involves the formation of a more
favourable Re face attack by the enamine. This enamine does not suffer from steric repulsion
from the trifluoroacetamide group and thus the HCα can generate a strong hydrogen bond
with the amide nitrogen. This generates a seven membered ring stabilising the Re face.
Figure 3.23: Putative transition states for the major syn-adduct induced by 363 (left) and 364 (right).
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3.6- Conclusion
In the first part of this work, the development of a methodology for the synthesis of the
enantiopure diamine 2-(aminomethyl)-piperidine (R)-251, leading to an efficient gram-scale
synthesis, was described (Figure 3.24).
Figure 3.24: 2-(Aminomethyl)piperidine is a versatile structural motif.
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As depicted in Figure 3.24, a N1-N4 cyclization was achieved on (R)-251 diHCl and lead to
an enantioselective synthesis of (R)-333.
The use of the tetrafluoroborate salt of (R)-251 significantly improved the regioselective
synthesis of the two N1-derivatives (R)-363 and (R)-364. In general, the tetrafluoroborate salt
of 251 offers excellent reactivity and solubility and constitutes the reagent of choice for all
syntheses to 2-(aminomethyl)piperidine derivatives.
When the development of organocatalysts started, it was not obvious that a piperidine
derivative would compete with a pyrrolidine in a catalytic process. This study has
demonstrated that both (R)-363 and (R)-364 have reasonable catalytic properties, comparable
to other chiral entities (up to 86% ee), and with a loading of (R)-363 as low as 5 mol%.
Further studies would certainly uncover new highly efficient organocatalysts derived from 2-
aminomethylpiperidine tetrafluoroborate (R)-251. (R)-251 Tetrafluoroborate should also
prove useful as an intermediate for the synthesis of other chiral amines.
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4- Experimental
4.1- General methods
4.1.1- Reagents, solvents and reaction conditions
All reagents were of synthetic grade and were used without further purification unless
otherwise stated. DCM, diethyl ether, hexane, THF were degassed and dried on a solvent
purification system MB SPS-800 MBraun by passage through two drying columns; dry
methanol was distilled from calcium hydride and dry isopropanol was obtained from Acros.
All moisture sensitive reactions were carried out under a positive pressure of nitrogen in
oven-dried glassware (140 °C). Reactions performed at -78 °C to -10 °C were conducted
using solid CO2 in acetone or a cooling bath apparatus Haake EK 90. Organic extracts were
dried over anhydrous MgSO4.
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4.1.2- Chromatography and mass spectrometry
Thin-layer chromatography (TLC) was performed using Macherey-Nagel Polygram
Sil G/UV254 plastic backed plates. Developed plates were analysed under UV light (254 nm)
or by the use of staining solutions, alkaline potassium permanganate solution, vanillin
solution, ethanolic phosphomolybdic acid solution (PMA), 2,4-dinitrophenylhydrazine
solution (2,4-DNP), or ninhydrin spray. Column chromatography was performed using silica
gel 60 (40-63 μm) from Apollo Scientific Ltd. For GC-MS analyses, columns Supelco MDN-
35 (30 m × 250 µm × 0.25 µm) or Supelco Beta-Dex 120 (30 m × 0.25 mm × 0.25 µm) were
set on an Agilent 6890 Series GC coupled to an Agilent 5973 Network MSD and 7683 Serie
Autosampler. Supplementary chiral analyses were carried out on a Daicel Chiralcel OD-H
column (25 cm × 4.6 mm × 5 µm) using a Varian Prostar HPLC equipped with a Model 410
Autosampler. High-resolution mass spectrometry was performed by Mrs. C. Horsburgh on a
Waters LCT electrospray or GCT time-of-flight mass spectrometer.
4.1.3- Nuclear magnetic resonance spectroscopy (NMR)
NMR spectra were acquired on either Bruker Avance 300 (1H at 300.06 MHz, 13C at 75.45
MHz, 19F at 282.34 MHz), or Bruker Avance II 400 (1H at 400.14 MHz, 13C at 100.62 MHz
and 19F at 376.41 MHz), or Bruker Avance 500 (1H at 499.90 MHz, 13C at 125 MHz, 19F at
470.33 MHz) spectrometers. Chemical shifts  are reported in parts per million (ppm) and
quoted relative to external standard Me4Si for 1H and 13C and to external standard CFCl3 for
19F. 1H, 13C and 19F spectroscopic data were assigned on a routine basis by a combination of
one- and two- dimensional experiments (COSY, HSQC, HMBC, NOESY).
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4.1.4- Other analysis
Melting points were measured using a GallenKamp Griffin MPA350.BM2.5 melting point
apparatus and are uncorrected. Optical rotations were determined using a Perkin Elmer Model
341 polarimeter, ሾߙሿ஽ values were measured at 589 nm and given in implied units of 10
-
1deg.cm2.g-1. pKa determinations were conducted on a EDT RE 357 Tx pH meter calibrated at
pH 4 and pH 7 with standard buffer solutions. Elemental analyses were carried out by Mrs
S. Williamson on a CE instrument EA 1110 CHNS analyser. IR spectra were recorded on a
Perkin Elmer Spectrum GX FT-IR system as thin film on PTFE disposable card. Single X-ray
diffraction analyses were carried out by Prof. A.M.Z Slawin.
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4.2- Protocols
(E)-8-Methylethylnon-6-enoate 146 and (E)-diethyl dodec-6-enedioate 147
Preparation of 146 and 147:
3-Methyl-1-butene (1.5 mL, 12.8 mmol) was added to a solution of ethyl 6-heptenoate
(0.12 mL, 0.64 mmol) and Grubbs II catalyst (71 mg, 0.064 mmol) in DCM (6 mL) at 0 °C.
The solution was then heated to 40 °C for 20 h. After evaporation of the solvent, the crude
product was purified on silica gel, using hexane/acetone (98/2) as eluent to give (E)-8-
methylethylnon-6-enoate 146 as a clear oil (15 mg, 12%) and (E)-diethyl dodec-6-enedioate
147 (28 mg, 22%).
Data for 146:
IR νmax (cm-1): 2921, 2851, 2311, 1730, 1445, 1373. δH (300 MHz, CDCl3): 0.95 (6 H, d,
J 6.8 Hz, 2 × CH3), 1.24 (3 H, t, J 7.1 Hz, CH3), 1.37 (2 H, t, J 7.1 Hz, CH2), 1.63 (2 H, m,
CH2), 1.98 (2 H, q, J 6.5 Hz, CH2), 2.19 (1 H, dq, J 1.2 Hz, J 6.7 Hz, CH2), 2.29 (2 H, t,
J 7.4 Hz, CH2), 4.11 (2 H, q, J 7.1 Hz, OCH2), 5.35 (2 H, m, CH=CH). δC (75 MHz, CDCl3):
14.3 (CH3), 22.6 (CH3), 22.7 (CH3), 24.5 (CH2) , 26.9 (CH2) , 31.0 (CH), 31.6 (2 × CH2),
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60.2 (OCH2), 125.8 (CH, Z, minor isomer), 126.5 (CH, E, major isomer), 138.0 (CH, E, major
isomer), 138.7 (CH, Z, minor isomer). m/z (EI): 198.15 [M]+.
Data for 147:
δH (300 MHz, CDCl3): 1.25 (6 H, t, J 7.1 Hz, 2 × CH3), 1.36 (4 H, m, 2 × CH2), 1.61 (4 H, m,
2 × CH2), 1.99, (4 H, m, 2 × CH2), 2.28 (4 H, t, J 7.5 Hz, 2 × CH2), 4.11 (4 H, q, J 7.1 Hz,
2 × OCH2), 5.38 (2 H, m, CH=CH). m/z (EI): 284.20 [M]+.
Hept-6-enoic acid 165
A solution of potassium hydroxide (17 mL, 2 M) was added dropwise at 0 °C to a solution of
ethyl 6-heptenoate (1.5 mL, 8.55 mmol) in methanol (35 mL). The mixture was stirred for 1 h
at 0 °C, then warmed to room temperature and stirred for another 14 h. Methanol was then
evaporated under reduced pressure and the residue dissolved in water (50 mL) and acidified to
pH = 1 with an aqueous HCl solution (2 M) before extraction into DCM (3 × 50 mL). The
combined organic layers were washed with brine (20 mL), dried, filtered and evaporated. The
oily product was distilled to give hept-6-enoic acid 165 as a clear oil (1.10 g, 100%).
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IR νmax (cm-1): 2921, 2844, 1708, 1022. δH (300 MHz, CDCl3): 1.44 (2 H, m, CH2), 1.65 (2 H,
m, CH2), 2.07 (2 H, m, CH2), 2.36 (2 H, t, J 7.3 Hz, CH2), 4.98 (2 H, m, CH=CH2), 5.79 (1 H,
m, CH=CH2). δC (75 Hz, CDCl3): 24.1 (CH2), 28.2 (CH2), 33.4 (CH2), 34.6 (CH2),
114.7 (CH=CH2), 138.0 (CH=CH2). m/z (EI): 110.07 [M-H2O]+.
(S)-3-Hept-6-enoyl-4-isopropyloxazolidin-2-one 170 and (S)-3-hept-6-enoyl-4-isopropyl-
5,5-diphenyloxazolidin-2-one 171
Preparation of 170:
Triethylamine (0.91 mL, 6.6 mmol) was added dropwise at 0 °C to a solution of hept-6-enoic
acid 165 (807.5 mg, 6.3 mmol) in THF (25.5 mL) and stirred for 15 min at 0 °C before
cooling down to -78 °C prior to addition of pivaloyl chloride (0.8 mL, 6.6 mmol). The
mixture was stirred for 1 h at -78 °C and then for 15 min at 0 °C. In a separate flask, n-
butyllithium (2.5 M, 2.6 mL, 6.3 mmol) was added to a solution of (S)-4-isopropyl-2-
oxazolidinone (814mg, 6.3 mmol) in THF (20 mL) at -78 °C and the reaction was stirred for
15 min. The resulting solution was added at -78 °C to the white suspension of the mixed
anhydride. The mixture was stirred for 30 min, and then an additional hour at 0 °C. The
reaction was quenched with saturated ammonium chloride solution (60 mL) and the volatiles
were evaporated under vacuum. The aqueous mixture was extracted into DCM (3 × 40 mL)
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and the organic layers were washed successively with solutions of 1 M HCl (25 mL) and
saturated sodium bicarbonate (25 mL), dried, and concentrated under vacuum. The residue
was purified over silica gel (hexane/ethyl acetate 80/20) to afford (S)-3-hept-6-enoyl-4-
isopropyloxazolidin-2-one 170 as a colourless oil (1.28 g, 86%).
Preparation of 171:
(S)-3-hept-6-enoyl-4-isopropyl-5,5-diphenyloxazolidin-2-one 171 was obtained as a white
solid (28 mg, 91%) by the same procedure.
Data for 170:
[ࢻሿࡰ૛૙ = +38 (c 1.6, CHCl3). IR νmax (cm-1): 3545, 3382, 3077, 2965, 2876, 1772, 1700, 1385.
δH (300 MHz , CDCl3): 0.88 (6 H, dd, J 7.0 Hz, J 13.0 Hz, 2 × CH3), 1.46 (2 H, m, CH2),
1.67 (2 H, m, CH2), 2.08 (2 H, m, CH2), 2.36 (1 H, m, CH(CH3)2), 2.93 ( 2 H, m, CH2),
4.22 (2 H, m, CH and CHAHB), 4.43 (1 H, m, CHAHB), 4.97 (2 H, m, CH=CH2), 5.80 (1 H, m,
CH=CH2). δC (75 Hz, CDCl3): 14.6 (CH3), 17.9 (CH3), 23.8 (CH2), 28.2 (CH (CH3)2),
28.3 (CH2), 33.4 (CH2), 35.3 (CH2), 58.3 (CH), 63.3 (CH2), 114.6 (CH=CH2),
138.4 (CH=CH2), 173.2 (C=O). m/z (HRMS) (ES+): calcd for C13H21NO3Na: 262.1419, found
262.1416 [M+Na]+.
Data for 171:
[ࢻሿࡰ૛૙ = -43.6 (c 1.2, CHCl3). Mp 87-89 °C. IR νmax (cm-1): 2956, 2363, 1778. δH (300 MHz,
CDCl3): 0.76 (3 H, d, J 6.8 Hz, CH3), 0.88 (3 H, d, J 7.0 Hz, CH3), 1.32 (3 H, m, CH2 and
CH(CH3)2), 1.55 (2 H, m, CH2), 1.99 (2 H, m, CH2), 2.82 (2 H, m, CH2), 4.94 (2 H, m,
CH=CH2), 5.34 (1 H, m, CH), 5.74 (1 H, m, CH=CH2), 7.33 (8 H, m, Ar H), 7.47 (2 H, m,
Ar H). m/z (HRMS) (ES+): calcd for C25H29NO3Na: 414.2045, found 414.2037 [M+Na]+.
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(S)-3-((S)-2-Fluorohept-6-enoyl)-4-isopropyloxazolidin-2-one 172a and (S)-3-((S)-2-
fluorohept-6-enoyl)-4-isopropyl-5,5-diphenyloxazolidin-2-one 173a
Preparation of 172a:
LiHMDS (1.15 mL, 1 M in hexanes) was added to a solution of 167 (250 mg, 1.05 mmol) in
dry THF (5 mL) and stirred for 1 h at -78 °C and then, the reaction was warmed to 0 °C. A
solution of NFSI (429 mg, 1.36 mmol) in dry THF (1.7 mL) was added at -78 °C and the
mixture stirred for 2 h. Purification over silica gel (neat hexane to hexane/ethyl acetate: 94/6)
gave the product as an oil which was precipitated in diethylether to afford the title compound
(S)-3-((S)-2-fluorohept-6-enoyl)-4-isopropyloxazolidin-2-one 172a as the major component
of a mixture of diastereoisomers (82% de), as a white solid (10 mg, 20%).
Preparation of 173a:
The same procedure was applied to obtain the title compound (S)-3-((S)-2-fluorohept-6-
enoyl)-4-isopropyl-5,5-diphenyloxazolidin-2-one 173a as a mixture of diastereoisomers
(38% de) as a white solid (5 mg, 17%).
Data for 172a:
Mp 63-65 °C. IR νmax (cm-1): 2919, 2866, 2336, 1717, 1482, 1388, 1015. δH (300 MHz,
CDCl3): 0.90 (6 H, dd, J 7.0 Hz, J 14.1 Hz, 2 × CH3), 1.64 (2 H, m, CH2), 1.82 (2 H, dd,
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J 7.3 Hz, J 14.2 Hz, CH2), 2.09 (2 H, m, CH2), 2.48 (1 H, m, CH(CH3)2), 4.34 (3 H, m, CH
and CH2), 4.99 (2 H, m, CH=CH2), 5.78 (1 H, ddt, J 6.7 Hz, J 10.3 Hz, J 17.0 Hz, CH=CH2),
5.90 (1 H, ddd, J 3.2 Hz, J 8.1 Hz, J 50.2 Hz, CHF). δF {1H} (282 MHz, CDCl3): -193.3
(91%, (S,S), CHF), -194.9 (9%, (S,R), CHF). m/z (HRMS) (ES+): calcd for C13H20NO3NaF:
280.1325, found 280.1318 [M+Na]+.
Data for 173a:
Mp 81-83 °C. IR νmax (cm-1): 2920, 2840, 2400, 1743, 1433, 1022. δH (300 MHz, CDCl3):
0.68 (3 H, d, J 6.6 Hz, CH3), 0.89 (3 H, d, J 6.9 Hz, CH3), 1.32 (3 H, m, CH2 and CH(CH3)2),
1.92 (4 H, m, 2 × CH2), 5.46 (5 H, m, CHF, and CH=CH2, and CH), 7.40 (10 H, m, Ar H).
δF {1H} (282 MHz, CDCl3): -193.9 (69%, (S,S), CHF), -194.5 (31%, (S,R), CHF).
m/z (EI): 409.21 [M]+.
(S)-3-((E)-(S)-2-Fluoro-8-methylnon 6-enoyl)-isopropyloxazolidin 2-one 174a
Preparation by cross-metathesis chain elongation of 172a:
3-Methyl-1-butene (0.08 mL, 0.74 mmol) was added at 0 °C to a solution of (S)-3-((S)-2-
fluorohept-6-enoyl)-4-isopropyloxazolidin-2-one 172a (9.6 mg, 0.037 mmol) and Grubbs II
catalyst (3.1 mg, 0.004 mmol, 0.1 eq) in dry DCM (0.33 mL). The solution was heated to
200
40 °C for 20 h. After evaporation of the solvent, the crude product was purified by flash
chromatography, using hexane/ethyl acetate (98/2) as eluent to provide (S)-3-((E)-(S)-2-
fluoro-8-methylnon 6-enoyl)-isopropyloxazolidin 2-one 174a as an oil (6 mg, 54%).
Preparation by fluorination of the N-acyl oxazolidinone 189:
LiHMDS (14.9 mL, 1 M in hexanes) was added to a solution of (S)-4-isopropyl 3-((E)-8-
methylnon-6-enoyl)oxazolidin 2-one 189 (3.80 g, 13.5 mmol) in THF (65 mL) and was stirred
for 1 h at -78 °C. The reaction was then warmed up to 0 °C for 20 min. A solution of NFSI
(5.50 g, 17.5 mmol) in dry THF (20 mL) was then added at -78 °C and the mixture stirred for
3 h. The reaction was quenched with saturated ammonium chloride solution (200 mL) and the
product was extracted into diethyl ether (3 × 200 mL). Purification over silica gel
(hexane/DCM 6/4 then 5/5) gave (S)-3-((E)-(S)-2-fluoro-8-methylnon 6-enoyl)-
isopropyloxazolidin 2-one 174a as an oil (765 mg, 20%).
Data for 174a:
IR νmax (cm-1): 3269, 2959, 1829, 1745, 1603, 1412, 1084. δH (300 MHz, CDCl3): 0.91 (6 H,
dd, J 7.0 Hz, J 14.1 Hz, 2 × CH3), 0.95 (6 H, d, J 6.7 Hz, 2 × CH3), 1.59 (2 H, dd, J 7.4 Hz,
J 14.6 Hz, CH2), 1.81 (2 H, m, CH2), 2.02 (2 H, m, CH2), 2.22 (1 H, m, CH), 2.49 (1 H, m,
CH), 4.30 (2 H, m, CH2), 4.42 (1 H, m, CH), 5.34 (2 H, m, CH=CH), 5.91 (1 H, ddd,
J 3.5 Hz, J 7.8 Hz, J 50.2 Hz, CHF). δC (75 MHz, CDCl3): 14.3 (CH3), 17.9 (CH3),
22.6 (2 × CH3), 24.8 (CH2), 27.9 (CH), 31.0 (CH), 32.0 (2 × CH2), 58.6 (CH), 64.1 (CH2),
89.1 (d, J 178.6 Hz, CHF), 126.0 (CH=CH), 138.5 (CH=CH), 153.5 (C=O), 169.9 (d,
J 22.8 Hz, C=O). δF {1H} (282 MHz, CDCl3): -193.2 (S, S, E). m/z (HRMS) (CI+): calcd for
C16H27NO3F: 300.1975, found 300.1977 [M+H]+.
201
Isobutyltriphenylphosphonium iodide 177
1-Iodo-2-methylpropane (0.30 mL, 2.67 mmol) was added to a solution of triphenylphosphine
(700 mg, 2.67 mmol) in toluene (0.30 mL). The reaction was then heated under reflux (110-
115 °C) for 20 h. After cooling, the precipitate formed was filtered and the filter cake was
washed with diethyl ether (3 × 6 mL) and dried under high vacuum to give
isobutyltriphenylphosphonium iodide 177 as a white powder (980 mg, 82%).
Mp 201 °C (lit.1 Mp: 198-201 °C). IR νmax (cm-1): 3020, 2951, 1584, 1482, 1435, 1191, 1139,
1109. δH (300 MHz, CDCl3): 1.03 (6 H, d, J 6.9 Hz, 2 × CH3), 2.10 (1 H, m, CH), 3.65 (2 H,
dd, J 12.9 Hz, J 6.9 Hz, CH2), 7.85 (15 H, m, Ar H). δC (75 Hz, CDC13): 24.5 (CH),
24.9 (2 × CH3), 31.2 (CH2), 118.9 (Ar C IV),130.1 (Ar CH), 133.5 (Ar CH), 134.8 (Ar CH).
Analytical data identical to literature1
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Ethyl 6-oxohexanoate 180
Sodium acetate (150 mg, 1.10 mmol) and pyridinium chlorochromate (1.07 g, 4.96 mmol)
were added to a solution of ethyl 6-hydroxylhexanoate (0.54 mL, 3.3 mmol) in DCM
(10 mL). After stirring at room temperature for 3 h, the mixture was diluted with diethyl ether
(100 mL) and filtered through a plug of Florisil®. The filtrate was evaporated under vacuum
to obtain the title compound ethyl 6-oxohexanoate 180 as a clear oil (470 mg, 90%).
δH (300 MHz, CDCl3): 1.19 (3 H, t, J 7.1 Hz , CH3), 1.58 (4 H, m, 2 × CH2), 2.27 (2 H, m,
CH2), 2.42 (2 H, dt, J 1.5 Hz, J 6.8 Hz, CH2), 4.06 (2 H, dq, J 0.9 Hz, J 7.1 Hz, OCH2),
9.67 (1 H, t, J 1.5 Hz, CHO). δC (75 Hz, CDCl3): 14.6 (CH3), 21.3 (CH2), 24.2 (CH2),
33.6 (CH2), 43.5 (CH2), 51.7 (OCH2), 173.6 (COOEt), 201.8 (CHO). m/z (EI): 158.08 [M]+.
203
(5-Carboxy-pentyl)-triphenylphosphonium salt 1852
A mixture of 6-bromohexanoic acid (25.8 g, 0.13 mmol) and triphenylphosphine (34.7 g,
0.13 mmol) was heated to 145 °C for 4 h. The cooled reaction mixture was triturated in
chloroform and precipitated into diethyl ether. The resultant precipitate was filtered, washed
with diethyl ether and dried under vacuum to give (5-carboxy-pentyl)-triphenylphosphonium
salt 185 as a solid (57.8 g, 97%).
Mp 195-199 °C (lit2 200-203 °C). IR νmax (cm-1): 3392, 3053, 2990, 2597, 2215, 1991, 1723,
1586, 1438, 1337. δH (300 MHz, CDCl3): 1.69 (6 H, m, 3 × CH2), 2.42 (2 H, t, J 6.8 Hz,
CH2), 3.64 (2 H, m, CH2), 7.75 (15 H, m, Ar H). δC (75 MHz, CDCl3): 21.7 (CH2),
22.9 (CH2), 23.9 (CH2), 29.6 (CH2), 34.3 (CH2), 118.1 (d, J 86.2 Hz, 3 × Ar C IV), 130.5 (d,
J 12.5 Hz, 6 × Ar CH), 133.6 (d, J 10 Hz, 6 × Ar CH), 135.1 (d, J 2.7 Hz, 3 × Ar CH),
175.7 (COOH).
204
(Z)-8-methylnon 6-enoic acid 187b
A mixture of (5-carboxy-pentyl)-triphenylphosphonium salt 185 (20.0 g, 43.7 mmol) and iso-
butylaldehyde (4.8 mL, 52.5 mmol) in DMF (90 mL) was added to a suspension of potassium
tert-butylate (10.0 g, 89.6 mmol) in DMF (110 mL) and the reaction stirred at 0 °C for
15 min. After vigorous stirring for 15 h at rt, the resulting slurry was poured into ice-water
(13 mL) and the precipitated triphenylphosphine oxide was removed by filtration. The filtrate
was washed with toluene (2 × 30 mL) and acidified with HCl (2 M) and then, the aqueous
layer was extracted into diethyl ether (4 × 20 mL), washed with brine (4 × 15 mL), and dried
over magnesium sulfate. The product was distilled at 110 °C (10-13 mbar) to obtain (Z)-8-
methylnon 6-enoic acid 187b (3.51 g, 47%, Z/E ratio: 9/1) as a colourless oil.
IR νmax (cm-1): 2957 (br), 2670, 1709 (br), 1464, 1164. δH (300 MHz, CDCl3): 0.93 (6 H, d,
J 6.7 Hz, 2 × CH3), 1.40 (2 H, dt, J 7.5 Hz, J 14.9 Hz, CH2), 1.65 (2 H, dt, J 7.3 Hz,
J 15.7 Hz, CH2), 2.06 (2 H, m, CH2), 2.22 (1 H, m, CH, (E) minor isomer), 2.35 (2 H, t,
J 7.3 Hz, CH2), 2.57 (1 H, m, CH, (Z) major isomer), 5.20 (2 H, m, CH=CH, (Z) major
isomer), 5.34(2 H, m, CH=CH, (E) minor isomer) , 11.99 (1 H, br s, COOH). δC (75 MHz,
CDCl3): 23.1 (2 × CH3), 24.2 (CH2), 26.4 (CH), 26.9 (CH2), 26.8 (CH2), 29.2 (CH2),
34.0 (CH2), 126.5 (CH=CH), 138.0 (CH=CH), 180.5 (COOH). m/z (EI): 170.13 [M]+.
205
(E)-8-Methylnon 6-enoic acid 187a
Solutions of sodium nitrate (1.5 mL, 2 M) and nitric acid (1.0 mL, 6 M) were added to (Z)-8-
methylnon 6-enoic acid 21 (3.51 g, 20.6 mmol). The mixture was stirred vigorously and
heated to 75 °C for 1 h. The cooled reaction mixture was diluted into diethyl ether (20 mL),
washed successively with water (20 mL) and saturated brine (3 × 12 mL), dried over
magnesium sulfate, and evaporated under vacuum to provide (E)-8-methylnon 6-enoic acid
187a as a colourless oil (3.3 g, 95%, E/Z ratio: 86/14).
δH (300 MHz, CDCl3): 0.95 (6 H, d, J 6.7 Hz, 2 × CH3), 1.39 (2 H, dt, J 7.8 Hz, J 15.1 Hz,
CH2), 1.63 (2 H, dt, J 7.1 Hz, J 14.9 Hz, CH2), 1.99 (2 H, dd, J 6.7 Hz, J 13.0 Hz, CH2),
2.22 (1 H, m, CH, (E) major isomer), 2.35 (2 H, t, J 7.4 Hz, CH2), 2.57 (1 H, m, CH, (Z) minor
isomer), 5.20 (2 H, m, CH=CH, (Z) minor isomer), 5.34 (2 H, m, CH=CH, (E) major isomer),
11.72 (1 H, br s, COOH). δC (75 Hz, CDCl3): 22.6 (2 × CH3), 24.1 (CH2), 29.0 (CH2),
31.0 (CH), 32.1 (CH2), 34.0 (CH2), 126.3 (CH=CH), 138.1 (CH=CH), 180.6 (COOH).
m/z (EI): 170.13 [M]+.
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(S)-4-Isopropyl 3-((E)-8-methylnon-6-enoyl)oxazolidin 2-one 189
Triethylamine (2.9 mL, 20.6 mmol) was added dropwise at 0 °C to a solution of 187a (3.30 g,
19.6 mmol) in THF (80 mL) and stirred for 15 min at 0 °C before cooling down to -78 °C for
addition of pivaloyl chloride (2.5 mL, 20.6 mmol). The mixture was stirred for 1 h at -78 °C
and then 15 min at 0 °C. In a separate flask, n-butyllithium (7.8 mL ,19.6 mmol, 2.5 M) was
added to a solution of (S)-4-isopropyl-2-oxazolidinone (2.50 g, 19.6 mmol) in THF (60 mL) at
-78 °C and the reaction was stirred for 15 min. The resultant solution was added at -78 °C to
the white suspension of the mixed anhydride. The mixture was stirred for 30 min, then for 1
additional hour at 0 °C. The reaction mixture was quenched with saturated ammonium
chloride solution and the volatiles were evaporated under vacuum. This aqueous mixture was
extracted into DCM (3 × 15 mL) and the organic layers were washed successively with
solutions of HCl (1 M) and saturated sodium bicarbonate, dried over magnesium sulfate, and
concentrated under vacuum. The residue was purified over silica gel (hexane/DCM 7/3 then
neat ethyl acetate) to afford (S)-4-isopropyl 3-((E)-8-methylnon-6-enoyl)oxazolidin 2-one 189
(3.9 g, 71%) as a clear oil.
δH (300 MHz, CDCl3): 0.89 (6 H, dd, J 7.0 Hz, J 12.9 Hz, 2 × CH3), 0.95 (6 H, d, J 6.7 Hz, 2
× CH3), 1.41 (2 H, dt, J 7.7 Hz, J 15.3 Hz, CH2), 1.66 (2 H, m, CH2), 2.00 (2 H, dd, J 6.6 Hz,
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J 12.8 Hz, CH2), 2.21 (1 H, m, CH), 2.37 (1 H, m, CH), 2.91 (2 H, m, CH2), 4.22 (2 H, m,
CH2), 4.43 (1 H, dt, J 3.5 Hz, J 7.5 Hz, CH), 5.35 (2 H, m, CH=CH). δC (75 MHz, CDCl3):
14.6 (CH3), 18.0 (CH3), 22.6 (2 × CH3), 23.9 (CH2), 28.3 (CH), 29.0 (CH2), 31.0 (CH), 32.2
(CH2), 35.4 (CH2), 58.3 (CH2), 63.3 (CH), 126.5 (CH=CH), 140.0 (CH=CH), 154.0 (C=O),
173.3 (C=O). νmax (cm-1): 2919, 1776, 1700, 1389. m/z (HRMS) (ES+): calcd for
C16H27NO3Na: 304.1889, found 304.1887 [M+Na]+.
(S)-4-isopropyl-3-((R)-3-phenylbutanoyl)oxazolidin-2-one 198
Triethylamine (0.47 mL, 3.42 mmol) was added dropwise at 0 °C to a solution of (R)-3-
phenylbutyric acid (0.50 mL, 3.25 mmol) in THF (13 mL) and stirred for 15 min at 0 °C
before cooling down to -78 °C for addition of pivaloyl chloride (0.42 mL, 3.42 mmol). The
mixture was stirred for 1 h at -78 °C, then 15 min at 0 °C. In a separate flask, n-butyllithium
(1.3 mL ,3.26 mmol, 2.5 M) was added to a solution of (S)-4-isopropyl-2-oxazolidinone
(421 mg, 3.26 mmol) in THF (10 mL) at -78 °C and the reaction was stirred for 15 min. The
resultant solution was added at -78 °C to the white suspension of the mixed anhydride. The
mixture was stirred for 30 min, then for 1 h further at 0 °C. The reaction mixture was
quenched with a saturated aqueous solution of ammonium chloride and the volatiles were
evaporated under vacuum. This aqueous mixture was extracted into DCM (3 × 10 mL) and
208
the organic layers were washed successively with solutions of HCl (1 M) and saturated
sodium bicarbonate, dried over magnesium sulfate, and concentrated under vacuum. The
residue was purified on silica gel (hexane/DCM 1/1 then neat ethyl acetate) to afford (S)-4-
isopropyl-3-((R)-3-phenylbutanoyl)oxazolidin-2-one 198 (679 mg, 76%) as a white wax.
[ࢻሿࡰ૛૙ = -12 (c 1.1, MeOH). IR νmax (cm-1): 2956, 2844, 2333, 1772, 1693, 1493, 1364.
δH (300 MHz, CDCl3): 0.65 (3 H, d, J 6.9 Hz, CH3), 0.81 (3 H, d, J 7.0 Hz, CH3), 1.32 (3 H,
d, J 6.9 Hz), 2.16 (1 H, m, CH), 2.99 (1 H, dd, J 7.2 Hz, J 15.6 Hz, CHAHB), 3.38 (1 H, m,
CH), 3.51 (1 H, dd, J 7.2 Hz, J 15.6 Hz, CHAHB), 4.13 (1 H, dd, J 3.2 Hz, J 9.1 Hz, OCH2),
4.21 (1 H, t, J 9.0 Hz, OCH2), 4.38 (1 H, dt, J 3.4 Hz, J 8.2 Hz, NCH), 7.19 (5 H, m, Ar H).
δC (75 MHz, CDCl3): 14.3 (CH3), 17.8 (CH3), 21.9 (CH3), 28.2 (CH(CH3)2), 36.2 (CH),
43.0 (CH2), 58.2 (NCH), 63.1 (OCH2), 126.3 (Ar CH), 126.9 (2 × Ar CH), 128.4 (2 × Ar CH),
145.6 (Ar C IV), 153.9 (O-C=O), 171.9 (N-C=O). m/z (EI): 275.15 [M]+.
(S)-3-((2S,3S)-2-fluoro-3-phenylbutanoyl)-4-isopropyloxazolidin-2-one 199
LiHMDS (2.42 mL, 1 M in hexanes) was added at -78 °C to a solution of (S)-4-isopropyl-3-
((R)-3-phenylbutanoyl)oxazolidin-2-one 198 (612 mg, 2.2 mmol) in THF (10 mL) and was
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stirred for 1 h at -78 °C. The reaction mixture was then warmed up to 0 °C for 20 min. A
solution of NFSI (902 mg, 2.8 mmol) in THF (4 mL) was added at -78 °C and the mixture
stirred for 3 h. The mixture was quenched with a saturated ammonium chloride solution
(35 mL) and was extracted into diethylether (3 x 40 mL). The gathered organic layers were
dried over magnesium sulfate and concentrated under vacuum to afford an oil which was
precipitated in diethylether to give (S)-3-((2S,3S)-2-fluoro-3-phenylbutanoyl)-4-
isopropyloxazolidin-2-one 199 as a solid (327 mg, 51%).
δH (300 MHz, CDCl3): 0.87 (6 H, t, J 6.7 Hz, 2 × CH3), 1.46 (3 H, dd, J 0.8 Hz, J 7.2 Hz,
CH3), 2.42 (1 H, m, CH(CH3)2), 3.41 (1 H, dm, J 26.8 Hz, CHF-CH), 4.18 (2 H, m, O-CH2),
4.25 (1 H, m, N-CH), 6.17 (1 H, dd, J 4.9 Hz, J 48.8 Hz, CHF), 7.28 (5 H, m, Ar H). δC (75
MHz, CDCl3): 14.4 (CH3), 17.2 (d, J 6.2 Hz, CHF-CH-CH3), 17.9 (CH3), 28.1 (CH(CH3)2),
42.1 (d, J 20.7 Hz, CHF-CH-CH3), 58.9 (NCH), 64.2 (O-CH2), 91.4 (d, J 184 Hz, CHF),
127.4 (Ar CH), 128.1 (2 × Ar CH), 128.4 (2 × Ar CH), 139.9 (Ar C), 153.7 (O-C=O), 168.3
(N-C=O). δF {1H} (282 MHz, CDCl3): -196.4 (3 %, (S,R,S)), -198.2 (97 %, (S,S,S)). δF (282
MHz, CDCl3): -196.4 (dd, J 22.7 Hz, J 49.1 Hz, (S,R,S)), -198.2 (dd, J 26.8 Hz, J 48.8 Hz,
(S,S,S)). νmax (cm-1): 2956, 2844, 1771, 1710, 1485, 1449, 1386. m/z (HRMS) (ES+): calcd for
C16H20NO3NaF: 316.1325, found 316.1326 [M+Na]+.
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(2S,3S)-2-fluoro-N-methoxy-N-methyl-3-phenylbutanamide 201
A solution of trimethylaluminium (0.28 mL, 2 M, 0.56 mmol,) was added slowly at 0 °C to a
suspension of N,O-dimethylhydroxylamine hydrochloride (55.2 mg, 0.57 mmol) in DCM
(0.8 mL). The reaction mixture was stirred at 0 °C until gas emission ceased (10 min), then
the solution was cooled to -10 °C prior addition of (S)-3-((2S,3S)-2-fluoro-3-phenylbutanoyl)-
4-isopropyloxazolidin-2-one 199 (55 mg, 0.19 mmol). After 1 h, the reaction was warmed up
to 0 °C until completion of the reaction (2 h). The mixture was poured with vigorous stirring
into an ice-cold mixture of HCl (5 mL, 0.5 M) and DCM (2.5 mL) and extracted into DCM.
The combined organic layers were washed with brine, dried over magnesium sulfate, filtered
and concentrated under vacuum. The crude product was purified on silica gel
(hexane/ethylacetate 7/3) to give (2S,3S)-2-fluoro-N-methoxy-N-methyl-3-phenylbutanamide
201 as a colourless oil (43 mg, 100%).
δH (300 MHz, CDCl3): 1.30 (3 H, d, J 7.2 Hz, CH3), 3.18 (3 H, s, CH3), 3.41 (1 H, m, CH),
3.68 (3 H, s, OCH3), 5.24 (1 H, dd, J 7.6 Hz, J 48.9 Hz, CHF), 7.26 (5 H, m, Ar H).
δC (75 MHz, CDCl3): 16.6 (d, J 7.0 Hz, CH3), 32.1 (NCH3), 40.5 (d, J 20.6 Hz, CH),
61.6 (OCH3), 90.7 (d, J 179.7 Hz, CHF), 127.1 (Ar CH), 128.0 (2 × Ar CH),
128.4 (2 × Ar CH), 141.1 (Ar C IV). δF (282 MHz, CDCl3): -189. 99 (98%, dd, J 18.4 Hz,
J 48.9 Hz, (S,S)), -196.50 (2%). m/z (EI): 225.12 [M]+.
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(2S,3S)-2-fluoro-3-phenylbutanoic acid 203
Hydrogen peroxide (0.9 mL, 35%) was added at 0 °C to a solution of (2S,3S)-2-fluoro-N-
methoxy-N-methyl-3-phenylbutanamide 201 (150 mg, 0.51 mmol) dissolved in a mixture of
THF and water (1:1, 6 mL). Lithium hydroxide (43 mg, 1.00 mmol) was added, and the
reaction was stirred for 1 h at 0 °C. The solvent was evaporated and the aqueous solution
(pH= 12) was acidified with HCl (2 M) to pH = 1 and was extracted into DCM (4 × 12 mL).
The organic layer was dried over magnesium sulphate and concentrated to give (2S,3S)-2-
fluoro-3-phenylbutanoic acid 203 as a white powder (85 mg, 92%).
Mp: 81 °C. [ࢻሿࡰ૛૙ = +26.4 (c 1.4, MeOH). IR νmax (cm-1): 3031, 2976, 1951, 1735, 1603,
1495, 1383, 1039. δH (300 MHz, CDCl3): 1.49 (3 H, d, J 7.3 Hz, CH3), 3.38 ( 1 H, ddq,
J 4.1 Hz, J 7.3 Hz, J 29.8 Hz, CH), 5.06 (1 H, dd, J 4.1 Hz, J 48.8 Hz, CHF), 7.29 (5 H,
Ar H). δC (75 MHz, CDCl3): (17.4, d, J 4.8 Hz, CH3), 42.1 (d, J 19.7 Hz, CH), 92.1 (d,
J 190.4 Hz, CHF), 127.82 (Ar CH), 128.1 (2 × Ar CH), 128.5 (2 × Ar CH).
δF {1H} (282 MHz, CDCl3): -196.78 (CHF). δF (282 MHz, CDCl3): -196.78 (dd, J 29.7 Hz,
J 48.3 Hz, CHF). m/z (HRMS) (ES-): calcd for C10H10O2F: 181.0665, found 181.0663 [M-H]-.
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(E)-(S)-2-Fluoro 8-methylnon 6-enoic acid 204
Hydrogen peroxide (4.5 mL, 35%) was added at 0 °C to a solution of 174a (756 mg,
2.55 mmol) dissolved in a mixture of THF and water (1:1, 35 mL). Then, lithium hydroxide
(214 mg, 5.10 mmol) was added, and the reaction was stirred for 1 h at 0 °C. THF was
evaporated under vacuum and the aqueous solution (pH = 12) was acidified with HCl (2 M) to
pH = 1 and was extracted into DCM (4 × 70 mL). The organic layer was dried over
magnesium sulfate and concentrated to give (E)-(S)-2-fluoro 8-methylnon 6-enoic acid 204 as
an oil (456 mg, 95%)
IR νmax (cm-1): 2958, 2644, 1734, 1460, 1362. δH (300 MHz, CDCl3): 0.95 (6 H, d, J 6.8 Hz,
2 × CH3), 1.56 (2 H, dd, J 7.3 Hz, J 14.9 Hz, CH2), 1.89 (2 H, m, CH2), 2.03 (2 H, m, CH2),
2.23 (1 H, m, CH(CH3)2), 4.94 (1 H, ddd, J 4.6 Hz, J 7.2 Hz, J 49.2 Hz, CHF), 5.29 (1 H, dt,
J 5.8 Hz, J 15.4 Hz, CH=CH), 5.40 (1 H, dd, CH=CH), 8.47 (1 H, br s, 8.47, COOH).
δC (75 MHz, CDCl3): 22.6 (2 × CH3), 24.2 (CH2), 31.0 (CH(CH3)2), 31.7 (CH2), 31.8 (CH2),
88.4 (d, J 184.3 Hz, CHF), 125.7 (CH2-CH=CH), 138.7 (CH=CH-CH), 175.1 (d, J 24.3 Hz,
COOH). δF {1H} (282 MHz, CDCl3): -192.67 (10%, (S,Z)) , -192.73 (90%, (S,E)).
m/z (EI):188.12 [M]+.
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(E)-(S)-Fluoro 8-methylnon 6-enoic acid ((S)-1-phenylethyl) amide (S,S,E)-206 and
(E)-(S)-Fluoro-8-methylnon 6-enoic acid ((R/S)-1-phenylethyl) amide 206
Preparation of 206a:
HOBt (38 mg, 0.28 mmol) and EDC (54 mg, 0.28 mmol) were added at 0 °C to a solution of
(E)-(S)-2-fluoro 8-methylnon 6-enoic acid 204 (50 mg, 0.27 mmol,) in DMF (4 mL). After
15 min stirring, (S)-(-)-1-phenylethylamine (32 mg, 2.66 mmol) and triethylamine (37 μL, 
0.27 mmol) were added, and the mixture was stirred for 14 h at rt. The mixture was then
diluted in brine, and extracted into ethyl acetate. The organic layers were washed successively
with a citric acid solution (10%), saturated brine, dried over magnesium sulfate, and
concentrated under vacuum to give (E)-(S)-fluoro 8-methylnon 6-enoic acid ((S)-1-
phenylethyl) amide 206a as a white solid (27 mg, 34%).
Preparation of 206:
(E)-(S)-Fluoro-8-methylnon 6-enoic acid ((R/S)-1-phenylethyl) amide 206 was obtained by
reacting (R/S)-(+/-)-1-phenylethylamine (32 mg, 2.66 mmol) on 204 according the same
procedure. 206 was obtained as a solid (29 mg, 37%).
Data for 206a:
Mp 71 °C. δH (300 MHz, CDCl3): 0.96 (6 H, d, J 6.7 Hz, 2 × CH3), 1.53 (3 H, d, J 6.9 Hz,
CH3), 1.54 (2 H, m, CH2), 1.84 (2 H, m, CH2), 2.03 (2 H, m, CH2), 2.23 (1 H, m, CH(CH3)2),
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4.87 (1 H, ddd, J 3.7 Hz, J 7.6 Hz, J 49.9 Hz, CHF), 5.17 (1 H, m, NCH), 5.32 (1 H, dt,
J 5.6 Hz, J 15.3 Hz, CH=CH), 5.41 (1 H, dd, J 5.8 Hz, J 15.4 Hz, CH=CH), 6.54 (1 H, br s,
NH), 7.33 (5 H, m, Ar H). δC (75 MHz, CDCl3): 21.8 (CH3), 22.6 (2 × CH3), 24.3 (CH2),
31.0 (CH(CH3)2), 32.0 (2 × CH2), 48.4 (NHCH), 92.1 (d, J 185.3 Hz, CHF), 126.0 (CH=CH),
126.2 (2 × Ar CH), 127.6 (Ar CH), 128.8 (2 × Ar CH), 138.5 (CH=CH). δF {1H} (282 MHz,
CDCl3): -190.48 (91%, (S,S,E)), -190.57 (9%, (S,S,Z)). δF (282 MHz, CDCl3): -190.48 (dddd,
J 4.7 Hz, J 26.3 Hz, J 30.0 Hz, J 54.9 Hz, (S,S,E)). m/z (HRMS) (CI+): calcd for C18H27NOF:
292.2077, found 292.2076 [M+H]+.
Data for 206:
δF {1H} (282 MHz, CDCl3): -190.44 (37%, (R,S,E)), -190.47 (6%, (R,S,Z)), -190.51 (51%,
(S,S,E)), -190.60 (6%, (S,S,Z)). m/z (EI): 291.20 [M]+.
4-Hydroxy 3-methoxybenzaldehyde oxime 207
A solution of hydroxylammonium hydrochloride (99.4 mg, 1.43 mmol) and sodium acetate
(176.9 mg, 1.30 mmol) in water (0.4 mL) was added to a solution of vanillin (200 mg,
1.30 mmol) in water (0.7 mL). The reaction was stirred at 50 °C for 5 min and then the
mixture was heated at 80 °C for 2-3 h. After cooling, the product was extracted into DCM
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(3 × 10 mL) and the organic layers were washed with a saturated bine solution, dried over
magnesium sulfate and evaporated under vacuum, to obtain 4-hydroxy 3-methoxy-
benzaldehyde oxime 207 as a white solid (170 mg, 78%).
Mp 125 °C (lit. Mp 118-120 °C). IR νmax (cm-1): 3448, 3283, 2996, 1641, 1596, 1520, 1455,
1428. δH (300 MHz, (CD3)2CO)): 2.95 (1 H, br s, NOH), 3.85 (3 H, s, OCH3), 6.83 (1 H, d,
J 8.1 Hz, Ar H), 7.02 (1 H, dd, J 1.9 Hz, J 8.1 Hz, Ar H), 7.24 (1 H, d, J 1.8 Hz, Ar H),
8.00 (1 H, s, CH=N), 8.36 (1 H, br s, Ar OH). δC (75 MHz, (CD3OD)): 56.3 (Ar OCH3),
109.8 (Ar CH), 116.2 (Ar CH), 122.5 (Ar CH), 150.5 (CH=N). ). m/z (HRMS) (TOF CI+):
found 168.0664, calcd for C8H10NO3: 168.0661 [M+H]+.
4-Hydroxy-3-methoxybenzylamine hydrochloride 118
A solution of 4-hydroxy 3-methoxybenzaldehyde oxime 207 (1.00 g, 5.98 mmol) in ethanol
(110 mL) and concentrated HCl (4.5 mL, 37%) was treated with hydrogen gas at atmospheric
pressure in presence of Pd/C 10% (220 mg) for 4 h. The mixture was then filtered through a
plug of Celite and the filtrate was concentrated to dryness to provide 4-hydroxy 3-methoxy-
benzylamine hydrochloride 118 as a yellow fluffy solid (1.11 g, 98%).
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Mp 225 °C (lit. 221-223 °C). IR νmax (cm-1): 3311, 3096, 2873, 2679, 2357, 1601, 1527,
1508, 1464, 1452, 1383, 1365, 1281. δH (300 MHz, (CD3)2SO): 3.77 (3 H, s, OCH3),
3.89 (2 H, dt, J 2.5 Hz, J 5.6 Hz, CH2), 6.78 (1 H, d, J 8.0 Hz, Ar H), 6.84 (1 H, dd, J 2.0 Hz,
J 8.1 Hz, Ar H), 7.10 (1 H, d, J 1.9 Hz, Ar H), 8.15 (3 H, br s, NH3), 9.18 (1 H, br s, Ar OH).
δC (75 MHz, (CD3OD)): 44.4 (NCH2), 56.5 (OCH3), 113.6 (Ar CH), 116.7 (Ar CH),
123.2 (Ar CH). ). m/z (ES+): 152.96 [M-HCl-H]+, (ES-): 188.99 [M-H]-.
(S)-α-Fluorocapsaicin  (S)-97a
HOBt (37.7 mg, 0.28 mmol) and EDC (53.5 mg, 0.28 mmol) were added at 0 °C to a solution
of (E)-(S)-2-fluoro 8-methylnon 6-enoic acid 204 (50 mg, 0.27 mmol) in DMF. After 15 min
stirring at 0 °C, vanillylamine 118 (50.4 mg, 2.66 mmol) and triethylamine (37 μL, 
0.27 mmol) were added, and the mixture was stirred overnight at 20 °C. The mixture was then
diluted with brine, and extracted into ethylacetate. The organic layer was washed successively
with a citric acid solution (10%), saturated brine, dried over magnesium sulfate, concentrated
under vacuum to afford (S)-α-fluorocapsaicin 97a as a white solid (28 mg, 32%).
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Mp: 78-79 °C. [ࢻሿࡰ૛૙ = -20.6 (c 0.9, MeOH). IR νmax (cm-1): 2911, 1654. δH (300 MHz,
CDCl3): 0.94 (6 H, d, J 6.7 Hz, 2 × CH3), 1.50 (2 H, m, CH2), 1.82 (2 H, m, CH2), 2.01 (2 H,
dd, J 7.4 Hz, J 13.3 Hz, CH2), 2.22 (1 H, dd, J 6.7 Hz, J 13.4 Hz, CH), 3.87 (3 H, s, OCH3),
4.39 (1 H, dd, J 2.8 Hz, J 5.7 Hz, CH2NH), 4.92 (1 H, ddd, J 3.7 Hz, J 7.5 Hz, J 49.8 Hz,
CHF), 5.29 (1 H, dt, J 5.7 Hz, J 15.3 Hz, CH=CH), 5.38 (1 H, dd, J 5.9 Hz; J 15.4 Hz,
CH=CH), 5.73 (1 H, br s, Ar OH), 6.60 (1 H, br s, NH), 6.77 (2 H, m, 2 x Ar H), 6.86 (1 H, d,
J 7.9 Hz, Ar H). δC (75 MHz, CDCl3): 22.6 (2 × CH3), 24.3 (CH2), 30.9 (CH(CH3)2),
32.0 (2 × CH2), 42.9 (N-CH2), 55.9 (OCH3), 92.0 (d, J 185.4 Hz, CHF), 110.5 (Ar CH),
114.4 (Ar CH), 120.8 (Ar CH), 125.9 (CH=CH), 129.5 (Ar C IV), 138.5 (CH=CH),
145.2 (Ar OH), 146.7 (Ar OMe), 170.0 (C=O). δF {1H} (282 MHz, CDCl3): -190.73 (90%,
(S,E)), -190.76 (10%, (S,Z)). δF (282 MHz, CDCl3): -190.73 (dddd, J 4.5 Hz, J 26.3 Hz,
J 30.3 Hz, J 55.2 Hz, (S,E)). ). m/z (HRMS) (ES+): found 346.1793, calcd for C18H26NO3FNa:
346.1794 [M+Na]+.
(S)-3-((S)-Fluoro 8-methylnonanoyl)-4-isopropyloxazolidin 2-one (S)-208
Preparation by hydrogenation of the double-bond:
A solution of (S)-3-((E)-(S)-2-fluoro-8-methylnon 6-enoyl)-isopropyloxazolidin 2-one 174a
(123 mg, 0.41 mmol) and 10% Pd/C (100 mg) in ethanol (20 mL) was treated with hydrogen
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gas at atmospheric pressure for 4 h. The catalyst was then removed by filtration through a
plug of Celite and the solvent was evaporated under reduced pressure to obtain unpure (S)-3-
((S)-fluoro 8-methylnonanoyl)-4-isopropyloxazolidin 2-one 208 as an oil (69 mg, 56%).
Preparation by fluorination of the N-acyl oxazolidinone:
LiHMDS (3.2 mL, 1 M in hexanes) was added to a solution of (S)-4-isopropyl 3-((E)-8-
methylnon-6-enoyl)oxazolidin 2-one 189 (700 mg, 2.47 mmol) in THF (12 mL) and stirred
for 1 h at -78 °C. A solution of NFSI (860 mg, 2.7 mmol) in THF (4 mL) was then added and
the mixture was stirred for 3 h. The mixture was quenched with a saturated solution of
ammonium chloride (30 mL) and extracted into diethylether (3 × 40 mL), and concentrated
under vacuum to provide (S)-3-((S)-fluoro 8-methylnonanoyl)-4-isopropyloxazolidin 2-one
208 (984 mg, 130%) as a not pure waxy product. This product was used further on without
any purification.
δH (300 MHz, CD3OD): 0.88 (6 H, dd, J 1.5 Hz, J 5.6 Hz, 2 × CH3), 0.93 (6 H, dd, J 1.5 Hz,
J 7.1 Hz, 2 × CH3), 1.18 (2 H, m, CH2), 1.32 (6 H, m, 3 × CH2), 1.53 (2 H, m, CH2),
1.77 (1 H, m, CH2CH(CH3)2), 2.43 (1 H, m, CHCH(CH3)2), 4.41 (1 H, m, NCH), 4.42 (2 H,
m, OCH2), 5.89 (1 H, ddd, J 2.8 Hz, J 8.6 Hz, J 50.4 Hz, CHF). δC (75 MHz, CDCl3):
14.8 (CH3), 18.0 (CH3), 23.1 (2 × CH3), 28.3 (CH2), 29.6 (CH), 30.4 (CH), 30.8 (2 × CH2),
60.2 (NCH), 65.3 (OCH2), 90.5 (d, J 177.1 Hz, CHF). δF {1H} (282 MHz, CD3OD): -194.28
(2%, (S,R)), -194.49 (98%, (S,S)). δF (282 MHz, CD3OD) -194.46 (ddd, J 21.2 Hz, J 34.4 Hz,
J 55.6 Hz). m/z (HRMS) (CI+): found 302.2134, calcd for C16H29NO3F: 302.2131 [M+H]+.
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8-Methylnonanoic acid 209
A solution of (Z)-8-methylnon 6-enoic acid 187b (800 mg, 0.47 mmol) and 10% Pd/C (1.15
g) in ethanol (120 mL) was treated with hydrogen gas at atmospheric pressure for 4 h. The
catalyst was removed by filtration through a plug of Celite and the solvent was evaporated
under vacuum. The crude product was distilled to provide 8-methylnonanoic acid 209 as
colourless oil (769 mg, 95%).
δH (300 MHz, CDCl3): 0.85 (6 H, d, J 6.6 Hz, 2 × CH3), 1.15 (2 H, m, CH2), 1.28 (6 H, m,
3 × CH2), 1.50 (1 H, m, CH), 1.63 (2 H, m, CH2), 2.34 (2 H, t, J 7.4 Hz, CH2), 11.37 (1 H, br
s, COOH). δC (75 Hz, CDCl3): 22.6 (2 × CH3), 24.7 (CH2), 27.2 (CH2), 27.9 (CH),
29.1 (CH2), 29.5 (CH), 34.1 (CH2), 38.9 (CH2), 180.6 (COOH). m/z (EI): 172.15.
(S)-4-Isopropyl 3-(8-methylnonanoyl) oxazolidin 2-one (S)-210
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Triethylamine (0.65 mL, 4.68 mmol) was added dropwise at 0 °C to a solution of 8-
methylnonanoic acid 209 (769 mg, 4.46 mmol) in THF (18 mL). This reaction was stirred for
15 min at 0 °C and then cooled to -78 °C prior addition of pivaloyl chloride (0.40 mL,
3.29 mmol). The mixture was then stirred for 1 h at -78 °C and then 15 min at 0 °C. In a
separate flask, n-butyllithium (1.8 mL, 2.5 M, 4.46 mmol) was added to a solution of (S)-4-
isopropyl-2-oxazolidinone (577 mg, 4.46 mmol) in THF (10 mL) at -78 °C and the reaction
was stirred for 15 min. The resultant solution was added at -78 °C to the white suspension of
the mixed anhydride. The mixture was stirred for 30 min, and then 1 h further at 0 °C. The
reaction was quenched with ammonium chloride and the volatiles were evaporated under
vacuum. This aqueous mixture was extracted into DCM and the organic layers were washed
successively with solutions of HCl (1 M) and saturated sodium bicarbonate, dried over
magnesium sulfate, concentrated under vacuum to afford (S)-4-isopropyl 3-(8-methyl-
nonanoyl) oxazolidin 2-one 210 (1.21 g, 96%) as a waxy product. The compound was used
further without any purification.
IR νmax (cm-1): 3542, 3377, 2932, 2871, 1780, 1704, 1466, 1387, 1301. δH (300 MHz,
CDCl3): 0.83 (6 H, d, J 6.6 Hz, 2 × CH3), 0.88 (6 H, dd, J 7.0 Hz, J 12.9 Hz, 2 × CH3),
1.14 (2 H, m, CH2), 1.28 (6 H, m, 3 × CH2), 1.49 (1 H, m, CH2CH(CH3)2), 1.63 (2 H, m,
CH2), 2.35 (2 H, m, CH2), 2.79 (1 H, m, CHCH(CH3)2), 2.89 (2 H, m, CH2), 4.25 (1 H, m,
NCH), 4.31 (2 H, m, OCH2). δC (75 MHz, CDCl3): 14.6 (CH3), 17.9 (CH3), 22.6 (2 × CH3),
24.4 (CH2), 27.2 (CH2), 27.2 (CH), 27.9 (CH), 29.1 (CH2), 29.6 (CH2), 35.5 (CH2),
38.9 (CH2), 58.3 (CH), 63.2 (CH2), 154.0 (COO), 173.4 (NC=O). m/z (HRMS) (ES+): found
306.2048, calcd for C16H29NO3Na: 306.2045 [M+Na]+.
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(S)-2-Fluoro 8-methylnonanoic acid (S)-211
Hydrogen peroxide (0.47 mL, 35 %) was added at 0 °C to a solution of (S)-3-((S)-fluoro 8-
methylnonanoyl)-4-isopropyloxazolidin 2-one 208 (400 mg, 1.33 mmol) dissolved in a
mixture of THF and water (1:1, 35 mL). Lithium hydroxide (112 mg, 2.66 mmol) was then
added, and the reaction was stirred for 1 h at 0 °C. The solvent was evaporated and the
aqueous solution (pH = 12) was extracted into DCM (3 × 30 mL) for recovery of the chiral
auxiliary. The aqueous solution was acidified with HCl (2 M) until pH = 1 and was extracted
into DCM (4 × 50 mL). The organic layer was dried over magnesium sulfate and concentrated
to give (S)-2-fluoro 8-methylnonanoic acid 211 (190 mg, 75 %) as a colourless oil.
[ࢻሿࡰ૛૙ = -7.6 (c 1.2, MeOH). IR νmax (cm-1): 3255, 2958, 2920, 2849, 1737, 1446, 1281.
δH (300 MHz, CDCl3): 0.86 (6 H, d, J 6.6 Hz, 2 × CH3), 1.17 (2 H, m, CH2), 1.31 (6 H, m,
3 × CH2), 1.51 (2 H, m, CH2), 1.94 (1 H, m, CH(CH3)2), 4.97 (1 H, ddd, J 4.9 Hz, J 6.9 Hz,
J 49.2 Hz, CHF). δC (75 MHz, CDCl3): 22.6 (2 × CH3), 24.4 (CH2), 27.0 (CH2), 27.9 (CH),
29.3 (CH2), 32.2 (d, J 20.8 Hz, CH2), 38.8 (CH2), 88.5 (d, J 184.3 Hz, CHF), 174.9 (d,
J 24.1 Hz, COOH). δF {1H} (282 MHz, CDCl3): -189.2 (1%), -192.5 (98%, (S)), -192.7 (1%).
δF (282 MHz, CDCl3): -192.5 (dt, J 25.7 Hz, J 50.6 Hz). m/z (HRMS) (ES-): found 189.1294,
calcd for C10H18O2F: 189.1279 [M-H]-.
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N-(4-hydroxy-3-methoxybenzyl)-4-methylpentanamide 223
HOBt (245 mg, 1.81 mmol) and EDC (347 mg, 1.81 mmol) were added at 0 °C to a solution
of 4-methyl valeric acid (0.22 mL, 1.72 mmol) in DMF (4 mL). After 30 min at rt,
vanillylamine hydrochloride 118 (343 mg, 1.81 mmol) and Et3N (0.25 mL, 1.81 mmol) were
added, and the mixture was stirred overnight at rt. The mixture was then diluted with brine,
and extracted into ethyl acetate. The organic layer was washed successively with a citric acid
solution (10%), saturated brine, dried over magnesium sulfate, and concentrated under
vacuum. Purification on silica gel (hexane/ethylacetate 1/1) provided N-(4-hydroxy-3-
methoxybenzyl)-4-methylpentanamide 213 as a white solid (186 mg, 43% yield).
Mp 63-64 °C. δH (300 MHz, CDCl3): 0.90 (6 H, d, J 6.3 Hz, 2 × CH3), 1.55 (3 H, m, CH and
CH2), 2.20 (2 H, m, CH2), 3.88 (3 H, s, OCH3), 4.35 (2 H, d, J 5.6 Hz, NCH2), 5.68 (1 H, br s,
Ar OH), 6.62 (1 H, br s, NH), 6.77 (2 H, dt, J 1.9 Hz, J 10.1 Hz, 2 Ar H), 6.86 (2 H, d,
J 8.0 Hz, Ar-H). δC (75 MHz, CDCl3): 22.2 (2 × CH3), 27.5 (CH), 32.8 (CH2), 34.8 (CH2),
42.8 (NCH2), 55.9 (OCH3), 110.6 (Ar CH), 114.4 (Ar CH), 120.9 (Ar CH), 129.5 (Ar C IV),
145.2 (Ar OH), 146.7 (Ar OMe). m/z (EI): 251.15 [M]+.
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(S)-2-fluoro-4-methylpentanoic acid (S)-227a, (R)-2-fluoro-4-methylpentanoic acid
(R)-227b and (R,S)-2-fluoro-4-methylpentanoic acid (R,S)-227
Preparation of 227a by deaminative fluorination:
Sodium nitrite (284 mg, 4.10 mmol) was cautiously added to a solution of L-leucine (300 mg,
2.29 mmol) in HF/Py [70:30] (3.45 mL) cooled down at -78 °C. After 2 h at this temperature,
the mixture was allowed to warm up to 0 °C and stirred for another 2 h. Then the mixture was
stirred for 6 h at rt before quenching with a solution of sodium carbonate (5 %). The solution
was extracted with diethyl ether (3 × 10 mL) and the organic layers washed with brine
(10 mL), dried over magnesium sulfate and concentrated under vacuum. The product was
distilled on kugelrohr (60 °C, 0.1 mBar) to provide (S)-2-fluoro-4-methylpentanoic acid 227a
as a clear oil (138 mg, 45%).
Preparation of 227b by deaminative fluorination:
(R)-2-fluoro-4-methylpentanoic acid 227b was obtained as a clear oil (461 mg, 43%)
according the procedure described above.
Preparation of 227 by deaminative fluorination:
(R,S)-2-fluoro-4-methylpentanoic acid 227 was obtained as a clear oil (492 mg, 48%) with the
same method.
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Preparation of 227a by oxidation:
(S)-2-fluoro-4-methylpentanal 235a (591 mg, 5.00 mmol) was dissolved in a mixture
acetone/water (30 mL, 5:1) and treated dropwise with CrO3 (1 M in 30 % H2SO4) for 30 min.
After addition of water (50 mL), the aqueous phase was extracted into diethyl ether
(3 × 30 mL). The organic layer was dried over magnesium sulfate and concentrated under
vacuum to give (S)-227a as pale yellow oil (656 mg, 98%).
Preparation of 227b by oxidation:
The method described above was used to obtained (R)-227b as pale yellow oil (499 mg,
97%).
Data for 227a:
IR νmax (cm-1): 3489, 2960, 1979, 1734, 1469. δH (300 MHz, CDCl3): 0.98 (6 H, d, J 6.2 Hz,
2 × CH3), 1.64 (1 H, m, CH(CH3)2), 1.88 (2 H, m, CH2), 4.99 (1 H, ddd, J 3.3 Hz, J 9.2 Hz,
J 49.6 Hz, CHF), 10.22 (1 H, br s, COOH). δC (75 MHz, CDCl3): 21.5 (CH3), 22.9 (CH3),
24.4 (CH), 40.8 (d, J 20.8 Hz, CH2), 87.3 (d, J 184.2 Hz, CHF), 175.9 (d, J 24.2 Hz, COOH).
δF {1H} (282 MHz, CDCl3): -191.49, CHF). δF (282 MHz, CDCl3): -191.49 (ddd, J 18.0 Hz,
J 34.5 Hz, J 50.2 Hz, (S), CHF). m/z (HRMS) (ES-): found 133.0667, calcd for C6H10O2F:
133.0665 [M-H]-.
Data for 227b:
All spectroscopic data are identical to (S)-227a
Data for 227:
Analytical data identical to (R)- and (S)-227
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(S)-2-fluoro-N-(4-hydroxy-3-methoxybenzyl)-4-methylpentanamide (S)-99a and
(R)-2-fluoro-N-(4-hydroxy-3-methoxybenzyl)-4-methylpentanamide (R)-99b
Preparation of 99a by acyl fluoride mediated amide-coupling:
2-Fluorocarboxylic acid (S)-227a (268 mg, 2.00 mmol) was dissolved in DCM (20 mL) under
an N2 atmosphere, cooled down to 0 °C prior addition of DIEA (523 μL, 3.00 mmol) and 
Deoxofluor (1.0 mL, 2.40 mmol). After stirring for 30 min, vanillylamine 118 (417 mg,
2.20 mmol) in DCM (5 mL) was added slowly. This mixture was warmed up to rt and stirred
for 6-8 h. The mixture was then diluted in DCM (30 mL), and consecutively washed with an
aqueous saturated sodium bicarbonate solution (5 mL), water (5 mL) and brine (5 mL). The
organic layers were dried over magnesium sulfate, filtered, concentrated under vacuum.
Purification on silica gel (hexane/ethyl acetate 1:1) allowed recovering (S)-2-fluoro-N-(4-
hydroxy-3-methoxybenzyl)-4-methylpentanamide (S)-99a as a clear oil, which recrystallised
after trituration in diethyl ether (121 mg, 24%).
Preparation of 99b by amide-coupling:
HOBt (130 mg, 1.02 mmol) and EDC (196 mg, 1.02 mmol) were added at 0 °C to a solution
of (R)-227b (130 mg, 0.97 mmol) in DMF (2 mL). After 30 min at rt, vanillylamine 118 (193
mg, 1.02 mmol) and Et3N (0.14 mL, 1.02 mmol) were added, the mixture was stirred
overnight at rt. The mixture was diluted in brine, and extracted into ethyl acetate. The organic
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layer was washed successively with citric acid (10% ), brine, dried over magnesium sulfate,
and concentrated under vacuum to recover (R)-2-fluoro-N-(4-hydroxy-3-methoxybenzyl)-4-
methylpentanamide (R)-99b (44 mg, 17% yield).
Preparation of 99b by acyl fluoride mediated amide-coupling:
(R)-2-fluoro-N-(4-hydroxy-3-methoxybenzyl)-4-methylpentanamide 99b (151 mg, 28% yield)
was obtained according the procedure described above.
Preparation of 99a by amide-coupling:
(S)-2-fluoro-N-(4-hydroxy-3-methoxybenzyl)-4-methylpentanamide 99a was prepared
according the same procedure (28 mg, 11%)
Data for 99a:
Mp 52 °C. [ࢻሿࡰ૛૙ = -12.8 (c 1.2, MeOH). IR νmax (cm-1): 3325, 3064, 2956, 2495, 1770, 1644,
1446, 1367, 1277. δH (300 MHz, CDCl3): 0.97 (6 H, dd, J 1.3 Hz, J 6.4 Hz, 2 × CH3), 1.76 (1
H, m, CH), 1.87 (2 H, m, CH2), 3.88 (3 H, s, OCH3), 4.39 (2 H, d, J 5.8 Hz, NCH2), 4.96 (1
H, ddd, J 2.7 Hz, J 9.4 Hz, J 50.1 Hz, CHF), 5.67 (1 H, br s, Ar OH), 6.58 (1 H, br s, NH),
6.78 (2 H, m, 2 Ar H), 6.88 (2 H, d, J 7.8 Hz, Ar H). δC (75 MHz, CDCl3): 21.6 (CH3), 23.1
(CH3), 24.6 (CH), 41.2 (d, J 19.6 Hz, CH2), 43.0 (NCH2), 55.9 (OCH3), 90.8 (d, J 185.2 Hz,
CHF), 110.6 (Ar CH), 114.4 (Ar CH), 120.9 (Ar CH), 129.5 (Ar C), 145.2 (Ar OH), 146.7
(Ar OMe). δF {1H} (282 MHz, CDCl3): -188.92. δF (282 MHz, CDCl3): -188.91 (dddd, J 4.7
Hz, J 20.7 Hz, J 37.3 Hz, J 50.3 Hz, CHF). m/z (HRMS) (CI+): found 270.1499, calcd for
C14H21NO3F: 270.1505 [M+H]+.
Data for 99b: Analytical data are identical to (S)-99a except: [ࢻሿࡰ૛૙ = + 12.8 (c 1.2, MeOH).
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(S)-2-fluoro-4-methyl-N-((S)-1-phenylethyl)pentanamide (S,S)-228a, (R)-2-fluoro-4-
methyl-N-((S)-1-phenylethyl)pentanamide (R,S)-228b and (R,S)-2-fluoro-4-methyl-N-
((S)-1-phenylethyl)pentanamide (S,R/S)-228
Preparation of 228a:
HOBt (318 mg, 2.35mmol) and EDC (451 mg, 2.35 mmol) were added at 0 °C to a solution of
2-fluorocarboxylic acid (S)-227a (300 mg, 2.24 mmol) in DMF (5 mL). After 30 min at rt,
(S)-(-)-1-phenylethylamine (0.30 mL, 2.35 mmol) was added, and the mixture was stirred
overnight at rt. The mixture was then diluted with brine, and extracted into ethyl acetate. The
organic layer was washed successively with a citric acid solution (10 %), brine, dried over
magnesium sulfate, and concentrated under vacuum to recover (S)-2-fluoro-4-methyl-N-((S)-
1-phenylethyl)pentanamide (S)-228 (155 mg, 29% yield).
Preparation of 228b:
(R)-2-fluoro-4-methyl-N-((S)-1-phenylethyl)pentanamide 228b was synthesised according the
same procedure (14 mg, 21% yield).
Preparation of 228:
The procedure described above allowed to obtain (R,S)-2-fluoro-4-methyl-N-((S)-1-
phenylethyl)pentanamide 228 (23 mg, 35% yield).
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Data for 228a:
IR νmax (cm-1): 2920, 2823, 1789, 1689, 1020. δH (300 MHz, CDCl3): 0.91 (6 H, dd, J 1.7 Hz,
J 6.5 Hz), 1.46 (3 H, d, J 6.9 Hz, CHCH3), 1.69 (1 H, m, CH(CH3)2), 1.81 (2 H, m, CH2),
4.83 (1 H, ddd, J 3.0 Hz, J 9.3 Hz, J 50.2 Hz, CHF), 5.08 (1 H, m, CHCH3), 6.47 (1 H, br s,
NH), 7.26 (5 H, m, Ar H). δC (75 MHz, CDCl3): 21.6 (CH3), 21.7 (CH3), 23.1 (NHCHCH3),
24.6 (d, J 1.5 Hz, CH), 41.2 (d, J 19.5 Hz, CH2), 48.3 (NCH), 91.1 (d, J 185.1 Hz, CHF),
126.2 (2 × Ar CH), 127.6 (Ar CH), 128.7 (2 × Ar CH). δF {1H} (282 MHz, CDCl3): -188.62
(2%, CHF, (S,R)), -188.75 (98%, CHF, (S,S)). m/z (HRMS) (CI+): found 238.1605, calcd for
C14H21NOF: 238.1607 [M+H]+.
Data for 228b:
Spectroscopic data are identical to (S,S)-228a, except: δF {1H} (282 MHz, CDCl3): -188.62
(96%, (S,R), CHF), -188.75 (4%, (S,S), CHF)
Data for 228:
Spectroscopic data are identical to (R)- and (S)-228, except: δF {1H} (282 MHz, CDCl3): -
188.62 (50%, (S,R)), -188.75 (50%, (S,S)).
(R)-2-fluorooctanal 230b and (S,E)-N-((R)-2-fluorooctylidene)-1-methoxypropan-2-
amine 232b
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Preparation of 230b and 232b:
To a solution of NFSI (8 mmol, 2.5g) and (R)-5-benzyl-2,2,3-trimethylimidazolin-4-one
dichloroacetic salt (0.8 mmol, 277 mg) in a mixture THF/iPropanol (30 mL, 9:1) cooled down
to -30 °C, was added octanaldehyde (4 mmol, 400 mg). After 10 hours at -15 °C, the solution
was filtered over a pad of silica gel and eluted with diethyl ether. After concentration under
vacuum, an aliquot of (R)-2-fluorooctanal 230b was derivatised with (S)-1-methoxy-2-
propylamine and the ee of (S,E)-N-((R)-2-fluorooctylidene)-1-methoxypropan-2-amine 232b
(92 % ee) was determined by 19F spectroscopy.
Data for 230b:
IR νmax (cm-1): 3445, 2932, 1977, 1820, 1742, 1581, 1367.δH (300 MHz, CDCl3): 0.88 (3 H, s,
CH3), 1.25 (8 H, br s, 4 × CH2), 4.75 (1 H, ddd, J 4.9 Hz, J 8.2 Hz, J 49.4 Hz, CHF),
9.77 (1 H, dd, J 0.8 Hz, J 6.3 Hz, CHO). δC (75 MHz, CDCl3): 22.5 (CH2), 24.2 (CH2),
28.8 (CH2), 29.7 (CH2), 31.5 (CH2), 95.1 (d, J 179.0 Hz, CHF), 200.4 (d, J 34.6 Hz, CHO).
δF {1H} (282 MHz, CDCl3): -200.10. δF (282 MHz, CDCl3): -200.10 (dddd, J 6.4 Hz,
J 23.3 Hz, J 27.9 Hz, J 49.7 Hz, CHF). m/z (EI): 146.1 [M]+.
Data for 232b:
δC (75 MHz, CDCl3): 13.7 (CH3), 18.3 (CH3), 22.2 (CH2), 23.9 (d, J 4.0 Hz, CH2),
28.7 (CH2), 31.3 (CH2), 32.8 (d, J 21.3 Hz, CH2), 48.9 (d, J 8.9 Hz, OCH2CHN),
64.8 (OCH3), 75.4 (OCH2), 92.7 (d, J 167.9 Hz, CHF), 162.3 (d, J 29.5 Hz, (E)-CH=N).
δF {1H} (282 MHz, CDCl3): -188.62 (4 %, (S,E,S), CHF), -189.38 (96 %, (S,E,R), CHF).
δF (282 MHz, CDCl3): -189.38 (dddd, J 8.5 Hz, J 20.1 Hz, J 28.4 Hz, J 48.7 Hz, (S,E,R),
CHF). m/z (EI): 217.2 [M]+.
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(R)-2-fluoro-4-methylpentanal (R)-235b, (S)-2-fluoro-4-methylpentanal (S)-235a,
(S,E)-N-((R)-2-fluoro-4-methylpentylidene)-1-methoxypropan-2-amine 235b’ and
(S,E)-N-((S)-2-fluoro-4-methylpentylidene)-1-methoxypropan-2-amine 235a’
Preparation of 235b:
To a solution of NFSI (8.00 mmol, 2.50 g) and (R)-5-benzyl-2,2,3-trimethylimidazolin-4-one
dichloroacetic salt (0.8 mmol, 277 mg) in THF/iPropanol (30 mL, 9:1) cooled down to -30 °C,
was added 4-methylpentanal (4.00 mmol, 400 mg). After 10 hours at -15 °C, the solution was
filtered over a pad of silica gel and eluted with diethyl ether to give (R)-2-fluoro-4-
methylpentanal 235b.
Preparation of 235a:
(S)-2-fluoro-4-methylpentanal 235a was obtained according the same procedure.
Preparation of 235b’:
After concentration under vacuum, an aliquot of the residue was derivatized with (S)-1-
methoxy-2-propylamine and the ee of (S,E)-N-((R)-2-fluoro-4-methylpentylidene)-1-
methoxypropan-2-amine 235b’ (90% ee) was determined by 19F spectroscopy.
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Preparation of 235a’:
(S,E)-N-((S)-2-fluoro-4-methylpentylidene)-1-methoxypropan-2-amine 235a’ was obtained
according the same procedure as 235b’ (88% ee).
Data for 235b:
δF {1H} (282 MHz, CDCl3): -199.48 (CHF)
Data for 235a:
δF {1H} (282 MHz, CDCl3): -199.41 (CHF)
Data for 235b’:
δF {1H} (282 MHz, CDCl3): -188.90 (5%, (S,S)), -189.38 (95%, (S,R)).
δF (282 MHz, CDCl3): -189.38 (ddq, J 7.7 Hz, J 34.6 Hz, J 49.6 Hz, CHF).
Data for 235a’:
δF {1H} (282 MHz, CDCl3): -188.93 (94%, (S,S)), -189.39 (6%, (S,R)).
δF (282 MHz, CDCl3): -189.38 (ddq, J 7.7 Hz, J 34.6 Hz, J 49.6 Hz, CHF).
(R)-2-fluoro-N-((S)-1-methoxypropan-2-yl)-4-methylpentanamide (R)-236b and
(S)-2-fluoro-N-((S)-1-methoxypropan-2-yl)-4-methylpentanamide (S)-236a
N
H
O
F
O
N
H
O
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O
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Preparation of 236b:
(S)-1-Methoxy-2-propylamine was added to a solution of 2-fluorocarboxilic acid (R)- 227b
(40 mg, 0.30 mmol) in DMF (1 mL), Et3N (92 μL, 0.66 mmol) and TBTU (96 mg, 
0.30 mmol). The reaction was stirred at rt for 1 h and then the mixture was quenched with
brine (5 mL), and extracted in ethyl acetate (2 × 5 mL). The organic layer was successively
washed with HCl (1 M), NaHCO3, brine, dried over magnesium sulfate and concentrated
under vacuum. The oily crude of (R)-2-fluoro-N-((S)-1-methoxypropan-2-yl)-4-methyl-
pentanamide 236b was directly analysed by 19F spectroscopy to determine the ee (89% ee)
(23 mg, 35%).
Preparation of 236a:
(S)-2-fluoro-N-((S)-1-methoxypropan-2-yl)-4-methylpentanamide 236a was obtained by the
same method (21 mg, 32% yield).
Data for 236b:
δF {1H} (282 MHz, CDCl3): -189.34 (6%, (S,S), CHF), -189.36 (94%, (S,R), CHF).
δF (282 MHz, CDCl3): -189.36 (dddd, J 4.2 Hz, J 22.1 Hz, J 35.6 Hz, J 50.5 Hz, (S,R), CHF).
Data for 236a:
Spectroscopic data identical to (S,R)-236a, except: δF {1H} (282 MHz, CDCl3): -189.34
(95%, (S,S), CHF), -189.36 (5%, (S,R), CHF). δF (282 MHz, CDCl3): -189.34 (dddd, J 4.1 Hz,
J 22.1 Hz, J 35.6 Hz, J 50.4 Hz, (S,S), CHF).
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2,2-difluoro-4-methylpentanal 241 and (S,E)-N-(2,2-difluoro-4-methylpentylidene)-1-
methoxypropan-2-amine 241’
Preparation of 241 and 241’:
To a solution of NFSI (4 g, 12.5 mmol) and (R)-5-benzyl-2,2,3-trimethylimidazolin-4-one
dichloroacetic salt (347 mg, 1 mmol) in THF/iPropanol (38.5 mL, 9:1) cooled down to -10 °C,
was added 4-methylpentanal (500 mg, 5 mmol). After 12 hours at rt, the solution was filtered
over a pad of silica gel and eluted with diethyl ether. An aliquot of the residue 2,2-difluoro-4-
methylpentanal 241 was derivatised with (S)-1-methoxy-2-propylamine to give (S,E)-N-(2,2-
difluoro-4-methylpentylidene)-1-methoxypropan-2-amine 241’ for analysis.
Data for 241:
δF {1H} (282 MHz, CDCl3): -112.52 (d, J 249.7 Hz, CFFCHO), -116.15 (d, J 250.2 Hz,
CFFCHO). δF (282 MHz, CDCl3): -112.52 (dddd, J 4.7 Hz, J 13.1 Hz, J 26.6 Hz, J 249.7 Hz,
CFFCHO), -116.15 (dm, J 250.2 Hz, CFFCHO).
Data for 241‘:
δF {1H} (282 MHz, CDCl3): -112.29 (dd, J 26.1 Hz, J 245.8 Hz, CFFCHN), -113.81 (dd,
J 49.2 Hz, J 245.6 Hz, CFFCHN).
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2,2-difluoro-4-methylpentanoic acid 242
Preparation by oxidation of 241:
2,2-Difluoro-4-methylpentanal 241 (680 mg, 5 mmol) was dissolved in acetone/water (40 mL,
5:1) and treated dropwise with CrO3 (1 M in 30 % H2SO4) for 30 min. After addition of water
(50 mL), the aqueous phase was extracted into diethyl ether (3 × 35 mL). The organic layer
was dried over magnesium sulfate and concentrated under vacuum to give 2,2-difluoro-4-
methylpentanoic acid 242 as pale yellow oil (91%, 692 mg).
Preparation by saponification of 246:
To a solution of difluoroester 246 (200 mg, 1.2 mmol) dissolved in EtOH (5 mL) was added
at 0 °C KOH (673 mg, 10 eq). The reaction mixture was stirred at rt for 2 days before
concentration under vacuum. The residue was diluted in water (5 mL) and acidified with HCl
(1 M) to pH= 2. Extraction into ethyl acetate (3 × 10 mL) and concentration of the organic
phase under vacuum provided 2,2-difluoro-4-methylpentanoic acid 242 in good yield (86%).
Data for 242:
IR νmax (cm-1): 2958, 1979, 1700, 1582, 1449, 1370. δH (300 MHz, CDCl3): 0.87 (6 H, dd,
J 1.2 Hz, J 6.2 Hz, 2 × CH3), 1.57 (1 H, m, CH), 1.69 (2 H, m, CH2), 9.63 (1 H, d, J 7.2 Hz,
COOH). δC (75 MHz, CDCl3): 22.5 (CH), 24.3 (2 × CH3), 40.6 (d, J 20.4 Hz, CH2), 42.1 (t,
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J 22.1 Hz, CH2 CF2), 118.0 (d, J 249.6 Hz, CF2), 165.8 (COOH). δF {1H} (282 MHz, CDCl3):
-104.87. δF (282 MHz, CDCl3): -104.87 (t, J 17.2 Hz, CF2). m/z (HRMS) (ES-): found
151.0568, calcd for C6H9OF2: 151.0571 [M-H]-.
Methyl 2,2-dimethoxy-4-methylpentanoate 244 and methyl 4-methyl-2-oxopentanoate
245
Preparation of 244/245:
To an ice-cooled solution of 4-methylvaleric acid (0.95 mL, 7.7 mmol) in MeOH (8 mL), was
added 4Å molecular sieves. Thionyl chloride (1.12 mL, 1.5 mmol) was then added dropwise
and the mixture was stirred at rt for 16 h. After filtration, the mixture was evaporated under
vacuum to give a 2:1 mixture of methyl 2,2-dimethoxy-4-methylpentanoate 244 and methyl 4-
methyl-2-oxopentanoate 245 (1.4 g).
Preparation of 245:
The residue was dissolved in acetonitrile (24 mL) and water (2.4 mL). Perchloric acid (1.2
mL) was then added slowly and the reaction mixture was stirred at rt for 4 h. Excess acid was
neutralised by a solution of saturated sodium carbonate (5 mL) before evaporation under
vacuum of the solvent. The aqueous phase was extracted into ethyl acetate (3 × 10 mL) and
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the organic layer washed by brine, dried over magnesium sulfate, and concentrated under
vacuum to give 245 as pale yellow oil (98%, 1.1 g)
Data for 244:
δH (300 MHz, CDCl3): 0.84 (6 H, d, J 6.5 Hz, 2 × CH3), 1.52 (1 H, m, J 6.5 Hz, CH),
1.73 (2 H, d, J 6.7 Hz, CH2), 3.15 (6 H, s, 2 × OCH3), 3.72 (3 H, s, OCH3).δC (75 MHz,
CDCl3): 22.4 (CH), 23.2 (2 × CH3), 41.9 (CH2), 49.6 (2 × OCH3), 52.4 (OCH3), 102.2 (C IV),
170.0 (CO).
Data for 245:
δH (300 MHz, CDCl3): 0.96 (6 H, d, J 6.7 Hz, 2 × CH3), 2.19 (1 H, m, J 6.8 Hz, CH),
2.71 (2 H, d, J 6.8 Hz, CH2), 3.85 (3 H, s, OCH3). δC (75 MHz, CDCl3): 23.7 (2 × CH3),
24.1 (CH), 47.9 (CH2), 52.9 (OCH3), 138.9 (CO), 161.7 (CO).
Methyl 2,2-difluoro-4-methylpentanoate 246
To a solution of methyl 4-methyl-2-oxopentanoate 245 (0.8 mmol, 100 mg) in DCM (2 mL)
was added dropwise at 0 °C a solution of DAST (0.9 mmol, 0.1 mL). The reaction mixture
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was stirred at rt for 14 h before addition of saturated NaHCO3 (5 mL) and extraction into
DCM (15 mL). The organic layer was dried over magnesium sulfate and concentrated under
vacuum to give methyl 2,2-difluoro-4-methylpentanoate 246 as oil (55%, 63 mg).
Data for 246:
IR νmax (cm-1): 2955, 1981, 1917, 1700, 1582, 1447, 1370. δH (300 MHz, CDCl3): 1.02 (6 H,
d, J 6.5 Hz, 2 × CH3), 1.86 (1 H, m, CH), 1.98 (2 H, t, J 17.2 Hz, CH2), 3.87 (3 H, s, OCH3).
δC (75 MHz, CDCl3): 22.9 (CH, t, J 3.6 Hz), 23.1 ( 2 × CH3), 42.7 (t, J 22.1 Hz, CH2),
53.2 (OCH3), 118.1 (d, J 250 Hz, CF2), 137.9 (CO). δF {1H} (282 MHz, CDCl3): -104.20.
δF (282 MHz, CDCl3): -104.20 (t, J 17.3 Hz, CF2). m/z (EI): 166.1 [M]+.
2,2-Difluoro-N-(4-hydroxy-3-methoxybenzyl)-4-methylpentanamide 247
Preparation by coupling of acyl chloride intermediate 249:
To a solution of 2,2-difluoro-4-methylpentanoic acid 242 (320 mg, 2.10 mmol) in a mixture
of chloroform/DMF 9:1 (15 mL), was added 4 Å MS and then dropwise at 0 °C oxalyl
chloride (0.54 mL, 6.3 mmol). The reaction mixture was stirred vigorously for 3 h at rt. An
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aliquot of the intermediate acyl chloride 246 was analysed by 19F NMR. A solution of
vanillylamine 118 (392 mg, 2.10 mmol), in DMF (12 mL) and previously treated by DIEA
(0.72 mL, 4.20 mmol), was then added. The reaction mixture was stirred for another 24 h. The
mixture was then diluted in chloroform (50 mL), and washed with a saturated sodium
bicarbonate solution (3 × 5 mL). The organic layers were dried over magnesium sulfate,
filtered and concentrated under vacuum. Purification over silica gel gave 2,2-difluoro-N-(4-
hydroxy-3-methoxybenzyl)-4-methylpentanamide 247 as a waxy solid (19%, 114 mg).
Preparation by fluorination of 250:
To a solution of N-(4-hydroxy-3-methoxybenzyl)-4-methyl-2-oxopentanamide 250 (20 mg,
7.5 × 10-5 mol) in DCM (1 mL) was added DAST (20 μL, 0.15 mmol), and the reaction was 
stirred at 40 °C for 3 days. The crude mixture was analysed directly.
IR νmax (cm-1): 2982, 2849, 2479, 2219, 1607, 1454, 1198. δH (300 MHz, CDCl3): 0.87 (6 H,
d, J 7.4 Hz, 2 × CH3), 1.50 (1 H, m, CH), 1.61 (2 H, m, CH2), 3.66 (3 H, s, OCH3), 4.41 (2 H,
NCH2), 6.87 (2 H, Ar H), 6.90 (1 H, Ar H). δC (75 MHz, CDCl3): 22.7 (2 × CH3), 24.6 (CH),
43.4 (CH2), 45.3 (NCH2), 56.0 (OCH3), 110.6 (Ar CH), 114.5 (Ar CH), 121.1 (Ar CH).
δF {1H} (282 MHz, CDCl3): -104.59.
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N-(4-hydroxy-3-methoxybenzyl)-4-methyl-2-oxopentanamide 250
To a solution of 2-oxo-4-methylvaleric acid (34.4 mg, 0.26 mmol) in THF (1.5 mL) cooled
down to -10 °C, were added dropwise N-methyl morpholine (29 μL, 0.26 mmol) and ethyl 
chloroformate (25.2 μL, 0.26 mmol). After 30 min, was added a solution of vanillylamine 
hydrochloride 118 (50 mg, 0.26 mmol) previously treated by K2CO3 (36.5 mg, 0.26 mmol).
The mixture was stirred at rt for further 12 h. Volatiles were evaporated under vacuum and the
residue dissolved in EtOAc (10 mL). The organic layer was successively washed with brine,
0.5 M HCl, brine, 5% NaHCO3, brine, dried over magnesium sulfate, concentrated under
vacuum. Purification on silica gel (Petroleum ether/EtOAc 7/3) gave N-(4-hydroxy-3-
methoxybenzyl)-4-methyl-2-oxopentanamide 250 as clear oil (76%, 52.2 mg).
IR νmax (cm-1): 2982, 2479, 2219, 1669, 1588, 1452, 1287. δH (500 MHz, CDCl3): 0.95 (6 H,
d, J 6.7 Hz, 2 × CH3), 2.15 (1 H, m, CH), 2.83 (2 H, d, J 6.9 Hz, CH2), 3.88 (3 H, s, OCH3),
4.37 (2 H, d, J 6.0 Hz, NCH2), 5.63 (1 H, s, OH), 6.78 (2 H, m, 2 × Ar-H), 6.87 (1 H, d,
J 8.5 Hz, Ar-H), 7.19 (1 H, br s, NH). δC (125 MHz, CDCl3): 22.5 (2 × CH3), 24.3 (CH),
43.4 (CH2), 45.3 (NCH2), 55.9 (OCH3), 110.6 (Ar CH), 114.5 (Ar CH), 121.1 (Ar CH),
128.9 (Ar C), 145.3 (Ar OH), 146.7 (Ar OMe), 160.0 (NHC=O), 198.8 (CH2C=O). m/z (EI):
265.13 [M]+.
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(S)-benzyl 2,6-bis(dibenzylamino)hexanoate (S)-315
Anhydrous potassium carbonate (242 g, 1.75 mol) and benzyl bromide (182 mL, 1.53 mol)
were added to a solution of (S)-L-lysine (40 g, 0.22 mol) in EtOH (400 mL). After stirring at
60 °C for 4 days, the resulting white slurry was filtered over Celite and the solids were
washed with ethyl acetate. After evaporation of solvents, the residue was re-dissolved in ethyl
acetate and washed with saturated NaCl solution. The organic layer was dried, filtered,
concentrate under vacuum. Purification of the residue by distillation (100 °C, 0.01 mBar)
gave (S)-benzyl 2,6-bis(dibenzylamino)hexanoate 315 as a pale yellow oil (125.5 g, 96%).
[ࢻሿࡰ૛૙ = -46.9 (c= 1.6, CHCl3), {lit [ߙሿ஽ଶ଴ = -52.5 ° (c 2.8, CHCl3). IR νmax (cm-1): 3032,
2941, 2798, 1731, 1494, 1454, 1365. δH (300 MHz, CDCl3): 1.11-1.72 (6 H, m, CH2), 2.30
(2 H, t, J 6.8 Hz, CH2N’), 3.30 (1 H, dd, J 6.2 Hz, J 8.7 Hz, CHN), 3.44 (4 H, d, J 3.94 Hz,
2 × PhCH2N’), 3.46 (2 H, d, J 13.8 Hz, 2 × PhCHAHBN), 3.86 (2 H, d, J 13.9 Hz,
2 × PhCHAHBN), 5.08 (1 H, d, J 12.3 Hz, PhCHAHBO), 5.20 (1 H, d, J 12.3 Hz, PhCHAHBO),
7.15-7.38 (25 H, m, Ar H). δC (75 MHz, CDCl3): 23.7 (CH2), 26.6 (CH2), 29.2 (CH2),
53.0 (CH2N’), 54.4 (2 × PhCH2N), 58.2 (2 × PhCH2N’), 60.6 (CHN), 65.8 (PhCH2O),
126.7 (2 × Ar CH), 126.9 (2 x Ar CH), 128.1 (4 × Ar CH), 128.2 (4 × Ar CH), 128.3 (Ar CH),
128.4 (2 × Ar CH), 128.5 (2 × Ar CH), 128.7 (4 × Ar CH), 128.8 (4 × Ar CH), 136.1 (Ar C),
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139.6 (2 × Ar C), 140.0 (2 × Ar C), 172.9 (COO). m/z (HRMS)(ES+): found 597.3475, calcd
for C41H45N2O2 : 597.3479 [M+H]+.
Spectroscopic data similar to literature 3
(S)-2,6-Bis(dibenzylamino)hexan-1-ol (S)-316
A solution of (S)-benzyl 2,6-bis(dibenzylamino)hexanoate 315 (126 g, 210 mmol) in THF
(600 mL) was added dropwise over 45 min at -10 °C to a suspension of LiAlH4 (12 g,
320 mmol) in THF (300 mL). The mixture was stirred for 3 h at this temperature and the
excess of hydride was quenched by successive addition of ethyl acetate and aq NaOH (1 M).
The mixture was extracted into ethyl acetate, the organic extracts were combined, dried over
magnesium sulfate and the solvent removed under reduced pressure. The product was distilled
(120 °C, 0.01 mbar) to give (S)-2,6-bis(dibenzylamino)hexan-1-ol 316 as a clear viscous oil
(92.1 g, 89%)
[ࢻሿࡰ૛૙ = +49.5 (c 0.8, CHCl3). IR νmax (cm-1): 3443, 3027, 2935, 2799, 2360, 1602, 1365,
1129. δH (300 MHz, CDCl3): 1.01-1.65 (6 H, m, 3 × CH2), 2.41 (2 H, dt, J 3.1 Hz, J 7.1 Hz,
CH2N’), 2.76 (1 H, m, CHN), 3.16 (1 H, br s, OH), 3.31-3.45 (2 H, m, CH2OH), 3.32 (2 H, d,
J 13.3 Hz, 2 × PhCHAHBN), 3.49 (2 H, d, J 13.6 Hz, 2 × PhCHAHBN’), 3.58 (2 H, d,
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J 13.6 Hz, 2 × PhCHAHBN’), 3.76 (2 H, d, J 13.3 Hz, 2 × PhCHAHBN), 7.30 (20 H, m,
20 × Ar H). δC (75 MHz, CDCl3): 24.6 (CH2), 24.7 (CH2), 27.3 (CH2), 52.8 (CH2N’),
53.1 (2 × PhCH2N), 58.4 (2 × PhCH2N’), 58.9 (CHN), 60.8 (CH2OH), 126.8 (2 × Ar CH),
127.2 (2 × Ar CH), 128.2 (4 × Ar CH), 128.4 (4 × Ar CH), 128.7 (4 × Ar CH),
129.0 (4 × Ar CH), 139.3 (2 × Ar C), 139.9 (2 × Ar C). m/z HRMS (CI+): found 493.3221,
calcd for C34H41N2O: 493.3219 [M+H]+.
(R)-1,1-dibenzyl-2 ((dibenzylamino)methyl)piperidinium chloride (R)-318
Preparation through cyclisation induced by DAST
Silica gel (3.46 g, 58 mmol) and then DAST (3.8 mL, 28.8 mmol) were added to a solution of
(S)-2,6-bis(dibenzylamino)hexan-1-ol 316 (9.45 g, 19.2 mmol) in DCM (200 mL) at 0 °C.
The mixture was warmed up to rt and stirred for 24 h and the reaction was quenched with
brine, before extraction into DCM. The combined organic layers were dried and evaporated to
dryness to provide (R)-1,1-dibenzyl-2 ((dibenzylamino) methyl)-piperidinium chloride 318
(7.76 g, 80%) as an off white powder.
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Preparation through cyclisation induced by trifluoromethanesulfonic anhydride
Et3N (0.85 mL, 6.09 mmol) and a catalytic amount of DMAP (50 mg, 0.41 mmol) were added
to a solution of (S)-316 (1.00 g, 2.03 mmol) in DCM (25 mL). The mixture was cooled to
0 °C and the trifluoromethanesulfonic anhydride (0.68 mL, 4.06 mmol) was added. The
reaction was allowed to stir for 2 h at 0oC, warmed up to rt and stirred at ambient temperature
for further 12 h. The reaction was then quenched with a saturated NaCl solution and the
products extracted into DCM. The organic layers were then washed with saturated NaHCO3
solution, dried over magnesium sulfate and evaporated to give (R)-1,1-dibenzyl-2
((dibenzylamino) methyl)-piperidinium chloride 318 (920 mg, 88%) as a pale orange powder.
Data for (R)-318:
Mp 200 °C. [ࢻሿࡰ૛૙ = -73.5 (c 1.1, CHCl3). IR νmax (cm-1): 2348, 2283, 1187, 1128, 929.
δH (300 MHz, CDCl3): 1.54-1.93 (6 H, m, 3 × CH2), 2.16 (1 H, d, J 14.8 Hz, N’CHAHB),
2.48 (1 H, d, J 14.8 Hz, N’CHAHB), 2.87 (1 H, dd J 9.9 Hz, J 13.5 Hz, N+CH), 3.09 (1 H, t,
J 10.3 Hz, N+CHACHB), 3.30 (1 H, t, J 10.6 Hz, N+CHACHB), 3.47 (2 H, d, J 13.5 Hz,
2 × N’CHAHB), 3.90 (2 H, d, J 13.5 Hz, 2 × N’CHAHB), 4.39 (1 H, d, J 13.5 Hz, N+CHAHB),
4.71 (1 H, d, J 12.9 Hz, N+CHAHB), 4.97 (1 H, d, J 12.9 Hz, N+CHAHB), 5.58 (1 H, d,
J 13.5 Hz, N+CHAHB)7.20-7.33 (8 H, m, 8 × Ar H), 7.36-7.54 (8 H, m, 8 × Ar H), 7.64 (2 H,
d, J 7.4 Hz, 2 × Ar CH), 7.74 (2 H, d, J 7.4 Hz, 2 × Ar H). δC (75 MHz, CDCl3): 20.8 (CH2),
22.1 (CH2), 25.9 (CH2), 52.7 (CH2N’), 57.3 (CH2N), 58.1 (PhCH2N), 59.0 (2 × PhCH2N’),
63.7 (PhCH2N), 67.0 (CHN), 128.4 (4 × Ar CH), 129.1 (2 × Ar CH), 129.2 (4 × Ar CH),
129.3 (2 × Ar CH), 130.5 (Ar CH), 130.7 (Ar CH), 133.7 (2 × Ar CH), 133.8 (2 × Ar CH),
138.5 (4 × Ar C). m/z HRMS (ES+): found 475.3113, calcd for C34H39N2 :475.3113 [M+H]+.
244
(R)-2-(Aminomethyl)piperidine dihydrochloride (R)-251, (S)-(2-(aminomethyl)piperidine
dihydrochloride (S)-251 and (R)-2-(aminomethyl)piperidine ditetrafluoroborate (R)-251
Preparation of (R)-251 diHCl:
Ammonium formate (315 mg, 5 mmol) and 20% Pd(OH)2 (250 mg) were added to a solution
of (R)-1,1-dibenzyl-2 ((dibenzylamino) methyl)piperidinium chloride 318 (510 mg, 1 mmol)
in MeOH (25 mL). The mixture was stirred for 24 h at room temperature. The black
suspension was then filtered over a pad of Celite and a solution of HCl in diethyl ether (4 mL,
1 M) was added to the filtrate. Solvents were removed under reduced pressure and the crude
product was re-crystallised from methanol/diethyl ether to yield (R)-2-(aminomethyl)-
piperidine dihydrochloride (R)-251 (144 mg, 77%) as a colourless crystalline solid.
Preparation of (S)-251 diHCl:
(S)-(2-(aminomethyl)piperidine dihydrochloride (S)-251 diHCl (140 mg, 75%) was prepared
following the same protocol as for (R)-251 diHCl.
Preparation of (R)-251 diHBF4:
To (R)-2-(aminomethyl)piperidine dihydrochloride 251 (1.7 g, 9.09 mmol) dissolved in
MeOH (25 mL) was added a solution of tetrafluoroboric acid-diethyl ether complex (2.5 mL,
18.17 mmol) at 0 °C. After 1 hour of stirring at rt, the mixture was evaporated under reduced
pressure, the residue was washed with diethyl ether and dried under high vacuum for 12 h.
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The ditetrafluoroborate salt was recrystallised from acetone/THF to give (R)-251 diHBF4 as
long clear needles (2.34 g, 89%).
Data: for (R)-251 diHCl:
Mp 213-215 °C. [ࢻሿࡰ૛૙ = +2.3 (c 1.4, MeOH). IR νmax (cm-1): 3416, 2955, 2842, 1584, 1514,
1484, 1476, 1440, 1407, 1133, 1022, 1008. δH (300 MHz, CD3OD): 1.43-1.75 (6 H, m,
3 × CH2), 2.93 (2 H, t, J 15.1 Hz, N+CH2), 3.09 (1 H, m, N+CH), 3.51 (1 H, dd, J 6.6 Hz,
J 11.4 Hz, CHAHBN’), 3.70 (1 H, dd, J 3.8 Hz, J 11.4 Hz, CHAHBN’). δC (75 MHz, CD3OD):
23.4 (CH2), 28.4 (CH2), 30.8 (CH2), 40.5 (CH2N+), 54.1 (CHN+), 63.4 (CH2N+). Elemental
analysis (%): found C 38.86, H 8.31, N 14.66, calcd for C6H16N2Cl2: C, 38.51; H, 8.62;
N, 14.97. m/z HRMS (CI+): found 115.1236, calcd for C6H15N2: 115.1234 [M+H]+.
Spectroscopic data similar to literature 4, 5
Data for (S)-251:
Analytical data were identical to (R)-251, except: [ࢻሿࡰ૛૙ = -2.9 (c 1.4, MeOH).
(lit. [ࢻሿࡰ૛૞ = -4.7 (c 2.8, MeOH), [ࢻሿࡰ૛૞ = -5.7 (c 0.42, MeOH),). (lit. Mp 240-242 °C)
Data: for (R)-251 diHBF4:
Mp 108-113 °C. δH (300 MHz, CD3OD): 1.27-1.39 (1 H, m), 1.47-1.73 (3 H, m), 1.94 (1 H,
ld, J 10.19 Hz), 2.10 (1 H, d, J 10.79 Hz), 2.96 (1 H, t, J 7.98 Hz), 3;03-3.17 (2 H, m),
3.27 (1 H, dd, J 4.9 Hz, J 13.4 Hz), 3.39-3.53 (2 H, m). δC (75 MHz, CD3OD): 22.3 (CH2),
23.0 (CH2), 27.3 (CH2), 42.2 (CH2N+), 46.5 (CH2N+), 55.3 (CHN+). δF {1H} (282 MHz,
CD3OD): -154.36, -154.41.
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2-(R)-[4,4,0]-1,4-diazo-5,6-diketobicyclodecane (R)-342
Diethyl oxalate (98 μL, 668 μmol) was added to a solution of (R)-2-(aminomethyl)piperidine
dihydrochloride 251 (125 mg, 668 μmol) in DMF (2 mL) previously treated by tBuOK for
12 h (185 μL, 1.34 mmol). The mixture was heated in a sealed tube at 140 °C for 6 h then 
160 °C for another 4 h. All volatiles were then evaporated under reduced pressure and the
residue diluted in ethyl acetate (5 mL) and washed with brine (1 mL). The organic layer was
dried over magnesium sulfate, and evaporated under vacuum to give 2-(R)-[4,4,0]-1,4-diazo-
5,6-diketobicyclodecane 342 as a white solid (24 mg, 21%).
Mp 137-139 °C. [ࢻሿࡰ૛૙ = +9.5 (c 1.8, MeOH). IR νmax (cm-1): 3303, 2929, 1655, 1525, 1434,
1180, 1118. δH (300 MHz, CDCl3): 1.45 (2 H, m,CH2), 1.61-1.95 (4 H, m, 2 × CH2),
3.35 (1 H, ddd, J 1.2 Hz, J 9.5 Hz, J 12.6 Hz, N’CHAHB), 3.54 (2 H, dt, J 4.2 Hz, J 12.9 Hz,
NCH2), 3.61 (1 H, m, N’CHAHB), 4.56 (1 H, dt, J 1.8 Hz, J 13.6 Hz, NCH), 7.63 (1 H, s, NH).
δC (75 MHz, CDCl3): 22.5 (CH2), 24.9 (CH2), 29.8 (CH2), 43.3 (N’CH2), 44.3(NCH2),
53.8 (NCH), 158.0 (C=O), 158.4 (C=O). m/z (HRMS) (ES+): found 191.0790, calcd for
C8H12N2O2Na: 191.0796 [M+Na]+.
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2-(R)-[4,4,0]-1,4-diazobicyclodecane (R)-333
To a suspension of lithium aluminium hydride (112 mg, 2.96 mmol) in THF (10 mL) was
added dropwise at 0 °C a solution of 2-(R)-[4,4,0]-1,4-diazo-5,6-diketobicyclodecane 342 (50
mg, 296 μmol) in THF (5 mL). The reaction was heated at reflux for 16 h. The reaction was 
then quenched by addition of aqueous NaOH (1 M) and water. The solvent was evaporated
before extraction of the aqueous layer in ethyl acetate. The organic layer was dried over
magnesium sulfate and evaporated under reduced pressure to give 2-(R)-[4,4,0]-1,4-
diazobicyclodecane 333 as a clear oil (22.3 mg, 54%).
[ࢻሿࡰ૛૙ = -7.4 (c 0.5, MeOH). IR νmax (cm-1): 3308, 2932, 2854, 1668, 1516, 1455.
δH (300 MHz, CDCl3): 1.08-1.33 (4 H, m, 2 × CH2), 1.45 (1 H, m, C7HAHB), 1.58 (2 H, m,
CH2), 1.71 (1 H, m, C7HAHB), 1.85 (1 H, tt, J 2.6 Hz, J 10.5 Hz, NCH), 2.02 ( 1 H, m,
C6HACHB), 2.16 (1 H, m, C6HACHB), 2.47 (1 H, dd, J 10.4 Hz, J 12.1 Hz, N’C3HAHB),
2.68 (1 H, dt, J 2.3 Hz, J 11.5 Hz, C5HACHB), 2.78 (1 H, td, J 2.6 Hz, J 12.6 Hz, C5HACHB),
2.92 (1 H, dd, J 2.4 Hz, J 8.9 Hz, N’C3HAHB), 3.76 (1 H, br s, NH). δC (75 MHz, CDCl3):
24.0 (CH2), 25.5 (CH2), 29.6 (CH2), 45.6 (N’CH2), 51.6 (NCH2), 55.6 (NCH2), 55.9 (N’CH2),
62.3 (NCH). m/z (EI): 140.12 [M]+.
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2-(R)-[4,4,0]-1,4-diazo-4-ethylbicyclodecane 348
To a suspension of lithium aluminium hydride (112 mg, 2.96 mmol) in THF (10 mL) was
added dropwise at 0 °Ca solution of 2-(R)-[4,4,0]-1,4-diazo-5,6-diketobicyclodecane 342
(50 mg, 296 μmol) in THF (5 mL). The reaction was stirred at reflux for 16 h. The reaction 
was then quenched by addition of ethyl acetate and water and the aqueous layer was extracted
into more ethyl acetate, dried over magnesium sulfate and evaporated under reduced pressure
to give 2-(R)-[4,4,0]-1,4-diazo-4-ethylbicyclodecane 348 (44 mg, 89%).
δH (300 MHz, CDCl3): 0.66 (3 H, t, J 7.2 Hz, CH3), 0.73-0.94 (4 H, m, 2 × CH2), 1.10 (1 H, d,
J 10.5 Hz, C7HAHB), 1.21 (2 H, m, C9H2), 1.33 (1 H, d, J 10.5 Hz, C7HAHB), 1.38 (1 H, t,
J 10.7 Hz, NCH), 1.62 (1 H, m, C6HAHB), 1.83 (1 H, ddd, J 2.6 Hz, J 11.4 Hz, J 28.8 Hz,
C6HAHB), 1.98 (2 H, q, J 7.1 Hz, C11H2), 2.32 (2 H, d, J 11.0 Hz, C3H2), 2.42 (2 H, td,
J 1.5 Hz, J 10.5 Hz, C5H2). δC (75 MHz, CDCl3): 11.5 (CH3), 23.5 (C9H2), 25.2 (C8H2),
29.5 (C10H2), 51.8 (C7H2), 52.3 (C11H2), 54.5 (C5H2), 55.1 (C3H2), 58.7 (C6H2), 60.3 (CH).
m/z (EI): 168.16 [M]+.
249
2-(2-fluoroethyl)octahydro-1 H-pyrido[1,2-a]pyrazine 350
To a suspension of lithium aluminium hydride (112 mg, 2.96 mmol) in ice cooled THF
(10 mL) was added dropwise at 0 °C a solution of 2-(R)-[4,4,0]-1,4-diazo-5,6-diketobicyclo-
decane 342 (50 mg, 296 μmol) in THF (5 mL). The reaction was stirred at reflux for 16 h. The 
reaction was then quenched by addition of ethyl 2-fluoroacetate then iPr. The aqueous layer
was extracted into more ethyl acetate, dried over magnesium sulfate and evaporated under
reduced pressure to give 2-(2-fluoroethyl)octahydro-1 H-pyrido[1,2-a]pyrazine 350 (42 mg,
76%).
δH (300 MHz, CDCl3): 1.02-1.24 (4 H, m, C8H2 and C10H2), 1.37 (1 H, d, J 10.5 Hz,
C7HAHB), 1.49 (2 H, m, C9H2), 1.60 (1 H, d, J 10.6 Hz, C7HAHB), 2.20 (1 H, m, NCH),
2.53 (2 H, dt, J 4.9 Hz, J 28 Hz, C3H2), 2.60-2.75 (2 H, m, C11H2), 3.49 (1 H, m, C6HAHB),
3.65 (2 H, m, C6HAHB and C5HAHB), 4.02 (1 H, m, C5HAHB), 4.42 (2 H, dt, J 5.3 Hz,
J 47.6 Hz, CH2F). δC (75 MHz, CDCl3): 23.5 (C9H2), 25.2 (C8H2), 29.4 (C10H2), 52.6 (C7H2),
54.4 (C3H2), 55.1 (C5H2), 57.8 (d, J 20.5 Hz, C11H2), 60.6 (CH), 63.2 (C6H2), 81.4 (d,
J 167.4 CH2F). δF {1H} (282 MHz, CDCl3): -218.4 Hz. δF (282 MHz, CDCl3): -218.4 (tt,
J 28.3 Hz, J 47.7 Hz, CH2F). m/z (EI): 186.16 [M]+.
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N1,N2-bis(piperidin-2-ylmethyl) 343
To a solution of 2-(aminomethyl)piperidine 251 (1.00 g, 8.76 mmol) in DCM (10 mL) cooled
down to -10 °C, was added dropwise diethyl oxalate (598 μL, 4.38 mmol). After 1 hour at this 
temperature, the white solid was filtered and washed by diethyl ether to give N1,N2-
bis(piperidin-2-ylmethyl) 343 (1.20 g, 97%) as an off white powder.
Mp 173-174 °C. δH (300 MHz, CD3OD): 1.07-1.21 (1 H, m, C3HAHB), 1.41 (2 H, m, C5H2),
1.56-1.73 (2 H, m, C4H2), 1.81 (1 H, d, J 6.9 Hz, C3HAHB), 2.59 (1 H, td, J 2.8 Hz, J 11.8 Hz,
C6HAHB), 2.70 (1 H, m, C6HAHB), 3.02 (1 H, d, J 11.3 Hz, CH), 3.23 (2 H, d, J 5.3 Hz, C7H2).
δC (75 MHz, CD3OD): 25.3 (CH2), 26.7 (CH2), 30.9 (CH2), 45.9 (CH2), 47.4 (CH2),
57.3 (CH), 162.2 (C=O). m/z (HRMS) (ES+): found 283.2139, calcd for C14H27N4O2:
283.2134 [M+H]+.
251
N1,N2-bis(piperidin-2-ylmethyl)ethane-1,2-diamine 347
To a suspension of lithium alumimium hydride (89 mg, 2.34 mmol) in THF (3 mL), was
added dropwise at 0 °C a solution of N1,N2-bis(piperidin-2-ylmethyl) 343 (66.3 mg,
234 μmol) in THF (10 mL). After 24 h at reflux, the reaction was then quenched by addition 
of aq NAOH (1 M) and water. The solvent was evaporated before extraction of the aqueous
layer into ethyl acetate. The organic layer was then dried over magnesium sulfate and
evaporated under reduced pressure. Purification over silica gel (DCM/methanol 9/1) did not
allow recovering N1,N2-bis(piperidin-2-ylmethyl)ethane-1,2-diamine 347 as a pure product
(59.7 mg, ~20% of the crude mixture).
IR νmax (cm-1): 3295, 3172, 2923, 2853, 2314, 1654, 1510, 1436, 1199, 1144. δC (75 MHz,
CDCl3): 24.4 (C4H2 and C4’H2), 26.2 (C5H2 and C5’H2), 30.6 (C3H2 and C3’H2), 46.0 (C6H2 and
C6H2), 52.2 (C9H2 and C9’H2), 56.2 (C7H2 and C7’H2), 62.9 (C2H and C2’H). m/z (HRMS)
(ES+): found 255.2546, calcd for C14H31N4: 255.2543 [M+H]+.
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(E)-N-4-methoxybenzyl-α-iminoglyoxalate  359 
To a solution of ethyl glyoxalate (4.07 mL, 50% in toluene, 20.0 mmol) dissolved in DCM
(75 mL) was added slowly p-anisidin (2.46 g, 20.0 mmol) in DCM (25 mL) and the reaction
mixture was stirred at room temperature for 30 min before addition of 4 Å molecular sieves.
After stirring one additional hour, the reaction mixture was filtered and the volatiles
evaporated under vacuum to give (E)-N-4-methoxybenzyl-α-iminoglyoxalate 359 as a yellow
oil (4.05 g, 98%)
IR νmax (cm-1): 3364, 2980, 2936, 2906, 2837, 2048, 1734, 1608, 1590, 1506. δH (300 MHz,
CDCl3): 1.40 (3 H, t, J 7.1 Hz, CH3), 3.83 (3 H, s, OCH3), 4.41 (2 H, q, J 7.1 Hz, OCH2),
6.93 (2 H, d, J 9.0 Hz, 2 × Ar H), 7.36 (2 H, d, J 9.0 Hz, 2 x Ar H), 7.93 (1 H, s, N=CH).
δC (75 MHz, CDCl3): 14.2 (CH3), 55.4 (OCH3), 61.8 (OCH2), 114.4 (2 × Ar CH),
123.5 (2 × Ar CH), 141.3 (Ar C IV), 147.9 (N=CH), 160.4 (Ar C OMe), 163.5 (C=O).
Spectroscopic data similar to literature6
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(S)-ethyl 2-((4-methoxyphenyl)amino)-2-((S)-2-oxocyclohexyl)acetate 360 and (R)-ethyl
2-((4-methoxyphenyl)amino)-2-((R)-2-oxocyclohexyl)acetate 360
Typical procedure for reactions catalysed by 363:
To the catalyst (R)-2,2,2-trifluoro-N-(piperidin-2-ylmethyl)acetamide trifluoroacetate 363
(20 mol%, 21 mg) dissolved in iPrOH (0.5 mL), were added (E)-N-4-methoxybenzyl-α-
iminoglyoxalate 359 (104 mg, 0.5 mmol) and cyclohexanone (0.5 mL, 0.60 mmol). The
reaction mixture was stirred 24 h at rt. The reaction mixture was quenched with a saturated
ammonium chloride solution (5 mL) and extracted in ethyl acetate (3 × 5 mL). The organic
layer was dried over magnesium sulfate, filtered and evaporated under vacuum. The residue
was purified on silica gel (ethyl acetate/ petroleum ether 1:1) to give ethyl 2-((4-
methoxyphenyl)amino)-2-(2-oxocyclohexyl)acetate 360 as a yellow oil.
Data for syn-adduct:
IR νmax (cm-1): 3367, 2936, 1727, 1710, 1509, 1233, 1034. δH (300 MHz, CDCl3): 1.22 (3 H,
t, J 7.1 Hz, CH3), 1.63-1.73 (2 H, m, C5HAHB and C4HAHB), 1.80 (1 H, dt, J 3.2 Hz, C4HAHB),
1.96 (1 H, m, C3HAHB), 2.06 (1 H, m, C3HAHB), 2.19 (1 H, m, C2HAHB ), 2.33 (1 H, m,
C2HAHB), 2.45 (1 H, m, C5HAHB), 2.82 (1 H, dt, J 4.9 Hz, J 10.9 Hz, C6H), 3.74 (3 H, s,
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OCH3), 4.15 (2 H, q, J 7.2 Hz, OCH2), 4.23 (1 H, d; J 5.1 Hz, C7H), 6.73 (2 H, d, J 9.1 Hz,
2 × Ar H), 6.77 (2 H, d, J 9.1 Hz, 2 × Ar H). δC (75 MHz, CDCl3): 14.1 (CH3), 24.8 (C3H2),
26.8 (C4H2), 29.6 (C5H2), 41.8 (C2H2), 53.6 (C6H), 55.7 (OCH3), 58.1 (C7H), 61.1 (OCH2),
114.7 (2 × Ar CH), 116.2 (2 × Ar CH), 141.0 (Ar C10 IV), 153.0 (Ar C13), 173.4 (C8=O),
211.0 (C1=O). m/z (HRMS) (ES+): found 328.1512, calcd for C17H23NO4Na: 328.1525
[M+Na]+.
Spectroscopic data similar to literature6
N-(piperidin-2-ylmethyl)benzamide 362
To a solution of 2-(aminomethyl)piperidine 251 (200 mg, 1.75 mmol) in a mixture of
ACN/water (6/1, 2.8 mL) was added ethyl benzoate (0.45 mL, 3.10 mmol). The reaction
mixture was refluxed for 24 h, and after cooling down, volatiles were evaporated under
reduced pressure. The residue was dissolved in ethyl acetate (10 mL) and washed by brine
(1 mL). The organic layer was then dried over magnesium sulfate and evaporated under
reduced pressure to give N-(piperidin-2-ylmethyl)benzamide 362 (237 mg, 62%)
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Mp: 103-104 °C. δH (300 MHz, CDCl3): 1.21 (1 H, m, C3HAHB), 1.43 (2 H, m, C3HAHB and
C5HAHB), 1.58-1.68 (1 H, m, C5HAHB), 1.75 (1 H, m, C4HAHB), 1.83 (1 H, m, C4HAHB), 2.62
(2 H, td, J 3.1 Hz, J 11.9 Hz, C6HAHB), 2.78 (1 H, m, C6HAHB), 3.05 (1 H, d, J 11.9 Hz, CH),
3.35 (2 H, d, J 6.2 Hz, C7H2), 7.43-7.54 (3 H, m, 3 x Ar H), 7.84 (2 H, dd, J 1.5 Hz, J 8.4 Hz,
2 x Ar H). δC (75 MHz, CDCl3): 25.1 (C4H2), 26.7 (C5H2), 31.1 (C3H2), 46.5 (C7H2), 47.4
(C6H2), 57.5 (CH), 128.4 (2 × Ar CH), 129.6 (2 × Ar CH), 132.7 (Ar C13H), 135.7 (Ar C9 IV).
νmax (cm-1): 3310, 2913, 2670, 2330, 1639, 1530, 1446, 1192, 1140. m/z (ES+): 219.07
(M+H), (HRMS) (ES+): found 219.1497 (M+H), calc for C13H19N2O: 219.1497.
(R)-2,2,2-trifluoro-N-(piperidin-2-ylmethyl)acetamide trifluoroacetate (R)-363
A suspension of (R)-2-(aminomethyl)-piperidine ditetrafluoroborate 251 170 mg, 0.59 mmol)
in THF (15 mL) was treated with DIEA (0.2 mL, 1.17 mmol) under sonication (~30 min).
Ethyl trifluoroacetate (84 μL, 0.70 mmol) was then added and the reaction mixture was 
refluxed for 14 h. Volatiles were evaporated under reduced pressure and the residue was
dissolved in ethyl acetate (10 mL) and washed with brine (3 × 2 mL). The organic layer was
dried over magnesium sulfate, evaporated under reduced pressure to give (R)-2,2,2-trifluoro-
N-(piperidin-2-ylmethyl)acetamide trifluoroacetate 363 as a solid (138 mg, 88%).
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[ࢻሿࡰ૛૙ = -29.6 (c 1.3, MeOH). IR νmax (cm-1): 3327, 3165, 2929, 2720, 1715, 1557, 1422,
1182, 1140.δH (300 MHz, CD3OD): 1.06-1.26 (1 H, m, C3HAHB), 1.41 (2 H, m, C5H2), 1.57-
1.71 (2 H, m, C3HAHB and C4HAHB), 1.82 (1 H, d, J 6.5 Hz, C4HAHB), 2.60 (1 H, td, J 2.9 Hz,
J 11.8 Hz, C6HAHB), 2.72 (1 H, m, C6HAHB), 3.03 (1 H, d, J 10.3 Hz, C2H), 3.25 ( 2 H, t,
J 6.6 Hz, C7H2). δC (75 MHz, CD3OD): 25.1 (C4H2), 26.6 (C5H2), 30.8 (C3H2), 46.0 (C7H2),
47.3(C6H2), 56.9 (C2H). δF (282 MHz, CD3OD): -77.34 (s, CF3). Elemental
analysis (%): found C 38.99, H 5.58, N 11.0, calcd for C8H13N2OF3: C 38.96, H 5.72,
N 11.36. m/z (HRMS) (CI+): found 211.1062, calcd for C8H14N2OF3: 211.1058 [M+H]+.
4-Methyl-N-(piperidin-2-ylmethyl)benzenesulfonamide (R)-364
DCM (2 mL) and DIEA (0.12 mL, 0.69 mmol) were added to (R)-2-(aminomethyl)piperidine
ditetrafluoroborate 251 (100 mg, 0.35 mmol) and the mixture dissolved by sonication
(~30 min). Then this solution was treated with K2CO3 (57 mg, 0.41 mmol), p-toluenesulfonyl
chloride (66 mg, 0.35 mmol) and the mixture stirred for 3 h at 0 °C. The reaction mixture was
diluted in DCM (10 mL), washed with brine (3 × 1 mL), dried over magnesium sulfate and
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evaporated under reduced pressure. The crude product was purified on silica gel (hexane/ethyl
acetate 8:2), to give 4-methyl-N-(piperidin-2-ylmethyl)benzenesulfonamide 364 (73 mg,
79%)
Mp: 93-94 °C. IR νmax (cm-1): 3562, 3276, 3062, 2929, 2853, 1598, 1442, 1326, 1150, 1092.
δH (300 MHz, CDCl3): 1.05 (1 H, qd, J 3.9 Hz, J 8.8 Hz, C3HAHB), 1.31 (2 H, m, C3HAHB and
C5HAHB), 1.45-1.61 (2 H, m, C5HAHB and C4HAHB), 1.75 (1 H, m, C4HAHB), 2.43 (3 H, s,
CH3), 2.57 (2 H, qu d, J 2.9 Hz, J 11.9 Hz, C7H2), 2.73 (1 H, dd, J 8.1 Hz, J 12.4 Hz,
C6HAHB), 2.92 (1 H, dd, J 3.9 Hz, J 12.4 Hz, C6HAHB), 3.0 (1 H, dd, J 2.5 Hz, J 12.1 Hz,
C2H), 7.3 (2 H, d, J 8.0 Hz, 2 × Ar H), 7.74 (2 H, d, J 8.3 Hz, 2 × Ar H). δC (75 MHz,
CDCl3): 21.5 (C16H3), 24.1 (C4H2), 26.4 (C5H2), 26.1 (C3H2), 46.4 (C6H2), 48.5 (C7H2),
55.5 (CH), 127.1 (2 × Ar CH), 129.7 (2 × Ar CH), 136.8 (Ar C10), 143.3 (Ar C13).
m/z (HRMS) (ES+): found 269.1325, calcd for C13H21N2O2S: 269.1324 [M+H]+.
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Appendix 1
Crystallographic data for (R)-342
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Table 1. Crystal data and structure refinement for (R)-342.
Identification code tmdh4
Empirical formula C8 H14 N2 O3
Formula weight 186.21
Temperature 173(2) K
Wavelength 1.54178 Å
Crystal system Orthorhombic
Space group P2(1)2(1)2(1)
Unit cell dimensions a = 6.939(3) Å a= 90°.
b = 7.847(4) Å b= 90°.
c = 16.454(7) Å g = 90°.
Volume 895.9(7) Å3
Z 4
Density (calculated) 1.381 Mg/m3
Absorption coefficient 0.887 mm-1
F(000) 400
Crystal size 0.3000 x 0.1000 x 0.1000 mm3
Theta range for data collection 5.38 to 68.11°.
Index ranges -8<=h<=8, -9<=k<=9, -19<=l<=19
Reflections collected 11795
Independent reflections 1617 [R(int) = 0.0591]
Completeness to theta = 67.00° 99.0 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.8548
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 1617 / 3 / 131
Goodness-of-fit on F2 1.146
Final R indices [I>2sigma(I)] R1 = 0.0304, wR2 = 0.0818
R indices (all data) R1 = 0.0325, wR2 = 0.0920
Absolute structure parameter -0.1(2)
Largest diff. peak and hole 0.175 and -0.218 e.Å-3
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Table 1. Crystal data and structure refinement for (R)-363.
Identification code tmdh5
Empirical formula C10 H14 F6 N2 O3
Formula weight 324.23
Temperature 173(2) K
Wavelength 1.54178 Å
Crystal system Monoclinic
Space group P2(1)/c
Unit cell dimensions a = 8.834(6) Å a= 90°.
b = 14.844(8) Å b= 90.01(3)°.
c = 10.865(7) Å g = 90°.
Volume 1424.7(15) Å3
Z 4
Density (calculated) 1.512 Mg/m3
Absorption coefficient 1.447 mm-1
F(000) 664
Crystal size 0.1000 x 0.1000 x 0.0300 mm3
Theta range for data collection 5.01 to 68.05°.
Index ranges -10<=h<=10, -17<=k<=17, -13<=l<=13
Reflections collected 18907
Independent reflections 2550 [R(int) = 0.1000]
Completeness to theta = 67.00° 98.4 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.7001
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2550 / 3 / 204
Goodness-of-fit on F2 2.615
Final R indices [I>2sigma(I)] R1 = 0.2103, wR2 = 0.5694
R indices (all data) R1 = 0.2193, wR2 = 0.5783
Extinction coefficient 0.15(4)
Largest diff. peak and hole 0.909 and -0.770 e.Å-3
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Table 1. Crystal data and structure refinement for (R)-364.
Identification code tmdh7
Empirical formula C13 H20 N2 O2 S
Formula weight 268.37
Temperature 93(2) K
Wavelength 0.71073 Å
Crystal system Triclinic
Space group P-1
Unit cell dimensions a = 5.756(3) Å a= 111.717(14)°.
b = 10.762(6) Å b= 90.020(5)°.
c = 12.622(6) Å g = 105.094(14)°.
Volume 697.3(6) Å3
Z 2
Density (calculated) 1.278 Mg/m3
Absorption coefficient 0.229 mm-1
F(000) 288
Crystal size 0.2700 x 0.0500 x 0.0500 mm3
Theta range for data collection 3.23 to 25.35°.
Index ranges -5<=h<=6, -12<=k<=12, -12<=l<=15
Reflections collected 4349
Independent reflections 2454 [R(int) = 0.0309]
Completeness to theta = 25.00° 97.2 %
Absorption correction Multiscan
Max. and min. transmission 1.0000 and 0.9509
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2454 / 2 / 174
Goodness-of-fit on F2 0.631
Final R indices [I>2sigma(I)] R1 = 0.0485, wR2 = 0.1270
R indices (all data) R1 = 0.0590, wR2 = 0.1467
Extinction coefficient 0.036(8)
Largest diff. peak and hole 0.258 and -0.373 e.Å-3
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